levodopa has been researched along with Parkinsonian Disorders in 852 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (0.59) | 18.7374 |
| 1990's | 4 (0.47) | 18.2507 |
| 2000's | 365 (42.84) | 29.6817 |
| 2010's | 377 (44.25) | 24.3611 |
| 2020's | 101 (11.85) | 2.80 |
| Authors | Studies |
|---|---|
| Ardashov, OV; Il'ina, IV; Karpova, EV; Korchagina, DV; Morozova, EA; Pavlova, AV; Salakhutdinov, NF; Tolstikova, TG; Volcho, KP | 1 |
| Gilmour, TP; Handly, E; Iyer, V; Kunselman, AR; Lieu, CA; Savaliya, S; Subramanian, T; Venkiteswaran, K | 1 |
| Chen, HY; Chen, YC; Cheng, ML; Cheng, YC; Chiu, CC; Huang, GJ; Huang, YC; Huang, YZ; Liu, HF; Liu, YC; Lu, CS; Yeh, TH | 1 |
| Borsek, M; Jeleňová, B; Necpál, J | 1 |
| Gourdon, JC; Huot, P; Maddaford, S; Nuara, SG | 1 |
| Chen, Y; Li, L; Tang, J; Yuan, L | 1 |
| Balint, B; Bhatia, KP; Fung, VSC; Morales-Briceno, H | 1 |
| Merello, M; Perez-Lloret, S; Rossi, M | 1 |
| Gao, L; González-Rodríguez, P; Guzman, JN; Ilijic, E; Kaplitt, MG; López-Barneo, J; Schumacker, PT; Stavarache, MA; Stout, KA; Surmeier, DJ; Tkatch, T; Wokosin, DL; Yang, B; Zampese, E | 1 |
| Blass, BE; Bohmann, J; Chen, PJ; Daadi, ES; Daadi, EW; Daadi, MM; Kim, J; Oh, T; Roy-Choudhury, G | 1 |
| Bergman, H; Deffains, M; Eitan, R; Fonar, G; Iskhakova, L; Israel, Z; Marmor, O; Paz, R; Rappel, P | 1 |
| Cubo, E; Miranda, J | 1 |
| Daida, K; Hattori, N; Kamo, R; Nishioka, K; Shimada, T; Tsunemi, T | 1 |
| Cerquera-Cleves, C; Dulski, J; Koziorowski, D; Kwiatek-Majkusiak, J; Milanowski, L; Pentela-Nowicka, J; Ross, OA; Sławek, J; Wszolek, ZK | 1 |
| Ahlskog, JE; Ali, F; Botha, H; Carlos, AF; Clark, HM; Coon, EA; Dickson, DW; Josephs, KA; Koga, S; Lowe, V; Pham, NTT; Sekiya, H; Trejo-Lopez, JA; Whitwell, JL | 1 |
| Bédard, D; Belliveau, S; Bourgeois-Cayer, É; Frouni, I; Hadj-Youssef, S; Hamadjida, A; Huot, P; Kang, W; Kwan, C; Ohlund, L; Sleno, L | 1 |
| Hu, BL; Huang, JF; Huang, SS; Liu, RP; Wang, JY; Zhang, X; Zhu, JH; Zhu, SG | 1 |
| Djoukhadar, I; Jabbari, E; Kobylecki, C; Lally, I; Leahy, CB; Morris, HR; Robinson, AC; Roncaroli, F | 1 |
| Kuo, MC; Tai, CH; Tseng, SH; Wu, RM | 1 |
| Anceaume, E; Caboche, J; Calabrese, V; Calabresi, P; Campanelli, F; Charvin, D; Conquet, F; Cuoc, E; Ghiglieri, V; Heck, N; Marino, G; Natale, G; Picconi, B; Sciaccaluga, M; Tozzi, A | 1 |
| Fanciulli, A; Sidoroff, V; Stankovic, I; Wenning, GK | 1 |
| McCarter, SJ; Savica, R | 1 |
| Isonishi, A; Kawabe, Y; Nakahara, K; Okuda, H; Tanaka, T; Tatsumi, K; Wanaka, A | 1 |
| Holla, VV; Kamble, N; Muthusamy, B; Neeraja, K; Pal, PK; Prasad, S; Surisetti, BK; Yadav, R | 1 |
| Bourque, M; Di Paolo, T; Dickens, D; Grégoire, L; Patel, W; Snodgrass, R | 1 |
| Chiu, R; Frank, C; Lee, J | 1 |
| Bernhard, D; Bonno, SQ; Briscione, MA; Campbell, SA; Donsante, Y; Downs, AM; Fan, X; Gutman, D; Hess, EJ; Ingram, J; Jinnah, HA; Roman, KM; Sardar, TA; Sutcliffe, DJ | 1 |
| Feng, J; Gao, R; Gao, S; Liu, K; Song, M; Wang, L; Wang, Y; Yao, L; Zhang, L | 1 |
| Fasano, A; Gorodetsky, C; Lang, AE; Lozano, AM; Youn, J | 1 |
| Chang, HJ; Joo, JY; Kim, HJ; Lee, HS; Woo, KA | 1 |
| Almela, P; Arenas-Betancur, L; Cuenca-Bermejo, L; De Pablos, V; Del Bel, E; Fernández-Villalba, E; Gonzalez-Cuello, A; Herrero, MT; Navarro-Zaragoza, J; Yuste, JE | 1 |
| Belloso-Iguerategui, A; Cotman, CW; Fernández-Irigoyen, J; Gago, B; Merino-Galan, L; Prieto, GA; Quiroga-Varela, A; Rodríguez-Chinchilla, T; Rodríguez-Oroz, MC; Santamaria, E; Zamarbide, M | 1 |
| Beltrami, D; Biagioli, N; Cavallieri, F; Di Fonzo, A; Di Rauso, G; Fioravanti, V; Fraternali, A; Gasparini, F; Grisanti, S; Marti, A; Monfrini, E; Napoli, M; Pascarella, R; Rossi, J; Toschi, G; Valzania, F; Versari, A | 1 |
| Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kang, W; Kwan, C; Nuara, SG | 1 |
| Del-Bel, E; Dias, FJ; Escobar-Espinal, D; Jacob, G; Leal-Luiz, G; Malzone, BL; Milan, BA; Nascimento, GC; Vivanco-Estela, AN | 1 |
| Abe, Y; Dantsuji, M; Hata, J; Inoue, T; Matsumoto, M; Mochizuki, A; Nambu, A; Ohno, N; Okano, H; Sano, H; Suematsu, M; Sugiura, Y; Suzuki, T; Taira, S; Takeuchi, H; Tanaka, KF; Watanabe, M; Yagishita, S; Yoshimaru, D | 1 |
| Abusrair, A; Aquino, CC; Mititelu, A; Pfeffer, G; Rosenegger, L | 1 |
| Greene, LA; Kovalchuke, L; Levy, OA; Mosharov, EV | 1 |
| Aristieta, A; Miguelez, C; Morera-Herreras, T; Ruiz-Ortega, JA; Ugedo, L | 2 |
| Manalo, RVM | 1 |
| Caparros Lefebvre, D | 1 |
| Attar, A; Fong, C; Lu, JQ | 1 |
| Adekenov, SM; Arystan, LI; Haydargalieva, LS; Muldaeva, GM; Nurmaganbetov, ZS | 1 |
| Mannoury-la-Cour, C; Mantas, I; Millan, MJ; Svenningsson, P; Yang, Y; Zhang, X | 1 |
| Clark, I; Egan, T; Rentsch, P; Stayte, S; Vissel, B | 1 |
| Afonso, ND; Chapela, D; Coelho, JE; Ferreira, JJ; Lopes, LV; Outeiro, TF; Sousa, S; Vaz, RL | 1 |
| Che, Y; Feng, X; Liu, Q; Tang, X; Zhang, S; Zhu, D | 1 |
| Berardelli, A; Bologna, M; Fasano, A; Hallett, M; Paparella, G | 1 |
| Ayala, A; Forjaz, MJ; Harmat, M; Janszky, J; Juhász, A; Kovács, N; Martinez-Martin, P; Pintér, D; Rodriguez-Blazquez, C | 1 |
| Honsberger, S; Husnain, MG; Su, JS | 1 |
| Andrén, PE; Bezard, E; Fridjonsdottir, E; Gunnarsdottir, H; Hulme, H; Nilsson, A; Shariatgorji, R; Svenningsson, P; Vallianatou, T; Wadensten, H; Zhang, X | 1 |
| Arisoy, S; Atalay, O; Comoglu, T; Onal, D; Pehlivanoglu, B; Sayiner, O | 1 |
| Bastioli, G; Caccia, C; Calabresi, P; Cardinale, A; Ghiglieri, V; Keywood, C; Mazzocchetti, P; Melloni, E; Mosci, P; Padoani, G; Picconi, B; Sciaccaluga, M; Tozzi, A; Vailati, S | 1 |
| Arakawa, K; Maehara, S; Yuge, N | 1 |
| Chen, PL; Chu, YT; Lin, CH; Lin, HY | 1 |
| Auger, F; Barthelemy, C; Bezard, E; Bordet, R; Carta, N; Defebvre, L; Demailly, A; Deramecourt, V; Devedjian, JC; Devos, D; Duce, J; Fisichella, M; Kuchcinski, G; Laloux, C; Lannoy, D; Li, Q; Moreau, C; Odou, P; Pioli, E; Rolland, AS | 1 |
| Baschieri, F; Calandra-Buonaura, G; Capellari, S; Contin, M; Cortelli, P; Provini, F; Sambati, L; Tonon, C; Vitiello, M | 1 |
| Altwal, F; Collier, TJ; Kordower, JH; Manfredsson, FP; Sandoval, IM; Sellnow, RC; Sortwell, CE; Steece-Collier, K; West, AR | 1 |
| Margabandhu, G; Vanisree, AJ | 1 |
| George, AL; Mitra, A; Ren, W; Shen, W; Surmeier, DJ; Vanoye, CG; Yang, B; Zhai, S | 1 |
| Ayikobua, ET; Eze, ED; Jjesero, E; Kalange, M; Kasolo, J; Kasozi, KI; Kimanje, KR; Kiyimba, K; Mwandah, DC; Namulema, J; Nansunga, M; Ninsiima, HI; Okpanachi, AO; Safiriyu, A; Semuyaba, I; Ssempijja, F | 1 |
| Bishop, C; Cole-Strauss, A; Collier, TJ; Conti, MM; Lipton, JW; Manfredsson, FP; Mercado, NM; Nillni, EA; Sellnow, R; Sortwell, CE; Stancati, JA; Steece-Collier, K; Winn, ME | 1 |
| Aristieta Arbelaiz, A; Degos, B; Derousseaux, W; Gangarossa, G; Piette, C; Touboul, J; Valverde, S; Vandecasteele, M; Venance, L | 1 |
| Gao, H; Li, W | 1 |
| Arai, A; Ichinohe, N; Kon, T; Mori, F; Nishijima, H; Okada, M; Suzuki, C; Tomiyama, M; Ueno, S; Wakabayashi, K; Zhu, G | 1 |
| Bédard, D; Frouni, I; Gourdon, JC; Hamadjida, A; Huot, P; Kwan, C; Nuara, SG | 3 |
| Manalo, RVM; Medina, PMB | 1 |
| Bloem, BR; Coelho, M; Dodel, R; Ferreira, JJ; Hommel, AALJ; Hosking, A; Lorenzl, S; Meissner, WG; Odin, P; Schrag, A | 1 |
| Frucht, S; Han, SC; Katus, L | 1 |
| Brugnoli, A; Morari, M; Pisanò, CA | 1 |
| Brotchie, JM; Depoortere, R; Fox, SH; Johnston, TH; Newman-Tancredi, A | 1 |
| Chelban, V; Cortese, A; Houlden, H; O'Connor, E; Rossi, S; Sullivan, R; Wood, NW; Yau, WY | 1 |
| Abe, K; Chan, CC; Chao, CC; Chen, ML; Cheng, J; Daida, K; Farrer, M; Funayama, M; Hattori, N; Hsieh, ST; Huang, CY; Hung, YC; Jeon, B; Ke, YC; Lai, HJ; Lee, NC; Li, Y; Lin, CH; Lin, HY; Lo, WC; Mukai, Y; Nishioka, K; Sato, K; Takahashi, Y; Tsai, HH; Tsai, PI; Tzeng, SR; Wu, RM; Wu, YS; Yen, RF; Yoshino, H | 1 |
| Bonifácio, MJ; Soares-da-Silva, P; Sousa, F | 1 |
| Costa, G; Marongiu, J; Morelli, M; Serra, M; Simola, N | 1 |
| Altschüler, J; Böckmann, S; Güttler, C; Haumesser, JK; Kühn, AA; Nikulin, VV; Tanev, K; van Riesen, C | 1 |
| Cairns, NJ; Criswell, S; Davis, AA; Hartlein, J; Kotzbauer, PT; Maiti, B; Martin, WRW; Miles, M; Norris, SA; Perlmutter, JS; Perrin, RJ; Racette, BA; Ushe, M; Zhong, Q | 1 |
| Bezard, E; Canron, MH; Deffains, M; Dehay, B; Fernagut, PO; Li, Q; Teil, M | 1 |
| Huang, X; Mailman, RB; Yang, Y | 1 |
| Hetzelt, KLML; Kerling, F; Kraus, C; Rauch, C; Reis, A; Thiel, CT; Winterholler, M; Zweier, C | 1 |
| Bédard, D; Frouni, I; Hamadjida, A; Huot, P; Kwan, C | 1 |
| Altun, M; Bezard, E; Borgkvist, A; Dehay, B; Feyder, M; Fisone, G; Li, Q; Lieberman, OJ; Nilsson, P; Piccin, A; Plewnia, C; Santini, E; Spigolon, G; Sulzer, D; Urbina, L | 1 |
| Agostinho, P; Aguiar, AS; Cunha, RA; Ferreira, SG; Prediger, RD; Silva, HB; Speck, AE; Tomé, ÂR | 1 |
| Chung, SJ | 1 |
| Calandra-Buonaura, G; Contin, M; Cortelli, P; Lopane, G; Mohamed, S; Sambati, L | 1 |
| Geng, X; Kan, D; Li, Y; Liu, C; Liu, H; Wei, S; Xie, J; Zhang, H | 1 |
| Bartlett, MJ; Cowen, SL; Falk, T; Sherman, SJ; Ye, T | 1 |
| Bortolanza, M; Del Bel, EA; Ferrari, DP | 1 |
| Dupré, N; Estiar, MA; Gan-Or, Z; Leveille, E; Rouleau, GA; Trempe, JF; Varghaei, P; Veyron, S; Yoon, G | 1 |
| Bower, JH; Camerucci, E; Hajeb, M; Martin, P; Mielke, MM; Mullan, AF; Ross, OA; Savica, R; Stang, CD; Turcano, P | 1 |
| Enomoto, T; Fujii, Y; Goda, M; Ikeda, K; Kitamura, A; Nakako, T; Wada, E | 1 |
| Ghosh, S; Malaty, I; Salamatova, Y | 1 |
| Grill, WM; Schmidt, SL | 1 |
| Güttler, C; Nikulin, VV; van Riesen, C | 1 |
| Ju, H; Kwon, KY; Lee, EJ; Lee, M | 1 |
| Bossert, I; Brumberg, J; Ceravolo, R; Fasano, A; Isaias, IU; Minafra, B; Pacchetti, C; Pisano, P; Pozzi, NG; Todisco, M; Trifirò, G; Zangaglia, R | 1 |
| Ishihara, T; Sawada, H; Togo, K; Yamamoto, K | 1 |
| Gourdon, JC; Huot, P; Kwan, C; Nuara, SG | 1 |
| Liu, Z; Song, L; Yan, A; Yang, S; Zhao, J | 1 |
| Cheaha, D; Kumarnsit, E; Niyomrat, K; Nukitram, J | 1 |
| Fukuda, T; Kawahara, Y; Kuroiwa, M; Miyamoto, Y; Nishi, A; Ohnishi, YN; Shuto, T; Sugiyama, K | 1 |
| Bicho, E; Erlhagen, W; Fernandes, C; Ferreira, F; Gago, MF; Lopes, RL; Sousa, N | 1 |
| Contu, L; Costa, G; Morelli, M; Pinna, A; Serra, M | 1 |
| Bonifati, V; Dobricic, V; Dulovic Mahlow, M; Höglinger, G; Huppertz, HJ; Kasten, M; Klein, C; König, IR; Kuhnke, N; Lill, CM; Lohmann, K; Madoev, H; Marras, C; Petkovic, S; Respondek, G; Schaake, S; Stamelou, M; Trinh, J; Vollstedt, EJ; Weissbach, A; Wittke, C | 1 |
| Armstrong, J; Artuch, R; Darling, A; De Oryazábal Sanz, AL; Díaz-Conradi, Á; García-Cazorla, À; Giraldo, P; Gort, L; Irún, P; O'Callaghan, M; Ormazábal, A; Yubero, D | 1 |
| Asensio, MJ; García-Montes, JR; Garcia-Sanz, P; Herranz, AS; Hiroi, N; Kang, G; Moratalla, R; Solís, O | 1 |
| Brefel-Courbon, C; Celebrini, S; Galitzky, M; Jardiné, V; Ory-Magne, F; Rosito, M; Séverac Cauquil, A | 1 |
| Angrisano, S; Cicolin, A; Lopiano, L; Merola, A; Montanaro, E; Priano, L; Romagnolo, A; Tribolo, A; Zibetti, M | 1 |
| Antonioli, L; Ballabeni, V; Barocelli, E; Bernardini, N; Blandini, F; Blandizzi, C; Cerri, S; Colucci, R; Fornai, M; Gentile, D; Ippolito, C; Levandis, G; Pellegrini, C; Segnani, C; Tirotta, E | 1 |
| Chen, NH; Heng, Y; Huang, JY; Mou, Z; Yuan, YH; Zhang, QS | 1 |
| Bhatkar, SR; Bhonsle, SK; de Souza, A; Fernandes, YS | 1 |
| de Souza, A; de Souza, RJ | 1 |
| Deng, M; Fang, Y; Gui, X; Huang, L; Lu, S; Zhang, S | 1 |
| Bezard, E; Calabresi, P; De Rosa, A; Di Luca, M; Gardoni, F; Ghiglieri, V; Li, Q; Longhi, A; Mellone, M; Minocci, D; Napolitano, F; Picconi, B; Racca, C; Stanic, J; Thiolat, ML; Usiello, A; Zianni, E | 1 |
| Avenali, M; De Icco, R; Fresia, M; Pacchetti, C; Perrotta, A; Sandrini, G; Serrao, M; Tassorelli, C | 1 |
| Kim, HJ; Kim, KS; Lee, KE; Lee, MK; Park, HJ; Shin, KS; Zhao, TT | 2 |
| Asselta, R; Blau, N; Cilia, R; Duga, S; Farrer, MJ; Follett, J; Goldwurm, S; Guella, I; Hattori, N; Nishioka, K; Parkkinen, L; Pezzoli, G; Priori, A; Rajput, A; Rajput, AH; Rimoldi, V; Soldà, G; Sossi, V; Stoessl, AJ; Straniero, L; Young, A | 1 |
| Altschüler, J; Beck, MH; Haumesser, JK; Kühn, AA; Kühn, J; Nikulin, VV; van Riesen, C | 1 |
| Donsante, C; Fan, X; Harrast, P; Hess, EJ; Jinnah, HA; Joers, V; Rose, SJ; Tansey, MG | 1 |
| Ando, K; Inoue, R; Kawai, K; Nishime, C; Nishinaka, E; Tsutsumi, H; Urano, K | 1 |
| Adams, DR; Bertoni, M; Burke, EA; Frucht, SJ; Gahl, WA; Huang, Y; Malicdan, MCV; Sincan, M; Taylor, RW; Thompson, K; Toro, C; Wolfe, LA; Yokoyama, T | 1 |
| Brotchie, JM; Corey, R; Fox, SH; Hill, MP; Howson, PA; Johnston, TH; Ravenscroft, P; Reidenberg, BE; Versi, E | 1 |
| Francardo, V; Tronci, E | 1 |
| Amaral, LLFD; Barsottini, OG; Bueno, FL; França, MC; Marussi, VHR; Pedroso, JL; Vale, TC | 1 |
| Gourdon, JC; Hamadjida, A; Huot, P; Nuara, SG | 1 |
| Aparicio-Juárez, A; Ávila-Cascajares, F; Bargas, J; Calderón, V; Duhne, M; Galarraga, E; Lara-González, E | 1 |
| Hershey, LA; Irwin, DJ | 1 |
| Alhadhrami, A; Alharthi, SS; Alrobaian, MM; Kabel, AM; Omar, MS | 1 |
| Ciucci, MR; Kelm-Nelson, CA; Trevino, MA | 1 |
| Hoshino, N; Ishikawa, T; Muraoka, S; Nishimura, T; Okano, M; Satoyoshi, H; Takahata, K; Tsunekawa, H | 1 |
| Baillargeon, J; Darlix, N; Lévesque, C; Lévesque, D; Maheux, J; Majeur, S; Paquet, B; Rouillard, C; St-Hilaire, M | 1 |
| Du, CX; Liu, J; Sun, YN; Wang, HS; Wang, Y; Yao, L; Zhang, GJ; Zhang, L | 1 |
| Bariotto-Dos-Santos, K; Bortolanza, M; Del-Bel, EA; Leite-Panissi, CRA; Nascimento, GC | 1 |
| Ikram, R; Riaz, B; Sikandar, B | 1 |
| Anand, T; Bhat, PV; Khanum, F; Mohan Manu, T | 1 |
| Gupta, S; Patel, RK; Sharma, AK; Wardhan, N | 1 |
| Ahanonu, B; Ding, JB; Ehlers, MD; Grewe, BF; Kim, TH; Li, JZ; Marshall, JD; Parker, JG; Schnitzer, MJ; Wu, YW; Zhang, Y | 1 |
| Mbiydzenyuy, NE; Ninsiima, HI; Pieme, CA; Valladares, MB | 1 |
| Baufreton, J; Bessière, B; Bezard, E; Chazalon, M; Courtine, G; Farjot, G; Ko, WKD; Li, Q; McGuire, S; Milekovic, T; Milet, A; Moraud, EM; Morin, S; Normand, E; Pioli, E; Porras, G; Pype, J; Sun, S | 1 |
| Lim, SY; Ng, RX; Tan, AH | 1 |
| Bair-Marshall, C; Nelson, AB; Ryan, MB | 1 |
| Hänninen, R; Koski, SK; Leino, S; Rannanpää, S; Salminen, O; Tapanainen, T | 1 |
| Gooneratne, IK; Udagedara, TB | 1 |
| Jeon, B; Kim, R; Lee, WW | 1 |
| Choi, DH; Go, J; Han, PL; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Noh, JR; Park, HY; Rhee, M; Ryu, YK | 1 |
| Furtado, SV; Hegde, AS; Jagannatha, AT; Joshi, KC; Khanapure, KS; Perikal, PJ | 1 |
| Ashkan, K; Aziz, TZ; Brown, P; Fischer, P; Foltynie, T; Green, AL; Limousin, P; Tan, H; Tinkhauser, G; Torrecillos, F; Zrinzo, L | 1 |
| Bezard, E; Charvin, D; Conquet, F; Di Paolo, T; Duvey, G; Gregoire, L; Halldin, C; Medori, R; Pioli, E; Takano, A | 1 |
| Bisagni, A; Cremaschi, F; De Marco, L; Di Fabio, S; Mengoli, MC; Montanari, P; Zanelli, M; Zanetti, E | 1 |
| Kamińska, K; Konieczny, J; Lenda, T; Lorenc-Koci, E; Wardas, J | 1 |
| Onder, H | 1 |
| Amorim, BJ; Barsottini, OGP; Faber, I; França, MC; Friedman, JH; Lopes-Cendes, Í; Lourenço, CM; Maia, ML; Marques, W; Martinez, ARM; Martins, CR; Montecchiani, C; Orlacchio, A; Pedroso, JL; Ramos, CD; Souza, JP | 1 |
| Caldarone, B; Dettmer, U; Ericsson, M; Minakaki, G; Müller, CP; Nuber, S; Rajsombath, M; Selkoe, DJ; Winkler, J | 1 |
| Abdul Halim, S; Mohd Amin, NA | 1 |
| Hamed, M; Lazarescu, A; Shetty, A; Suchowersky, O; Tremain, G | 1 |
| Koya Kutty, S; Mohamed Ibrahim, N; Ramli, R; Shah, SA | 1 |
| Avnor, Y; Bishop, C; Chambers, NE; Conti, MM; Gross, L; Lanza, K; Meadows, SM; Ostock, CY | 1 |
| Kohtala, S; Koski, SK; Leino, S; Rannanpää, S; Rantamäki, T; Salminen, O | 1 |
| Nambu, A; Sano, H | 1 |
| Aguilera, J; Kulisevsky, J; Limón, ID; Palafox-Sanchez, V; Ramirez-García, G; Sosti, V | 1 |
| Abd El Fattah, MA; Badawi, GA; El Sayed, MI; Zaki, HF | 1 |
| Kuo, MC; Lin, CH; Lin, HI | 1 |
| Gao, G; Gao, Y; Geng, X; Han, H; He, F; Wang, M; Wang, X; Wang, Y; Xie, J; Yao, X; Zhang, H; Zhang, X | 1 |
| Beck, G; Calabresi, P; Cardinale, A; Costa, C; de Iure, A; Durante, V; Ghiglieri, V; Mancini, A; Mazzocchetti, P; Megaro, A; Napolitano, F; Papa, SM; Picconi, B; Punzo, D; Quiroga Varela, A; Sciaccaluga, M; Tantucci, M; Tozzi, A; Usiello, A | 1 |
| Morris, GP; Rentsch, P; Stayte, S; Vissel, B | 1 |
| Konishi, O; Manabe, Y; Odawara, T | 1 |
| Chen, L; Deng, F; Liu, X | 1 |
| Keifman, E; Moratalla, R; Murer, MG; Pafundo, DE; Paz, RM; Ruiz-DeDiego, I; Solís, O | 1 |
| Bian, ZX; Chan, HY; Cheung, CY; Li, Y; Lyu, H; Poon, WS; Wang, KKW; Zheng, ZV | 1 |
| Caetano, A; Meira, B; Pinto, M; Roque, R | 1 |
| Alty, J; Currie, S; Khan, S; Sivakumar, G | 1 |
| Cacace, F; Calabresi, P; Campanelli, F; Cardinale, A; Ghiglieri, V; Mancini, M; Marino, G; Mineo, D; Natale, G; Picconi, B; Vannelli, A | 1 |
| Collier, NJ; Collier, TJ; Manfredsson, FP; Mercado, NM; Sandoval, IM; Sortwell, CE; Stancati, JA; Steece-Collier, K | 1 |
| Jia, J; Jiang, X; Su, W; Wang, K; Wei, J; Yan, Y | 1 |
| Chen, YC; Ho, PL; Huang, P; Teng, CH; Wu, CC | 1 |
| Bezard, E; Fernagut, PO; Li, Q | 1 |
| Goto, S; Kasahara, J; Ogawa, M; Tsuji, R; Zhou, Y | 1 |
| Bicho, E; Carvalho, C; Ferreira, C; Ferreira, F; Gago, MF; Gama, J; Mollaei, N; Rodrigues, L; Rodrigues, PP; Sousa, N | 1 |
| Ahn, TB; Cho, JW; Chung, SJ; Hong, JY; Jeon, B; Koh, SB; Kwon, DY; Lee, JH; Lee, JY; Lee, WW; Park, HY; Shin, C | 1 |
| Agúndez, L; Antunes, AS; Bardelli, M; Bezard, E; Björklund, A; Björklund, T; Dovero, S; Henckaerts, E; Li, Q; Linden, RM; Pioli, EY; Rosenblad, C | 1 |
| Jankovic, J; Niemann, N | 1 |
| Di Paolo, T; Grégoire, L; Jourdain, VA; Roach, A; Townsend, M | 1 |
| Berbellini, A; Cacchiò, G; De Michele, G; De Rosa, A; Di Marzio, F; Manca, A; Pianese, L; Ragno, M; Scarcella, M; Silvestri, S | 1 |
| Choi, HS; Choi, SO; Kwon, IH; Lee, MK; Shin, KS; Suh, KH; Zhao, TT | 1 |
| Aguiar, AS; Córdova, FM; Cunha, RA; Glaser, V; Hoeller, AA; Latini, A; Leal, RB; Moreira, EL; Oliveira, PA; Prediger, RD; Walz, R | 1 |
| Adlard, PA; Ayton, S; Bush, AI; Cherny, RA; Finkelstein, DI; George, JL | 1 |
| Bär, KJ; Brodoehl, S; Klingner, C; Mentzel, H | 1 |
| D'Andrea, JN; Furtado, S; Goodyear, BG; Haffenden, AM; Suchowersky, O | 1 |
| Campos, FL; Carvalho, MM; Coimbra, B; Lima, R; Pêgo, JM; Rodrigues, AJ; Rodrigues, C; Salgado, AJ; Sousa, N | 1 |
| Lambrecht, C; Richter, A; Sander, SE | 1 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M | 1 |
| Caramés, JM; Moratalla, R; Murer, MG; Solís, JM; Solís, O; Suárez, LM; Taravini, IR | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Higashi, Y; Miyazaki, I; Namba, M; Ogawa, N | 1 |
| Amboni, M; Annesi, G; Barbosa, ER; Barone, P; Bonifati, V; Breedveld, GJ; Chien, HF; Erro, R; Fang, M; Graafland, J; Olgiati, S; Oostra, BA; Pappatà, S; Picillo, M; Quadri, M; Quarantelli, M; Quattrone, A; Wang, J; Wu, B; Xu, F | 1 |
| Angrisano, S; Artusi, CA; Cocito, D; Lopiano, L; Merola, A; Rizzone, MG; Troiano, M; Zibetti, M | 1 |
| Fox, S | 1 |
| Coelho, M; Ferreira, JJ; Mestre, TA; Pita Lobo, P; Rosa, MM | 1 |
| Ishii, K; Katayama, Y; Nagayama, H; Nakajima, N; Nishiyama, Y; Ueda, M | 1 |
| Bergquist, F; Eklund, M; Holmberg, B; Thorlin, T; Zackrisson, T | 1 |
| Carta, M; Collu, M; Devoto, P; Fidalgo, C; Lisci, C; Stancampiano, R; Tronci, E | 1 |
| Bimpisidis, Z; Cenci, MA; Iderberg, H; Rylander, D | 1 |
| Arbizu, J; Collantes, M; DiCaudo, C; Luquin, MR; Marcilla, I; Ordóñez, C; Peñuelas, I; Riverol, M | 1 |
| Czarnecka, A; Domin, H; Konieczny, J; Lenda, T; Lorenc-Koci, E; Smiałowska, M | 1 |
| Björklund, A; Carta, M; Fidalgo, C; Lisci, C; Shin, E; Stancampiano, R; Tronci, E | 1 |
| Bézard, E; Björklund, A; Carta, M; Li, Q; Muñoz, A; Pioli, EY; Porras, G; Tronci, E | 1 |
| Bonastre, M; Cortés, R; Marin, C; Mengod, G; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| Andrén, PE; Bezard, E; Bourdenx, M; Crossman, AR; Fälth, M; Li, Q; Nilsson, A; Wadensten, H | 1 |
| Barraud, Q; Bezard, E; Ghorayeb, I; Hyacinthe, C; Tison, F | 1 |
| Hagiwara, M; Kasahata, N; Kato, H; Nakamura, A; Uchihara, T | 1 |
| Armentero, MT; Bonaventura, J; Canela, EI; Casadó, V; Cortés, A; Farré, D; Franco, R; Lanciego, JL; Lluís, C; Luquin, N; Mallol, J; Martínez-Pinilla, E; McCormick, PJ; Moreno, E; Müller, CE; Pinna, A; Rico, AJ; Sánchez, M; Sierra, S | 1 |
| Carlsson, T; Chiu, WH; Depboylu, C; Höglinger, GU; Oertel, WH; Ries, V | 1 |
| Hamasaki, T; Kuratsu, J; Yamada, K | 1 |
| Morelli, M; Pinna, A | 2 |
| Aristieta, A; Azkona, G; Pérez-Navarro, E; Ruíz-Ortega, JA; Sagarduy, A; Sánchez-Pernaute, R; Ugedo, L; Vazquez, N; Zubillaga, V | 1 |
| Barbui, C; Bovi, T; Cannas, A; Ceravolo, R; Cipriani, A; Dallocchio, C; Di Stefano, A; Frosini, D; Luca, A; Marrosu, F; Matinella, A; Minafra, B; Morgante, F; Morgante, L; Nicoletti, A; Pacchetti, C; Rossi, S; Sciarretta, M; Solla, P; Tinazzi, M; Ulivelli, M; Zappia, M | 1 |
| Bonastre, M; Cortés, R; Giralt, A; Marin, C; Mengod, G; Obeso, JA; Schapira, AH | 1 |
| Liu, Z; Song, L; Wei, J; Wu, N; Yang, X | 1 |
| Miletić, V; Ozretić, D; Relja, M | 1 |
| Arai, A; Baba, M; Migita, K; Nishijima, H; Tomiyama, M; Ueno, S; Ueno, T; Yamada, J | 1 |
| Benecke, R; Walter, U; Wittstock, M; Wolters, A | 1 |
| Farag, NE; Hammad, LN; Zaitone, SA | 1 |
| Kelsey, JE; Neville, C | 1 |
| Armentero, MT; Baqi, Y; Bonaventura, J; Canela, EI; Casadó, V; Cortés, A; Costa, G; Farré, D; Franco, R; Lanciego, JL; Lluís, C; Mallol, J; Martínez-Pinilla, E; McCormick, P; Müller, CE; Pinna, A; Sánchez, M; Simola, N | 1 |
| Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Lewis, KD; Piggott, MJ; Reyes, MG | 1 |
| Di Paolo, T; Grégoire, L; Jourdain, VA; Morin, N; Morissette, M | 2 |
| Gan, J; Liu, ZG; Pan, JL; Xie, CL; Zhang, SF | 1 |
| Ding, Y; Kang, UJ; Singh, P; Won, L | 1 |
| Corrigan, F; Hassall, MM; Thornton, E; Vink, R | 1 |
| Doo, AR; Hahm, DH; Jeon, S; Kim, J; Kim, SN; Lee, H; Park, HJ; Park, JY; Park, SU; Yoo, HH | 1 |
| Jenner, P; Kanda, T; Kawai-Uchida, M; Mori, A; Tashiro, T; Uchida, S | 1 |
| Czech, H; Zeidman, LA | 1 |
| Azkona, G; López de Maturana, R; Luquin, MR; Marcilla, I; Pérez-Navarro, E; Sanchez-Pernaute, R; Sousa, A | 1 |
| Chen, CH; Chen, NF; Chen, WF; Feng, CW; Hsiao, CD; Huang, SY; Hung, HC; Wang, HM; Wen, ZH; Yang, SN | 1 |
| Ain, NM; Fakurazi, S; Hussein, MZ; Hussein-Al-Ali, SH; Kura, AU | 1 |
| Choi, HS; Hwang, BY; Lee, CK; Lee, MK; Shin, KS; Zhao, TT | 1 |
| De Deurwaerdère, P; Di Giovanni, G; Khalki, H; Lagière, M; Milan, L; Navailles, S | 1 |
| Bagetta, V; Brambilla, R; Calabresi, P; Cerovic, M; Fasano, S; Ghiglieri, V; Giampà, C; Hardingham, N; Heuer, A; Marchisella, F; Morella, I; Papale, A; Pendolino, V; Picconi, B | 1 |
| Andrade, DM; Borlot, F; Fasano, A; Lang, AE | 1 |
| Mellstrom, B; Moratalla, R; Naranjo, JR; Ruiz-DeDiego, I; Vallejo, M | 1 |
| Ampe, B; Aourz, N; Bentea, E; De Deurwaerdère, P; El Arfani, A; Massie, A; Michotte, Y; Sarre, S; Smolders, I; Van Eeckhaut, A | 1 |
| Charlton, CG; Dent, L; Griffin, B; King, J; Mackey, V; Muthian, G; Smith, ML | 1 |
| Cai, H; Matsubara, S; Mukai, M; Nakano, I; Sasaki, H; Sugaya, K; Yabe, I | 1 |
| Bezard, E; Crossman, AR; Ko, WK; Martin-Negrier, ML; Ravenscroft, P | 1 |
| Dopeso-Reyes, IG; Franco, R; Gómez-Bautista, V; Labandeira-García, JL; Lanciego, JL; Luquin, N; Martínez-Pinilla, E; Rico, AJ; Roda, E; Sierra, S; Vázquez, A | 1 |
| Adrien, J; Arnulf, I; Belaid, H; Clark, SD; Drouot, X; François, C; Grabli, D; Hirsch, EC; Karachi, C; Laffrat, E; Tandé, D | 1 |
| Agosta, F; Caso, F; Filippi, M; Inuggi, A; Kostic, VS; Petrovic, I; Stankovic, I; Svetel, M | 1 |
| Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA | 2 |
| Di Paolo, T; Grégoire, L; Morin, N; Morissette, M | 2 |
| Bagetta, V; Branchi, I; Calabresi, P; Ghiglieri, V; Latagliata, EC; Morelli, E; Pascucci, T; Pendolino, V; Picconi, B; Poggini, S; Puglisi-Allegra, S; Sgobio, C | 1 |
| Brazhnik, E; Cruz, AV; McCoy, AJ; Novikov, N; Walters, JR | 1 |
| Chung, BH; Han, PL; Hwang, JH; Kang, Y; Kang, YM; Kim, KS; Kim, MR; Kim, YH; Lee, CH; Nam, KH; Park, HY; Park, TS; Ryu, YK | 1 |
| Dyavarshetty, B; Greven, AC; Mouradian, MM; Papa, SM; Potts, LF; Uthayathas, S | 1 |
| Brotchie, JM; Chen, B; Gertler, TS; Lo, C; Nash, JE; Surmeier, JD; Thiele, SL; Warre, R | 1 |
| Appel-Cresswell, S; Dickson, DW; Dinelle, K; Farrer, MJ; McCormick, SE; McKenzie, J; Rajput, A; Rajput, AH; Robinson, CA; Silva, V; Sossi, V; Stoessl, AJ; Thompson, C; Vilariño-Güell, C | 1 |
| Barros, P; Gago, MF; Martins, J; Miguel, R; Rosas, MJ; Vale, J | 1 |
| Caboche, J; Feyder, M; Fisone, G; Gomes, AL; Hansen, K; Kryh, H; Lerdrup, M; Södersten, E; Spigolon, G | 1 |
| Brotchie, JM; Espinosa, MC; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Reyes, MG | 1 |
| Danysz, W; Dekundy, A; Hofmann, M; Mela, F | 1 |
| Garcia-Rubio, S; Giuliano, C; Karasawa, H; Pietra, C; Taché, Y; Wang, L; Xu, X; Yakabi, S | 1 |
| Canela, EI; Canet-Pons, J; Casadó, V; Cortés, A; Dopeso-Reyes, IG; Farré, D; Franco, R; Labandeira-García, JL; Lanciego, JL; Lluís, C; Mallol, J; Moreno, E; Muñoz, A; Navarro, G; Reyes-Resina, I; Rico, AJ | 1 |
| Cote, SR; Kuzhikandathil, EV | 1 |
| Bergeron, Y; Bermejo, MK; Caron, MG; Cyr, M; Gainetdinov, RR; Hossain, MM; Kile, B; Masoud, ST; Miller, GW; Nguyen, LT; Ramsey, AJ; Richardson, JR; Salahpour, A; Siesser, WB; Sotnikova, TD; Vecchio, LM; Wightman, RM | 1 |
| Ando, K; Inoue, T; Itoh, T | 1 |
| Bernardi, G; Castelli, V; Cavaliere, F; D'Angelo, V; Ferrazzoli, D; Giorgi, M; Martorana, A; Morrone, LA; Sancesario, G; Sica, F; Sorge, R | 1 |
| Antonini, A; Cantello, R; Carecchio, M; Comi, C; Fleetwood, T; Magistrelli, L; Mancini, F; Oggioni, GD | 1 |
| Carta, AR; Cassano, T; Giuffrida, A; Macheda, T; Martinez, AA; Morgese, MG; Paquette, MA; Pisanu, A; Seillier, A | 1 |
| Dutta, D; Mohanakumar, KP; Naskar, A; Prabhakar, V; Singh, R | 1 |
| Bamford, NS; Borgkvist, A; Choi, SJ; Mosharov, EV; Sulzer, D; Wong, MY | 1 |
| Limón, ID; Palafox-Sánchez, V; Ramírez-García, G | 1 |
| Akita, H; Habata, T; Igarashi, M; Noda, K; Ogata, M; Saji, M | 1 |
| Bubser, M; Cenci, MA; Conn, PJ; Hopkins, CR; Iderberg, H; Jones, CK; Lindsley, CW; Maslava, N; Niswender, CM; Thompson, AD | 1 |
| Di Paolo, T; Goodenowe, D; Grégoire, L; Miville-Godbout, E; Mochizuki, A; Senanayake, V; Smith, T | 1 |
| Cao, X; Chen, Z; Shi, Q; Tang, B; Wang, T; Zhang, T | 1 |
| Gut, NK; Winn, P | 1 |
| Bordia, T; Drenan, RM; McGregor, M; McIntosh, JM; Quik, M | 1 |
| Bhide, N; Bishop, C; Conti, M; George, JA; Hallmark, J; Ostock, CY; Palumbo, N | 1 |
| Chiu, WH; Depboylu, C; Hermanns, G; Höglinger, GU; Maurer, L; Oertel, WH; Ries, V; Windolph, A | 1 |
| Barnum, CJ; Bhide, N; Bishop, C; George, JA; Lindenbach, D; Surrena, MA | 1 |
| Hwang, BY; Lee, CK; Lee, MK; Park, HJ; Park, KH; Shin, KS; Zhao, TT | 1 |
| Cruz, AV; Delaville, C; Gerber, CM; McCoy, AJ; Walters, JR | 1 |
| Li, L; Sagot, B; Zhou, FM | 1 |
| Ambrosi, G; Antoninetti, G; Baqi, Y; Blandini, F; Cerri, S; Costa, G; Fuzzati-Armentero, MT; Levandis, G; Montepeloso, E; Müller, CE; Pinna, A; Simola, N; Volpini, R | 1 |
| Bortolanza, M; Cavalcanti-Kiwiatkoski, R; Del-Bel, E; Dos Santos-Pereira, M; Mitkovski, M; Padovan-Neto, FE; Raisman-Vozari, R | 1 |
| Bonastre, M; Cortés, R; Marin, C; Mengod, G; Rodríguez-Oroz, MC | 1 |
| Garg, A; Jha, S; Khanna, A | 1 |
| De Deurwaerdère, P; Di Giovanni, G; Navailles, S | 1 |
| Bishop, C; Conti, MM; Dupre, KB; Lindenbach, D; Ostock, CY | 1 |
| Feld, Y; Finberg, JP; Gross, RE; Gutekunst, CA; Mewes, K; Papa, SM; Singh, A; Uthayathas, S | 1 |
| Hattori, N; Ishiguro, Y; Kawajiri, S; Noda, K; Okuma, Y; Tomizawa, Y; Tosaka, Y | 1 |
| Daniels, WM; Mabandla, MV; Ndlovu, BC | 1 |
| Alvarsson, A; Kadkhodaei, B; Millan, MJ; Perlmann, T; Schintu, N; Stan, TL; Svenningsson, P; Zhang, X | 1 |
| Garcia-Montes, JR; González-Granillo, A; Moratalla, R; Solís, O; Xu, M | 1 |
| Burgess, T; Cunningham, V; Glamuzina, E; Hill, R; Jacobsen, JC; Lehnert, K; Love, DR; Prosser, DO; Robertson, SP; Snell, RG; Swan, B; Taylor, J; Wilson, C | 1 |
| Case, DT; Collier, TJ; Divito, CB; Edwards, RH; Rubio, ME; Seal, RP; Sortwell, CE; Stancati, JA; Steece-Collier, K; Sulzer, D; Williams, SP; Zhang, H; Zhi, L | 1 |
| Bordia, T; Decker, MW; McGregor, M; McIntosh, JM; Perez, XA; Quik, M; Zhang, D | 1 |
| Cruz, AV; Delaville, C; Dupre, KB; Eyring, KW; Gerber, CM; McCoy, AJ; Walters, JR | 1 |
| Girasole, AE; Nelson, AB | 1 |
| Bezard, E; Cenci, MA; Conn, PJ; Fieblinger, T; Francardo, V; Greengard, P; Ko, WK; Li, Q; Lindsley, CW; Neubig, RR; Plotkin, JL; Shen, W; Surmeier, DJ; Wess, J; Xie, Z | 1 |
| Feng, Z; Gupta, DK; Hang, X; Hasan, A; Liu, R | 1 |
| Jeon, BS; Park, H; Park, SH; Shin, JH | 1 |
| Canning, SD; Wang, XP; Zhang, LL | 1 |
| Cacace, F; Calabresi, P; Carta, M; di Maio, A; Fidalgo, C; Gardoni, F; Ghiglieri, V; Mancini, M; Mellone, M; Mineo, D; Napolitano, F; Pendolino, V; Picconi, B; Stancampiano, R; Stanic, J; Tronci, E; Usiello, A; Vannelli, A | 1 |
| Daumas, S; El Mestikawy, S; Gangarossa, G; Guzman, M; Prado, MA; Prado, VF; Valjent, E | 1 |
| Alam, M; Jin, X; Krauss, JK; Schwabe, K | 1 |
| Kokare, DM; Shelkar, GP; Subhedar, NK; Upadhya, MA | 1 |
| McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Alvarsson, A; Greengard, P; Kaplitt, MG; Marongiu, R; Schintu, N; Svenningsson, P; Zhang, X | 1 |
| Bishop, C; Conti, MM; Eissa, S; Goldenberg, AA; Kuberka, A; Lindenbach, D; Mohamed, M | 1 |
| Choi, DH; Go, J; Hwang, JH; Kim, KS; Kim, YH; Lee, CH; Park, HY; Park, TS; Rhee, M; Ryu, YK | 1 |
| Cheng, J; Fan, Q; Gan, J; Hu, R; Li, L; Liu, Z; Song, L; Wu, N; Zhang, Z; Zhou, M | 1 |
| Black, MA; Dearden, PK; Duncan, EJ; Gemmell, NJ; Parr-Brownlie, LC; Reynolds, JN; Smith, LM | 1 |
| Deng, M; Fang, Y; He, Y; Huang, L; Lu, S; Ma, R | 1 |
| Lin, JY; Liu, ZG; Wang, MH; Wang, XJ; Xie, CL; Zhang, SF; Zhang, Y | 1 |
| Moustafa, YM; Teema, AM; Zaitone, SA | 1 |
| Dorban, S; Gustin, T; Mormont, E | 1 |
| Abe, T; Fujita, K; Harada, M; Izumi, Y; Kaji, R; Osaki, Y | 1 |
| Bhattacharjee, N; Borah, A; Choudhury, A; Choudhury, S; Mazumder, MK; Paul, R | 1 |
| da-Silva, CA; Del-Bel, E; Dos-Santos-Pereira, M; Guimarães, FS | 1 |
| Bishop, C; Conti, MM; Hallmark, J; Lindenbach, D; Meadows, SM; Melikhov-Sosin, M; Werner, DF | 1 |
| Cerquetti, D; Fariña, S; Merello, M; Morisset, P; Rossi, M; Wilken, M | 1 |
| Barros, IS; Brito, BS; de Araújo, DF; de Araújo, IT; de Melo Neto, AP; Gondim, Fde A; Horta, WG; Lima, JW; Oliveira, ÍS | 1 |
| Bale, E; Gray, WK; Hand, A; Jones, C; Oates, LL; Todd, A; Walker, RW; Wood, BH; Woolford, M | 1 |
| Bishop, C; Conti, MM; George, JA; Goldenberg, AA; Lindenbach, D; Melikhov-Sosin, M; Nuss, EE; Ostock, CY | 1 |
| Bender, D; Bjarkam, CR; Doudet, D; Glud, AN; Mogensen, P; Møller, A; Nielsen, MS; Sørensen, JC | 1 |
| Khatoon, H; Mirza, T; Najam, R; Sikandar, B | 1 |
| Czarnecka, A; Dudek, M; Kamińska, K; Knutelska, J; Lorenc-Koci, E; Zygmunt, M | 1 |
| Cao, X; Chen, G; Han, C; Ma, K; Nie, S; Papa, SM; Wang, T; Xiong, N; Xu, Y; Zhang, Z | 1 |
| Gee, L; Pilitsis, JG; Ramirez-Zamora, A; Shin, DS; Youn, Y | 1 |
| Coenen, VA; Fischer, J; Frings, L; Jost, M; Klebe, S; Meyer, PT; Piroth, T; Rauschendorf, MA; Reinacher, PC; Rijntjes, M; Rösler, B; Stock, F; Weiller, C; Zimmer, A | 1 |
| Itin, I; Jimenez-Shahed, J; Mehanna, R | 1 |
| Rajput, AH; Rajput, EF | 1 |
| Frouni, I; Gourdon, JC; Hamadjida, A; Harraka, MJ; Huot, P; Kwan, C; Nuara, SG; Sid-Otmane, L; Veyres, N | 1 |
| Damberg, P; Monnot, C; Nikkhou-Aski, S; Svenningsson, P; Zhang, X | 1 |
| Grabli, D | 1 |
| Bordia, T; Perez, XA; Quik, M; Zhang, D | 1 |
| Abdelhameed, AS; Ajmal, MR; Khan, RH; Nusrat, S; Siddiqi, MK; Siddique, IA; Zaidi, N; Zaman, M | 1 |
| A Figge, D; Standaert, DG | 1 |
| Arai, A; Kannari, K; Kawarabayashi, T; Kimura, T; Shen, H; Shoji, M; Suzuki, C; Tomiyama, M; Watanabe, M | 1 |
| Bishop, C; Dupre, KB; Eskow, KL; Klioueva, A; Lormand, L; Negron, GE; Park, JY; Steiniger, A | 1 |
| Bagetta, V; Barone, I; Calabresi, P; Ghiglieri, V; Picconi, B; Sgobio, C | 1 |
| Aceves, J; Erlij, D; Florán, B; Floran, L; García-Ramírez, M; Rangel-Barajas, C; Sánchez-Lemus, E; Silva, I | 1 |
| Ferrario, JE; Gershanik, OS; Larramendy, C; Murer, MG; Saborido, MD; Taravini, IR | 1 |
| DeLong, MR; Liang, L; Papa, SM | 1 |
| Barnum, CJ; Bishop, C; Blandino, P; Deak, T; Dupre, K; Eskow, KL | 1 |
| Jin, GZ; Mo, J; Sun, PH; Yu, LP; Zhang, H; Zhen, X | 1 |
| Evans, AH; Farrell, MJ; Gibson, SJ; Helme, RD; Lang, AE; Lim, SY | 1 |
| Bernardi, G; D'Angelo, V; Esposito, Z; Giorgi, M; Martorana, A; Nuccetelli, V; Sancesario, G; Sorge, R; Stefani, A | 1 |
| Glavan, G | 1 |
| Aguilar, E; Cortés, R; Marin, C; Mengod, G; Obeso, JA; Rodríguez-Oroz, MC | 1 |
| Ferrario, JE; Gomes, MZ; Hunot, S; Raisman-Vozari, R; Rojas-Mayorquín, AE; Saldaña-Ortega, M; Salum, C | 1 |
| Gunzler, SA; Hogarth, P; Jamerson, B; Kirchhoff, T; Krams, M; Landen, JW; Menniti, FS; Nutt, JG; Weaver, JL | 1 |
| Danysz, W; Dekundy, A; Quack, G; Valastro, B | 1 |
| Björklund, A; Carlsson, T; Carta, M; Kirik, D; Muñoz, A | 1 |
| Abdin, AA; Hamouda, HE | 1 |
| Butz, M; Gross, J; Makhloufi, H; Pollok, B; Schnitzler, A; Timmermann, L; Wojtecki, L | 1 |
| Bi, M; Fath, T; Götz, J; Gunning, P; Ittner, LM; Ke, YD; Li, KM; van Eersel, J | 1 |
| Domino, EF; Ni, L | 1 |
| Akamatsu, Y; Fujimori, K; Kawagishi, N; Miyagi, S; Sato, A; Satomi, S; Sekiguchi, S | 1 |
| Berciano, J; Bonifati, V; Breedveld, G; Di Fonzo, A; García, A; Infante, J; Oostra, B; Sánchez-Juan, P | 1 |
| Bezard, E; Björklund, A; Carlsson, T; Carta, M; Di Luca, M; Gardoni, F; Kirik, D; Li, Q; Marcello, E; Muñoz, A; Qin, C | 1 |
| Marti, M; Morari, M; Trapella, C | 1 |
| Fukuyama, H; Hashikawa, K; Hattori, N; Kohriyama, T; Matsumoto, M; Ohshita, T; Takahashi, T; Yamashita, H | 1 |
| Ceda, G; Lauretani, F; Maggio, M; Nardelli, A; Saccavini, M | 1 |
| Aguiar, PM; Barsottini, OG; Borges, V; Felício, AC; Ferraz, HB; Godeiro-Junior, C; Silva, SM | 1 |
| Barnum, CJ; Bishop, C; Deak, T; Dupre, KB; Eskow, KL; Krolewski, DM; Walker, PD | 1 |
| Brotchie, JM; Fox, SH; Johnston, T; Millan, MJ; Reyes, G; Visanji, NP | 1 |
| Barodia, SK; Luthra, PM; Raghubir, R | 1 |
| McCairn, KW; Turner, RS | 1 |
| García-Horsman, JA; Kääriäinen, TM; Männistö, PT; Piltonen, M | 1 |
| Bartoszyk, GD; Bédard, PJ; Di Paolo, T; Graham, J; Grégoire, L; Samadi, P | 1 |
| Benabid, AL; Berger, F; Buggia-Prevot, V; El Atifi-Borel, M; Platet, N; Sgambato-Faure, V | 1 |
| Calon, F; Di Paolo, T; Grégoire, L; Hornykiewicz, O; Rajput, A; Rajput, AH; Samadi, P | 1 |
| Caron, MG; Fuentes, R; Nicolelis, MA; Petersson, P; Siesser, WB | 1 |
| Ugrumov, MV | 1 |
| Lima, MA; Maradei, S; Maranhao Filho, P | 1 |
| Berthet, A; Bezard, E; Bloch, B; Cador, M; Doudnikoff, E; Porras, G; Stark, H | 1 |
| Brundin, P; Cenci, MA; Lane, EL; Vercammen, L | 1 |
| Collier, TJ; Maries-Lad, E; Soderstrom, KE; Sortwell, CE; Steece-Collier, K | 1 |
| Blume, SR; Cass, DK; Tseng, KY | 1 |
| Barbanoj, M; Gich, I; Kulisevsky, J; Pérez, V; Rodríguez-Alvarez, J; Rubio, A; Sosti, V | 1 |
| Ballion, B; Chetrit, J; Frenois, F; Gonon, F; Murer, MG; Zold, CL | 1 |
| Astradsson, A; Brownell, AL; Choi, JK; Hallett, PJ; Isacson, O; Jenkins, BG; Levesque, MA; McDowell, JS; Spealman, RD | 1 |
| Ares, S; Darmopil, S; De Diego, IR; Martín, AB; Moratalla, R | 1 |
| Di Paolo, T; Grégoire, L; Lévesque, D; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P; Tamim, MK | 1 |
| Jiang, JJ; Lee, VS; Wang, EQ; Zhou, XP | 1 |
| Cenci, MA; Lindgren, HS; Ohlin, KE | 1 |
| Kerkerian-Le Goff, L; Khaindrava, V; Lacombe, E; Melon, C; Oueslati, A; Salin, P | 1 |
| Fisone, G; Greengard, P; Heiman, M; Santini, E; Valjent, E | 1 |
| Bishop, C; Dupre, KB; Jaunarajs, KL; Kelly, C; Klioueva, A; Moore, A; Steiniger, A | 1 |
| Aguilar, E; Bonastre, M; Jiménez, A; Marin, C | 2 |
| Diaz, J; Guilloux, JP; Massart, R; Mignon, V; Sokoloff, P | 1 |
| Brocco, M; Mela, F; Millan, MJ; Morari, M | 1 |
| Kostrzewa, RA; Kostrzewa, RM; Nowak, P; Skaba, D | 1 |
| Ahn, YH; Lee, PH; Park, HJ; Shin, JY | 1 |
| Menkes, DL; Silvers, DS | 1 |
| Buck, K; Ferger, B | 1 |
| Borah, A; Mohanakumar, KP | 4 |
| Lee, KY; Lee, PH; Yong, SW | 1 |
| Racette, BA; Sterling, C; Willis, AW | 1 |
| Bezard, E; Brotchie, JM; Dunah, AW; Hallett, PJ; Kobylecki, C; Li, Q; Ravenscroft, P; Silverdale, MA | 1 |
| Alp, R; Alp, SI; Ure, H | 1 |
| Aoki, T; Hamaue, N; Hirafuji, M; Ogata, A; Sasaki, H; Terado, M; Togashi, H; Tsuchida, S; Yabe, I | 1 |
| Alty, JE; Clissold, BG; Kempster, PA; McColl, CD; Reardon, KA; Shiff, M | 1 |
| Biagioni, F; Fornai, F; Fulceri, F; Murri, L; Paparelli, A; Ruggieri, S | 1 |
| Dick, JP; Kellett, MW; Kobylecki, C; Silverdale, MA; Varma, A | 1 |
| Asmus, F; Berg, D; Reimold, M; Schöls, L; Synofzik, M | 1 |
| Chung, CY; Hallett, PJ; Isacson, O; Koprich, JB | 1 |
| Bélanger, N; Di Paolo, T; Hadj Tahar, A; Morissette, M; Samadi, P | 1 |
| Chen, L; Wang, H; Xue, Y; Yung, WH; Zhang, SJ | 1 |
| Bilbe, G; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Hornykiewicz, O; Johns, DR; Morissette, M; Ouattara, B; Rajput, A; Rajput, AH; Vranesic, I | 1 |
| Cho, C; Cohen, B; Kudo, K; Kunin, M; Olanow, CW; Osaki, Y; Raphan, T | 1 |
| Bureau, G; Chagniel, L; Cyr, M; Lebel, M | 1 |
| Adam, OR; Ferrara, JM; Ondo, WG | 1 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N | 1 |
| Anderson, AM; Johnson, SW; Lewis, JR; Meshul, CK; Paquette, MA; Paul Berger, S | 1 |
| Bonanni, L; Cossu, G; Manca, D; Onofrj, M; Stocchi, F; Thomas, A | 1 |
| Bioulac, B; De Deurwaerdère, P; Gross, C; Navailles, S | 1 |
| Marti, M; Morari, M; Viaro, R | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Huot, P; Johnston, T; Reyes, G; Visanji, N | 1 |
| Dale, RC; Earl, J; Fung, VS; Grattan-Smith, P; Houlden, H; Melchers, A | 1 |
| Reichmann, H | 1 |
| Glass, GA; Ku, S | 1 |
| Ahmed, MR; Aubert, I; Berthet, A; Bezard, E; Bioulac, BH; Bloch, B; Bychkov, E; Carl, YT; Doudnikoff, E; Dovero, S; Gurevich, EV; Gurevich, VV; Kook, S; Li, Q; Porras, G | 1 |
| Andersen, ML; Barnabé, GF; Dombrowski, PA; Lima, MM; Reksidler, AB; Tufik, S; Vital, MA | 1 |
| Dunnett, SB; Lane, EL | 1 |
| Fish, M; Hack, M; Majounie, E; Morris, HR; Newsway, V; Rohrer, JD; Warren, JD; Williams, N | 1 |
| Hayashi, Y; Hozumi, I; Inuzuka, T; Kimura, A; Sakurai, T; Tanaka, Y; Yamada, M | 1 |
| Jeong, SH; Kim, JM; Kim, JS; Kim, SE; Kim, SH; Kim, Y; Kim, YK | 1 |
| Guan, Q; He, Y; Jin, L; Liu, X; Zhao, L | 1 |
| Chen, CC; Chen, RS; Grattan-Smith, P; Jung, SM; Lai, SC; Lang, AE; Lin, YW; Lu, CS; Sugo, E; Wu-Chou, YH | 1 |
| Liu, Z; Ren, T; Song, L; Wu, N; Yang, X; Yuan, W | 1 |
| Espay, AJ; Metman, LV; O'Sullivan, JD; Paviour, DC; Revilla, FJ; Schmidt, RE | 1 |
| Bajaj, N; Bhatia, KP; Brandner, S; Elahi, E; Emre, M; Federoff, M; Guevara, R; Hanagasi, H; Hardy, J; Houlden, H; Lees, AJ; Paisán-Ruiz, C; Schneider, SA; Schwingenschuh, P; Sina, F; Singleton, AB | 1 |
| de la Fuente-Fernández, R; Dinelle, K; Doudet, DJ; Mak, E; Schulzer, M; Sossi, V | 1 |
| Iravani, MM; Jackson, MJ; Jenner, P; Parent, A; Rose, S; Zeng, BY | 1 |
| Fang, C; Gao, C; Wang, Y; Xu, H; Xu, Z; Yin, J; Zhou, H | 1 |
| Aceves, J; Erlij, D; Florán, B; Lopéz-Santiago, LM; Rangel-Barajas, C; Silva, I | 1 |
| Damon-Perrière, N; Meissner, WG; Tison, F | 1 |
| Gupta, A; Lang, AE | 1 |
| Bezard, E; Dovero, S; Fisone, G; Li, Q; Santini, E; Savasta, M; Sgambato-Faure, V | 1 |
| Barraud, Q; Bezard, E; Fernagut, PO; Ghorayeb, I; Tison, F | 1 |
| Chan, KY; Fung, CW; Hui, J; Ko, CH; Lam, CW; Low, L; Mak, CM; Siu, S; Wong, VC; Yau, E; Yeung, WL | 1 |
| Brotchie, JM; Fox, SH; Johnston, TH; Piggott, MJ; Savola, JM | 1 |
| Dowd, E; Finn, DP; Gorman, AM; Walsh, S | 1 |
| Abele, M; Albanese, A; Barone, P; Berciano, J; Boesch, S; Bozi, M; Cardozo, A; Coelho, M; Colosimo, C; Daniels, C; Del Sorbo, F; Deuschl, G; Djaldetti, R; Dupont, E; Fowler, C; Galitzky, M; Gasser, T; Geser, F; Giladi, N; Gonzalez-Mandly, A; Gurevich, T; Kamm, C; Klockgether, T; Köllensperger, M; Mathias, CJ; Meco, G; Ndayisaba, JP; Nilsson, CF; Oertel, W; Ostergaard, K; Pellecchia, MT; Poewe, W; Quinn, N; Rascol, O; Sampaio, C; Schimke, N; Schrag, A; Seppi, K; Siebert, U; Tison, F; Tolosa, E; Wenning, GK; Widner, H; Yekhlef, F | 1 |
| Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Winkelmolen, L | 1 |
| Auguet, M; Chabrier, PE; Charnet, C; Cornet, S; Roubert, V; Spinnewyn, B | 1 |
| Archer, T; Fredriksson, A; Johansson, B | 1 |
| Auguet, M; Chabrier, PE; Ferrandis, E; Grandoulier, AS; Marin, JG; Mautino, G; Rocher, MN; Spinnewyn, B | 1 |
| Deogaonkar, M; Gilmour, TP; Lieu, CA; Nolt, MJ; Piallat, B; Subramanian, T | 1 |
| Kim, BJ; Kim, JS; Kim, KK; Kim, SM; Lee, MC; Lim, YM; Park, HK | 1 |
| Bagetta, V; Calabresi, P; Di Filippo, M; Fusco, FR; Ghiglieri, V; Giampà, C; Paillè, V; Pendolino, V; Picconi, B; Sgobio, C; Tozzi, A | 1 |
| Gerlach, M; Grünblatt, E; Riederer, P; Scheller, DK; Schmidt, WJ | 1 |
| Hu, WD; Huang, YX; Li, D; Liu, CF; Luo, WF | 1 |
| Daly, CS; Dunnett, SB; Lane, EL; Smith, GA | 1 |
| Bartoszyk, GD; Dean, O; Gerlach, M; Riederer, P; van den Buuse, M | 1 |
| Bilbe, G; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Johns, D; Morin, N; Ouattara, B; Sahasranaman, S; Vranesic, I | 1 |
| Gendelman, HE; Hutter-Saunders, JA; Kosloski, LM; McMillan, JM; Mosley, RL; Rinat, T; Yotam, N | 1 |
| Barnum, CJ; Bhide, N; Bishop, C; Dupre, KB; Eskow Jaunarajs, KL; Lindenbach, D; Ostock, CY | 1 |
| Braschinsky, M; Doherty, K; Hotter, A; Lees, AJ; Ling, H; Lüüs, SM; Poewe, W; Taba, P | 1 |
| Brotchie, JM; DeHaven, RN; DeHaven-Hudkins, DL; Dolle, RE; Fox, SH; Goodman, A; Johnston, TH; Koprich, JB; Le Bourdonnec, B; Little, PJ | 1 |
| Di Paolo, T; Morissette, M; Parent, M; Riahi, G | 1 |
| Abe, H; Ebihara, K; Ishida, Y; Kawai, K; Magata, Y; Matsuo, H; Nishimori, T; Takeda, R | 1 |
| Barroso-Chinea, P; Conte-Perales, L; Gómez-Bautista, V; Lanciego, JL; Luquin, N; Rico, AJ; Roda, E; Sierra, S | 1 |
| Alachkar, A; Brotchie, JM; Jones, OT | 1 |
| Gomez Heredia, MJ; Pérez Errazquin, F | 1 |
| Carlsson, T; Döbrössy, M; García, J; Nikkhah, G; Winkler, C | 1 |
| Jog, MS; Rahimi, F; Typlt, M | 1 |
| Egeland, M; Svenningsson, P; Zhang, X | 1 |
| Ludin, HP | 1 |
| Irie, S; Kanazawa, N; Mochizuki, H; Nomura, Y; Ryoh, M; Segawa, M | 1 |
| Barroso-Chinea, P; Berthet, A; Bezard, E; Canron, MH; Charron, G; Delalande, F; Doudnikoff, E; Giros, B; Goumon, Y; Laux, A; Li, Q; Nosten-Bertrand, M; Porras, G; Qin, C; Van Dorsselaer, A; Vital, A | 1 |
| Cenci, MA; Francardo, V; Konradi, C; Lees, AJ; Lindgren, HS; Luksik, AS; O'Sullivan, SS; Ohlin, KE; Sillivan, SE; Vassoler, FM | 1 |
| Ahlskog, JE; Josephs, KA; Klassen, BT; Lee, KH; Matsumoto, JY; Savica, R; Stead, M | 1 |
| Dziubina, A; Gołembiowska, K | 1 |
| Cai, Y; Liu, Z; Ren, T; Wu, N; Yang, X; Yuan, W | 1 |
| Ahlskog, JE; Josephs, KA; Kumar, N; Matsumoto, JY; McKeon, A; Savica, R | 1 |
| Johnston, TH; Lane, EL | 1 |
| Aristieta, A; Cenci, MA; Miguelez, C; Ugedo, L | 1 |
| Bagetta, V; Bonito-Oliva, A; Calabresi, P; Carta, M; Di Luca, M; Errico, F; Fisone, G; Gardoni, F; Marinucci, S; Napolitano, F; Picconi, B; Romano, R; Usiello, A; Vitucci, D; Zianni, E | 1 |
| Inoue, M; Inoue, Y; Kishimoto, T; Kiuchi, K; Kosaka, J; Morikawa, M; Norimoto, K | 1 |
| Gerhardt, E; Kermer, P; Schulz, JB; Szego, ÉM | 1 |
| Babapour, V; Mahmoudi, J; Nayebi, AM; Reyhani-Rad, S; Samini, M | 1 |
| Janssen, ML; Sager, TN; Temel, Y; Westin, JE | 1 |
| Dietrichs, E; Toft, M | 1 |
| Modo, M; Vernon, AC | 1 |
| Chao, OY; Huston, JP; Mattern, C; Nikolaus, S; Pum, ME; Ruocco, LA; Silva, AM; Wessler, J | 1 |
| Chiba, S; Kadoyama, K; Kato, S; Suzuki, N; Tadokoro, M; Takada, E; Takenokuchi, M; Taniguchi, T | 1 |
| Cacciatore, I; Conte, C; Cornacchia, C; Minelli, A; Pinnen, F | 1 |
| Brioschi, A; Mauro, A; Pignatti, R; Semenza, C; Wenter, J; Zamarian, L | 1 |
| Barroso-Chinea, P; Baufreton, J; Berthet, A; Bezard, E; Bloch, B; Dehay, B; Fasano, S; Giros, B; Li, Q; Martin-Negrier, ML; Martinez, A; Nosten-Bertrand, M; Porras, G; Thiolat, ML | 1 |
| Ago, Y; Hiramatsu, N; Matsuda, T; Ota, Y; Takahashi, T; Takuma, K; Tanaka, T | 1 |
| Goldstein, DS; Holmes, C; Sharabi, Y | 1 |
| Abuirmeileh, A; Bloom, SR; Harkavyi, A; Lever, R; Rampersaud, N; Tadross, JA; Whitton, PS | 1 |
| Abbruzzese, G; Antonini, A; Barone, P; Bonuccelli, U; Capus, L; Ceravolo, R; Cilia, R; Colosimo, C; Guerra, UP; Lopiano, L; Marconi, R; Morgante, L; Petrone, A; Quatrale, R; Ramat, S; Righini, A; Stefani, A; Tamma, F; Tinazzi, M; Vitale, C; Zappia, M | 1 |
| Billet, F; Costentin, J; Dourmap, N | 1 |
| Grady, SR; Hrachova, M; Huang, LZ; Mallela, A; McIntosh, JM; Park, KM; Quik, M | 1 |
| Bishop, C; Eskow Jaunarajs, KL; George, JA | 1 |
| Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB | 1 |
| Chung, SJ; Kim, J; Kim, JS; Kim, KK; Lee, CS; Lim, YM; Park, HK | 1 |
| Bateup, HS; Feyder, M; Fisone, G; Gangarossa, G; Greengard, P; Santini, E | 1 |
| Quintana, A; Savasta, M; Sgambato-Faure, V | 1 |
| Bishop, C; Buchta, W; Dickinson, SO; Eissa, S; Eskow Jaunarajs, KL; George, JA; Goldenberg, AA; Mohamed, M | 1 |
| Darmopil, S; Espadas, I; Martín, ED; Moratalla, R; Oliva, I; Ortiz, O; Vergaño-Vera, E; Vicario-Abejón, C | 1 |
| Camargos, S; Cardoso, F; Lees, AJ; Singleton, A | 1 |
| Berger, SP; Giuffrida, A; Johnson, SW; Macheda, T; Martinez, AA; Meshul, CK; Paquette, MA | 1 |
| Chang, CC; Chang, WN; Chen, CH; Chen, NC; Huang, CW; Huang, SH; Lee, CC; Lin, YT; Lui, CC | 1 |
| Desrayaud, S; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Morin, N; Morissette, M | 1 |
| Everett, CM; Houlden, H; Kara, E; Maresh, KE | 1 |
| Brotchie, JM; Damude, S; Fox, SH; Huot, P; Johnston, TH; Jones, SW; Rusche, JR | 1 |
| Di Paolo, T; Lévesque, D; Morissette, M; Parent, M; Riahi, G; Rouillard, C; Samadi, P | 1 |
| Camargos, S; Cardoso, F | 1 |
| Agosti, V; Amboni, M; Barone, P; Fasano, A; Iavarone, A; Iuppariello, L; Lista, I; Picillo, M; Santangelo, G; Sorrentino, G; Tranfaglia, R; Vitale, C | 1 |
| Gittis, A | 1 |
| Breger, LS; Dunnett, SB; Lane, EL | 1 |
| Hatano, T; Hattori, N; Kubo, S; Niijima-Ishii, Y; Sugita, Y | 1 |
| Chen, Y; Hong, X; Liu, Z; Song, L; Wu, N; Yang, X; Yuan, W | 1 |
| Bagetta, V; Calabresi, P; Del Papa, G; Gardoni, F; Ghiglieri, V; Giampà, C; Pendolino, V; Picconi, B; Sgobio, C; Tozzi, A; Zianni, E | 1 |
| Auburger, G; Dehorter, N; Gispert, S; Hammond, C; Klinkenberg, M; Lopez, C; Lozovaya, N; Mdzomba, BJ; Michel, FJ; Tsintsadze, T; Tsintsadze, V | 1 |
| Arai, A; Baba, M; Kimura, T; Migita, K; Mori, F; Nishijima, H; Tomiyama, M; Ueno, S; Wakabayashi, K; Yamada, J | 1 |
| Bezard, E; Dupouy, S; Galitzky, M; Li, Q; Marquine, L; Meissner, WG; Milhet, A; Nègre-Pagès, L; Ory-Magne, F; Rascol, O; Spampinato, U; Thiolat, ML; Thiollier, T; Tison, F | 1 |
| Burne, JA; Cathers, I; Cordato, D; Tawadros, PB | 1 |
| Baraduc, P; Broussolle, E; Desmurget, M; Gan, J; Thobois, S | 1 |
| Barbon, A; Fiorentini, C; Missale, C; Savoia, P; Savoldi, D | 1 |
| Bjarnason, I; Charlett, A; Dobbs, RJ; Dobbs, SM; Iguodala, O; Lawson, AJ; Smee, C; Taylor, D; Weller, C | 1 |
| Bordia, T; McIntosh, JM; Quik, M | 1 |
| Hong, JY; Kim, KM; Lee, PH; Sohn, YH; Sunwoo, MK | 1 |
| Bezard, E; Björklund, A; Carta, M; Li, Q; Pioli, EY; Porras, G; Tronci, E | 1 |
| Barone, P; Cicarelli, G; De Michele, G; Pellecchia, MT; Pizzolato, G | 1 |
| Björklund, A; Cenci, MA; Kirik, D; Winkler, C | 1 |
| Dass, B; Engber, TM; Galdes, A; Iravani, MM; Jackson, MJ; Jenner, P | 1 |
| Balestre, E; Chrysostome, V; Poewe, W; Quinn, NP; Tison, F; Wenning, GK; Yekhlef, F | 1 |
| Berciano, J; Ferrer, I; Marín, C; Pascual, J; Rey, MJ; Rumià, J; Tolosa, E; Valldeoriola, F | 1 |
| Bar-Gad, I; Bergman, H; Goldberg, JA; Heimer, G | 1 |
| Chang, JW; Kang, UJ; Lee, WY; Milstien, S | 1 |
| Chang, HC; Chen, RS; Lu, CS; Tsai, CH; Wu Chou, YH; Yen, TC | 1 |
| Archer, T; Fredriksson, A; Palomo, T | 1 |
| Cenci, MA | 2 |
| Archer, T; Fredriksson, A | 2 |
| Bacci, JJ; Kerkerian-Le Goff, L; Salin, P | 1 |
| Bonastre, M; Bové, J; Marin, C; Tolosa, E | 2 |
| Ohye, C; Shibazaki, T | 1 |
| de Rooij, SE; Jansen, PA; Moons, CG; Samson, MM; Verhaar, HJ | 1 |
| Aziz, TZ; Giladi, N; Nandi, D; Stein, JF; Winter, J | 1 |
| Bibbiani, F; Chase, TN; Oh, JD | 2 |
| Feldon, J; Mintz, M; Mura, A | 1 |
| Battaglia, G; Bernardi, G; Calabresi, P; Centonze, D; Nicoletti, F; Picconi, B; Pisani, A; Storto, M | 1 |
| Cannizzaro, C; Jenner, P; Pearce, RK; Rose, S; Tel, BC; Zeng, BY | 1 |
| Bioulac, B; Fernagut, PO; Ghorayeb, I; Stefanova, N; Tison, F; Wenning, GK | 1 |
| Caudle, WM; Miller, GW; Reverón, ME; Tillerson, JL | 1 |
| Hirsch, EC; Muriel, MP; Orieux, G | 1 |
| Brotchie, J; Crossman, A; Fox, SH; Henry, B; Hill, M | 1 |
| Al-Barghouthy, G; Jackson, M; Jenner, P; Kuoppamäki, M; Quinn, N; Smith, L; Zeng, BY | 1 |
| Chacón, J; García-Moreno, JM | 1 |
| Angelucci, ME; Canteras, NS; Da Cunha, C; Takahashi, RN; Wonnacott, S | 1 |
| Bonastre, M; Hirsch, EC; Marin, C; Périer, C; Tolosa, E | 1 |
| Cannizzaro, C; Jackson, MJ; Jenner, P; Maratos, EC; Pearce, RK | 1 |
| D'Andreamatteo, G; Iacono, D; Luciano, AL; Onofrj, M; Thomas, A | 1 |
| Benecke, R | 1 |
| Aniello, MS; De Mari, M; Defazio, G; Lamberti, P; Zenzola, A | 1 |
| Ferrannini, E; Fraddosio, A; Iliceto, G; Lamberti, S; Maggio, F; Palagano, G; Russo, I; Serlenga, L; Zoccolella, S | 1 |
| Beani, L; Bianchi, C; Marti, M; Mela, F; Morari, M; Paganini, F; Stocchi, S | 1 |
| Minagar, A; Shulman, LM; Weiner, WJ | 1 |
| Bezard, E; Bioulac, B; Dovero, S; Gross, CE; Jaber, M; Ravenscroft, P | 1 |
| Cenci, MA; Lundblad, M; Vaudano, E | 1 |
| Farrer, MJ; Hulihan, M; Hussey, JM; Krygowska-Wajs, A; Tsuboi, Y; Uitti, RJ; Wszolek, ZK | 1 |
| Balmaceda, C; Chuang, C; Constantino, A; Eidelberg, D; Frucht, SJ | 1 |
| Chung, YA; Han, SR; Kim, JS; Lee, KS | 1 |
| Gerlach, M; Riederer, P | 1 |
| Bernardi, G; Calabresi, P; Cenci, MA; Centonze, D; Fisone, G; Greengard, P; Håkansson, K; Picconi, B | 1 |
| Bird, T; Farrer, M; Gancher, S; Gwinn-Hardy, K; Hardy, J; Hussey, J; Lockhart, P; McNeal, MG; Nutt, J; Payami, H; Seltzer, WK; Singleton, AA; Singleton, AB | 1 |
| Chase, TN; Geller, AI; Oh, JD; Zhang, Gr | 1 |
| Bari, M; Battista, N; Bernardi, G; Calabresi, P; Centonze, D; Finazzi-Agrò, A; Gubellini, P; Maccarrone, M; Picconi, B | 1 |
| Hansard, MJ; Jackson, MJ; Jenner, P; Maratos, E; Smith, LA | 1 |
| Bhatia, KP; Critchley, P; Graham, E; Khan, NL; Lees, AJ; Quinn, N; Schrag, AE; Wood, NW | 1 |
| Balash, Y; Bartels, AL; Giladi, N; Gurevich, T; Hausdorff, JM; Schaafsma, JD | 1 |
| Love, R | 1 |
| Brotchie, JM; Crossman, AR; Engstrom, M; Fox, SH; Hill, M; McGuire, SG; Merivuori, H; Savola, JM; Wurster, S | 1 |
| Brice, A; Illarioshkin, SN; Ivanova-Smolenskaya, IA; Limborska, SA; Lücking, CB; Markova, ED; Miloserdova, OV; Periquet, M; Rawal, N; Slominsky, PA; Zagorovskaya, TB | 1 |
| Chassain, C; Durif, F; Eschalier, A | 2 |
| Iida, Y; Saji, H; Shimazu, S; Takahata, K; Tamashiro, A; Yoneda, F | 1 |
| Hironishi, M; Kondo, T; Miwa, H; Nakanishi, I | 1 |
| Culjković, B; Djarmati, A; Dragasević, N; Kostić, VS; Romac, S; Savić, D; Svetel, M | 1 |
| Bonastre, M; Hirsch, EC; Jimenez, A; Marin, C; Périer, C; Tolosa, E | 1 |
| Albin, RL; Desmond, TJ; Frey, KA; Kemmerer, ES; Kilbourn, MR | 1 |
| Landry, E; Lévesque, D; Rouillard, C; St-Hilaire, M | 1 |
| GERSTENBRAND, F; PATEISKY, K; PROSENZ, P | 1 |
| BAUMANN, D; UMBACH, W | 1 |
| HIRSCHMANN, J; MAYER, K | 1 |
| DIEMATH, HE; ENGE, S; HEPPNER, F; LECHNER, H | 1 |
| BIRKMAYER, W; HORNYKIEWICZ, O | 1 |
| Geser, F; Stampfer-Kountchev, M; Tison, F; Wenning, GK | 1 |
| Jenner, P | 1 |
| Grossman, RG; Hamilton, WJ; Jankovic, J; Kalhorn, CG; Ondo, WG; Sanghera, MK | 1 |
| Iravani, MM; Jackson, MJ; Jenner, P; Kuoppamäki, M; Smith, LA | 1 |
| Avila Cobo, MR; Cardozo, A; Katzenschlager, R; Lees, AJ; Tolosa, E | 1 |
| Bösch, S; Brenneis, C; Büchel, C; Löscher, WN; Luginger, E; Müller, J; Poewe, W; Schocke, MF; Seppi, K; Wenning, GK | 1 |
| Liu, HM; Su, PC; Tseng, HM | 1 |
| Dryhurst, G; Foster, SB; Han, J; Wrona, MZ | 1 |
| Ceballos-Baumann, A | 1 |
| Lualdi, MM; Pasetti, C; Pinelli, P | 1 |
| Komatsu, Y; Matsuda, W; Matsumura, A; Nose, T; Yanaka, K | 1 |
| Bonastre, M; Bové, J; Jiménez, A; Marin, C; Tolosa, E | 1 |
| Delfino, MA; Douhou, A; Ferrario, JE; Gershanik, OS; Murer, MG; Raisman-Vozari, R; Stefano, AV; Zbarsky, V | 1 |
| Hwang, WJ; Ting, G; Wey, SP; Yao, WJ | 1 |
| Bezard, E; Brotchie, JM; Crossman, AR; Grimée, R; Hill, MP; Klitgaard, H; McGuire, SG; Michel, A | 1 |
| Carta, AR; Morelli, M; Pinna, A; Tronci, E | 1 |
| Bastia, E; Chen, JF; Fredduzzi, S; Moratalla, R; Ongini, E; Schwarzschild, MA; Yu, L | 1 |
| Aoyama, S; Bedard, P; Borrelli, E; Chase, TN; Hauser, RA; Ichimura, M; Ikeda, K; Ishii, A; Jenner, P; Kanda, T; Kase, H; Koga, K; Koike, N; Kurokawa, M; Kuwana, Y; Mori, A; Nakamura, J; Nonaka, H; Ochi, M; Richardson, PJ; Saki, M; Shimada, J; Shindou, T; Shiozaki, S; Suzuki, F; Takeda, M; Yanagawa, K | 1 |
| Bara-Jimenez, W; Bibbiani, F; Chase, TN; Dimitrova, T; Oh-Lee, JD | 1 |
| Ghil, GS; Joo, WS; Kim, EY; Kim, YS; Lee, YJ; Lim, J; Park, S; Wang, KC | 1 |
| Brotchie, JM; Chalon, S; Crossman, AR; Ravenscroft, P | 1 |
| Cheetham, SC; Hansard, MJ; Jackson, MJ; Jenner, P; Smith, LA | 1 |
| Bruno, MK; Considine, E; Garraux, G; Gwinn-Hardy, K; Hallett, M; Hanson, M; Johnson, J; Ptacek, L; Ravina, B; Singleton, A | 1 |
| Kase, H; Ochi, M; Shiozaki, S | 1 |
| Allard, M; Guyot, M; Sibon, I; Tison, F | 1 |
| De Groote, C; Fischer, G; Jenner, P; Kemp, JA; Klockgether, T; Löschmann, PA; Smith, L; Wüllner, U | 1 |
| Der, TC; Hagner, D; Joyce, JN; Osredkar, T; Renish, L; Reploge, M; Sakakibara, S; Ueda, S | 1 |
| Alam, M; Mayerhofer, A; Schmidt, WJ | 1 |
| Benecke, R; Classen, J; Grossmann, A; Kunesch, E; Wolters, A | 1 |
| Arai, H; Fujihara, K; Ichinose, H; Itoyama, Y; Kikuchi, A; Kimpara, T; Nagai, M; Okamura, N; Shiga, Y; Takeda, A; Tanji, H; Urano, F | 1 |
| Barker, RA; Brown, JM; Wilkins, A | 1 |
| Carter, JH; Nutt, JG; Sexton, GJ | 1 |
| Bernardi, G; Calabresi, P; Cenci, MA; Centonze, D; Di Luca, M; Gardoni, F; Mauceri, D; Picconi, B | 1 |
| Brotchie, JM; Crossman, AR; Millan, MJ; Nicholson, SL; Ravenscroft, P; Silverdale, MA | 1 |
| Bird, TD; Bower, J; Calne, DB; de la Fuente-Fernandez, R; Farrer, M; Furtado, S; Gwinn-Hardy, K; Hanson, M; Hardy, J; Klimek, ML; Lockhart, PJ; Nutt, JG; Payami, H; Singleton, A; Singleton, AA; Stoessl, AJ; Suchowersky, O; Tsuboi, Y; Utti, RJ; Wszolek, ZK | 1 |
| Brotchie, JM; Crossman, AR; McGuire, S; Menniti, FS; Nash, JE; Ravenscroft, P | 1 |
| Berciano, J; Combarros, O; Corral, J; Infante, J; Pascual, J; Polo, JM; Volpini, V | 1 |
| Chen, CM; Lee-Chen, GJ; Tang, LM; Wang, CK; Wang, SC; Wu, YR | 1 |
| Alam, M; Schmidt, WJ | 1 |
| Al-Din, A; Lily, O | 1 |
| Baba, H; Hida, H; Isono, M; Jung, CG; Kobayashi, H; Kodama, Y; Nishino, H | 1 |
| Asaoka, E; Dohgu, N; Inoue, H; Taguchi, Y; Takashima, S | 1 |
| Annesi, F; Annesi, G; Bellesi, M; Candiano, IC; Capecci, M; Carrideo, S; Ceravolo, MG; Civitelli, D; De Marco, EV; Iacoangeli, M; Passamonti, L; Provinciali, L; Quattrone, A; Ricciuti, R; Scerrati, M; Tarantino, P; Zappia, M | 1 |
| Auberson, YP; Greenamyre, JT; Papa, SM | 1 |
| Antenor, J; Black, KJ; Burkey, A; Esper, GJ; Kotagal, V; Moerlein, SM; Ojemann, JG; Perlmutter, JS; Racette, BA; Videen, TO | 1 |
| Aubert, I; Barthe, N; Bezard, E; Bioulac, BH; Bloch, B; Dovero, S; Fisone, G; Gross, CE; Guigoni, C; Håkansson, K; Li, Q | 1 |
| Shinotoh, H | 1 |
| Birman, S; Coulom, H | 1 |
| Chang, S; Davis, M; Eunson, L; Graham, E; Horta, W; Johnson, JO; Khan, NL; Lees, AJ; Singleton, A; Wood, NW | 1 |
| Bielicki, G; Chassain, C; Donnat, JP; Durif, F; Eschalier, A; Renou, JP | 1 |
| Glöckler, T; Junghanns, S; Reichmann, H | 1 |
| Akalan, N; Arica, B; Hincal, AA; Kaş, HS; Moghdam, A | 1 |
| Benovic, JL; Bezard, E; Gross, CE; Gurevich, EV; Gurevich, VV; Qin, L | 1 |
| Aguilar, E; Bonastre, M; Marin, C; Obeso, JA; Tolosa, E | 1 |
| Amalric, M; Baunez, C; Breysse, N; Turle-Lorenzo, N | 1 |
| Aubert, I; Bezard, E; Bioulac, BH; Bloch, B; Crossman, AR; Dovero, S; Gross, CE; Guigoni, C; Li, Q | 2 |
| Ardayfio, P; Chesselet, MF; Fleming, SM; Hwang, DY; Kim, H; Kim, KS; Moran-Gates, T; Tarazi, FI | 1 |
| Birk Møller, L; Diepold, K; Güttler, F; Hougaard, P; Romstad, A; Rostasy, K; Schütz, B; Wilken, B | 1 |
| Jech, R; Mecír, P; Roth, J; Růzicka, E; Urgosík, D; Vladyka, V; Vymazal, J | 1 |
| Berendse, HW; Booij, J; Farrer, MJ; Hulihan, MM; Kachergus, JM; Krygowska-Wajs, A; Searcy, JA; Wolters, ECh; Wszolek, ZK | 1 |
| Chen, L; Di Monte, DA; Langston, JW; Quik, M; Togasaki, DM | 1 |
| Connell, MA; Emborg, ME; Li, Q; Meglasson, MD; Merchant, K; Simmons, C; Stephenson, DT | 1 |
| Alvarez, L; Castro, A; Gimenez-Roldan, S; Grandas, F; Hernandez, B; Jenner, P; Linazasoro, G; Luquin, MR; Macias, R; Marin, C; Obeso, JA; Pavon, N; Rodriguez, M; Rodriguez-Oroz, MC; Stochi, F; Tolosa, E; Vaamonde, J; Valldeoriola, F | 1 |
| Carta, M; Cenci, MA; Fisone, G; Håkansson, K; Lundblad, M; Usiello, A | 1 |
| Bernauer, E; Finsterer, J | 1 |
| Ding, JH; Hu, G; Liu, SY; Liu, X; Long, Y; Sun, YH; Wang, F; Wang, H; Wu, J; Yang, Y; Yao, HH | 1 |
| Alvano, A; Battaglia, G; Malaguarnera, M; Raffaele, R; Rampello, L; Vecchio, I | 1 |
| Bédard, PJ; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R | 1 |
| Albanese, A; Bellacchio, E; Dallapiccola, B; Elia, AE; Romito, LM; Valente, EM | 1 |
| al-Din, AS; Hadeed, A; Lees, AJ; Williams, DR; Wreikat, AL | 1 |
| Bédard, PJ; Di Paolo, T; Grégoire, L; Hadj Tahar, A; Rouillard, C; Samadi, P | 1 |
| Cha, GH; Cho, KS; Chung, J; Kim, JM; Kim, M; Kim, S; Lee, E; Lee, SB; Park, J | 1 |
| Brown, AM; Colbran, RJ; Deutch, AY | 1 |
| Aubert, I; Bezard, E; Bioulac, BH; Bloch, B; Dovero, S; Gross, CE; Guigoni, C; Gurevich, EV; Li, Q | 1 |
| Benabid, AL; Fraix, V; Gentil, M; Krack, P; Pinto, S; Pollak, P; Sauleau, P | 1 |
| Diguet, E; Fernagut, PO; Ghorayeb, I; Tison, F | 1 |
| Glavan, G; Zivin, M | 1 |
| Bédard, PJ; Calon, F; Di Paolo, T; Dridi, M; Hadj Tahar, A; Meltzer, LT; Morissette, M | 1 |
| Martín, AB; Mendialdua, A; Moratalla, R; Pavón, N | 1 |
| Hedrich, K; Kann, M; Kis, B; Klein, C; Kömpf, D; Pramstaller, PP; Schwinger, E | 1 |
| Bhat, V; Weiner, WJ | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Miyazaki, I; Miyoshi, K; Ogawa, N | 1 |
| Obara, K; Ohta, K | 1 |
| Bédard, PJ; Bélanger, N; Di Paolo, T; Grégoire, L | 1 |
| Björklund, A; Carlsson, T; Cenci, MA; Kirik, D; Lundblad, M; Winkler, C | 1 |
| Haapasalo, H; Honkaniemi, J; Kähärä, V; Liimatainen, S; Paetau, A | 1 |
| Haberkorn, U; Hähnel, S; Krause, M; Meinck, HM | 1 |
| Goto, S; Kaji, R; Kuratsu, J; Yamada, K | 1 |
| Cersosimo, MG; Koller, WC | 1 |
| Brundin, P; Cenci, MA; Lane, EL; Winkler, C | 1 |
| Aguilar, E; Marin, C; Obeso, JA | 1 |
| Bédard, PJ; Berthiaume, L; Calon, F; Di Paolo, T; Hadj-Tahar, A; Julien, C; Julien, P; Rajput, AH | 1 |
| Barthel, H; Hesse, S; Oehlwein, C; Polster, D; Sabri, O; Schwarz, J; Wagner, A | 1 |
| Annie Hsieh, W; Chen, SY; Chou, YC; Hsin, YL; Lee, CC; Lee, CW; Lee, TW; Lin, SH; Lin, SZ; Su, CF; Yen, PS | 1 |
| Aguilar, E; Bové, J; Cortés, R; Marin, C; Mengod, G; Serrats, J | 1 |
| Brundin, P; Popovic, N | 1 |
| Ahlskog, JE; Josephs, KA; Matsumoto, JY | 1 |
| Carta, M; Cenci, MA; Fadda, F; Lindgren, HS; Lundblad, M; Stancampiano, R | 1 |
| Bagetta, V; Bernardi, G; Calabresi, P; Cattabeni, F; Di Luca, M; Gardoni, F; Ghiglieri, V; Picconi, B; Polli, F | 1 |
| Konitsiotis, S; Tsironis, C | 1 |
| Aziz, TZ; Jenkinson, N; Nandi, D; Stein, JF | 1 |
| Linazasoro, G; Magariños, C; Van Blercom, N | 1 |
| Berry-Kravis, E; Hagerman, PJ; Hagerman, RJ; Hall, DA; Leehey, MA; Rice, CD | 1 |
| Baraldi, PG; Fenu, S; Morelli, M; Simola, N; Tabrizi, MA | 1 |
| Bishop, C; Eskow, KL; Kuhn, DM; Park, JY; Taylor, JL; Walker, PD | 1 |
| Fujiki, N; Sasaki, H; Soma, H; Takei, A; Yabe, I; Yanagihara, T | 1 |
| Bex, V; Daenen, F; Maertens de Noordhout, A | 1 |
| Bain, PG; Hensman, DJ | 1 |
| Carta, AR; Morelli, M; Pinna, A | 1 |
| Ai, Y; Andersen, AH; Gash, DM; Gerhardt, GA; Hardy, PA; Loveland, A; Zhang, Z | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Pires, D; Visanji, NP; Voon, V | 1 |
| Brotchie, JM; Fox, SH; Gomez-Ramirez, J; Johnston, TH; Visanji, NP; Voon, V | 1 |
| Brundin, P; Cenci, MA; Gardi, J; Lindgren, HS; Mohapel, P; Nyengaard, JR; Westin, JE | 1 |
| Kanzato, N; Murao, H; Nishihira, T; Takara, H | 1 |
| Aggarwal, A; Bhatt, M; Desai, S; Shah, S; Singh, J; Vaidya, S | 1 |
| Eusebio, A; Gubellini, P; Kerkerian-Le Goff, L; Melon, C; Oueslati, A; Salin, P | 1 |
| Giasson, BI; Ischiropoulos, H; Lynch, DR; Mazzulli, JR; Mishizen, AJ; Nagatsu, T; Nakashima, A; Ota, A; Thomas, SA | 1 |
| Pierce, RC; Soghomonian, JJ; Yamamoto, N | 1 |
| Ahmed, M; Bohlega, S; Carroll, P; Chishti, MA; Loualich, A; Rogaeva, E; Sato, C; St George-Hyslop, P; Westaway, D | 1 |
| Battaglia, F; Di Rocco, A; Eidelberg, D; Feigin, AS; Ghilardi, MF; Mattis, P; Silvestri, G | 1 |
| Caron, MG; Gainetdinov, RR | 1 |
| Köllensperger, M; Poewe, W; Reindl, M; Stefanova, N; Wenning, GK | 1 |
| Barker, RA; Kuan, WL; Lin, R; Tyers, P | 1 |
| Bastia, E; Benn, CL; Cha, JH; Chen, JF; Peterson, TS; Schwarzschild, MA; Xiao, D; Xu, YH | 1 |
| Jenner, P; Ramsay Croft, N; Rose, S | 1 |
| Dagostino, P; Katz, J; Soghomonian, JJ; Wang, H | 1 |
| Muhlack, S; Müller, T; Welnic, J; Woitalla, D | 1 |
| Gacsalyi, I; Harsing, LG; Juranyi, Z; Levay, G; Marko, B; Megyeri, K; Sziray, N | 1 |
| Marti, M; Morari, M; Trapella, C; Viaro, R | 1 |
| Colau, JC; Ha, DE; Legendre, G | 1 |
| Cenci, MA; Danysz, W; Dekundy, A; Lundblad, M | 1 |
| Chen, L; Cox, H; Di Monte, DA; Langston, JW; Quik, M; Togasaki, DM | 1 |
| Bezard, E; Bloch, B; Doudnikoff, E; Guigoni, C; Li, Q | 1 |
| de Freitas, GR; Fontenelle, LF; Garcia, RF; Mendlowicz, MV; Nazar, BP; Ordacgi, L; Rosso, AL | 1 |
| Jackson, MJ; Jenner, P; Katzenschlager, R; Lees, AJ; Rose, S; Smith, LA; Stockwell, K; Tayarani-Binazir, KA; Zubair, M | 1 |
| Finberg, JP; Sader-Mazbar, O | 1 |
| Abin-Carriquiry, JA; Costa, G; Dajas, F; Ferreira, M; Urbanavicius, J; Wonnacott, S | 1 |
| Ding, Y; Hwang, DY; Kang, UJ; Kim, KS; Restrepo, J; Won, L | 1 |
| Carvajal-Gonzalez, S; Childs, MA; Emborg, ME; Li, Q; Meglasson, MD; Merchant, K; Opsahl, A; Stephenson, DT; Tengowski, M | 1 |
| Chung, EJ; Jeon, MY; Kang, HY; Lee, WY | 1 |
| Constantinescu, R; Kurlan, R; Richard, I | 1 |
| Aarsland, D; Boeve, B; Gjerstad, MD; Larsen, JP; Wentzel-Larsen, T | 1 |
| Damier, P; Meyniel, C | 1 |
| Choi, JK; Iris Chen, YC; Isacson, O; Jenkins, BG; Sánchez-Pernaute, R | 1 |
| Kaneda, D; Oyanagi, K; Shintaku, M | 1 |
| Mosekilde, L; Rejnmark, L; Vestergaard, P | 1 |
| Calon, F; Di Paolo, T; Dridi, M; Huot, P; Lévesque, M; Morissette, M; Parent, A | 1 |
| Aalto, S; Chang, JW; Lee, KO; Lee, MS; Lyoo, CH; Oh, SH; Rinne, JO | 1 |
| Pavanni, R; Tan, EK; Tong, J; Wong, MC; Zhao, Y | 1 |
| Bédard, PJ; Di Paolo, T; Grégoire, L; Guidetti, P; Izzo, E; Rassoulpour, A; Samadi, P; Schwarcz, R | 1 |
| Guan, Q; He, Y; Tan, L; Zhan, Q | 1 |
| Cox, H; Di Monte, D; Langston, JW; O'Leary, K; Parameswaran, N; Quik, M | 1 |
| Ha Paek, S; Jeon, BS; Kim, HJ; Kim, JY | 1 |
| Dressler, D; Lindemann, C; Miranda, M; Slachevsky, A; Walter, U | 1 |
| Bédard, PJ; Belanger, N; Calon, F; Di Paolo, T; Dridi, M; Hadj Tahar, A; Meltzer, LT; Morissette, M; Samadi, P | 1 |
| Chen, ST; Chu, YC; Huang, YC; Lyu, RK; Wu, YR | 1 |
| Binelli, S; Bugiani, O; Capobianco, R; Di Fede, G; Fociani, P; Giaccone, G; Grisoli, M; Limido, L; Mangieri, M; Suardi, S; Tagliavini, F | 1 |
| Alvarez-Erviti, L; Barroso-Chinea, P; Blesa, FJ; Guridi, J; Lanciego, JL; Obeso, JA; Rodríguez-Oroz, MC; Smith, Y | 1 |
| Agid, Y; Brice, A; Durr, A; Fraix, V; Houeto, JL; Krack, P; Laine, S; Lesage, S; Lohmann, E; Mesnage, V; Pollak, P; Tanguy, ML; Welter, ML | 1 |
| Chung, SJ; Ki, CS; Kim, MJ; Lee, MC; Park, HK | 1 |
| Brotchie, JM; Gomez-Ramirez, J; Johnston, TH; Lee, J; Visanji, N | 1 |
| Asanuma, M; Diaz-Corrales, FJ; Eslava-Alva, MJ; Higashi, Y; Miyazaki, I; Ogawa, N; Shimizu, M | 1 |
| Cheetham, S; Jenner, P; Lane, EL | 1 |
| Maeda, T; Nagata, K; Yoshida, Y | 1 |
| Muthane, U; Ragothaman, M | 1 |
| Bordet, R; Derambure, P; Destée, A; Houdayer, E; Jacquesson, JM; Laloux, C; Monaca, C | 1 |
| Brown, P; Doyle, LM; Lees, AJ; Williams, DR | 1 |
| Bermejo, PG; Espiga, PJ; López, IC; Tapia, DQ | 1 |
| Artusi, R; Caselli, G; Lanza, M; Makovec, F; Michotte, Y; Sarre, S | 1 |
| Kamogawa, K; Kawabata, K; Okamoto, K; Okuda, B; Tachibana, H | 1 |
| Bezard, E; Brotchie, JM; Fox, SH; Hallett, PJ; Lubin, FD; Nicholas, AP; Ravenscroft, P; Standaert, DG; Sweatt, JD; Vattem, P; Zhou, S | 1 |
| Bankiewicz, KS; Cummins, A; Eberling, J; Kohutnicka, M; Oiwa, Y; Sanchez-Pernaute, R | 1 |
| Cenci, MA; Lundblad, M | 1 |
| Netravathi, M; Pal, PK; Panda, S; Prashantha, DK; Ravishankar, S | 1 |
| Orta Daniel, SJ; Ulises, RO | 1 |
| Caslake, R; Counsell, C; Gordon, JC; Harris, CE; Moore, JN | 1 |
| Abuirmeileh, A; Biggs, CS; Harkavyi, A; Kingsbury, AE; Lever, R; Whitton, PS | 1 |
| Willis, GL | 1 |
| Boxer, PA; Gregory, TF; Meltzer, LT; Serpa, KA; Wise, LD; Wright, JL | 1 |
| Desimone, R; Fiorani, M; Oldfield, EH; Papa, SM | 1 |
| Andersson, M; Cenci, MA; Hilbertson, A; Tranberg, A | 1 |
| Andersson, M; Cenci, MA; Hilbertson, A | 1 |
| Ben-Aire, L; Contant, C; Grossman, R; Jankovic, J; Lai, E; Ondo, WG | 1 |
| Albanese, A; Colosimo, C; Moro, E; Rossi, P; Tonali, P | 1 |
| Bonastre, M; Chase, TN; Jimenez, A; Marin, C; Tolosa, E | 1 |
| Di Monte, DA; He, L; Langston, JW; Police, S; Quik, M | 1 |
| Bangassoro, E; Bédard, PJ; Bélanger, N; Grégoire, L; Hadj Tahar, A | 1 |
| Brusa, L; Gasparini, M; Meco, G; Vanacore, N | 1 |
| Emre, M; Hanağasi, HA; Kaptanoglu, G; Sahin, HA | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Doucet, JP; Goulet, M; Grondin, R; Hadj Tahar, A; Morissette, M; Nestler, E; Robertson, GS | 1 |
| Chase, TN; Oh, JD | 1 |
| Asanuma, M; Higashi, Y; Miyazaki, I; Nakanishi, T; Ogawa, N; Sogawa, CA; Tanaka, KI | 1 |
| Ebinger, G; Jonkers, N; Michotte, Y; Sarre, S | 2 |
| Vingerhoets, F | 1 |
| Abbruzzese, G; Buccolieri, A; Marchese, R; Trompetto, C | 1 |
| Cabral, J; Gálvez-Jiménez, N; Hanson, MR | 1 |
| Discalzi, G; Herrero Hernandez, E; Meliga, F; Pira, E; Turbiglio, M; Valentini, C | 1 |
| de Rijk-Van Andel, JF; Gabreëls, FJ; Geurtz, B; Smeitink, JA; Steenbergen-Spanjers, GC; van Den Heuvel, LP; Wevers, RA | 1 |
| Kidd, PM | 1 |
| Nutt, JG | 1 |
| Hubble, J; Kieburtz, K | 1 |
| Bangassoro, E; Bédard, PJ; Ekesbo, A; Grégoire, L; Hadj Tahar, A; Svensson, KA; Tedroff, J | 1 |
| Mueller, J; Poewe, W; Puschban, Z; Scherfler, C; Seppi, K; Stefanova, N; Wenning, GK | 1 |
| Hara, A; Matsushita, S; Mita, S; Murakami, T; Nakajima, M; Nakamura, T; Uchino, M; Uyama, E | 1 |
| Casas, M; Pérez, V; Prat, G; Rubi, A; Unzeta, M | 1 |
| Linazasoro, G | 1 |
| Renier, WO; Rondot, P; Steenbergen-Spanjers, GC; Swaans, RJ; Van Den Heuvel, LP; Wevers, RA | 1 |
| Masson, C | 1 |
| García de Yébenes, J; Godoy, M; Hoenicka, J; Ochoa, JJ; Vidal, L | 1 |
| Archer, T; Danysz, W; Fredriksson, A; Quack, G | 1 |
| Gerlach, M; Kuhn, W; Lehnfeld, R; Riederer, P; Sontag, KH; Waldmeier, P; Xiao, AY | 1 |
| Konieczny, J; Lorenc-Koci, E; Wardas, J | 1 |
| Nutt, JG; Nygaard, TG | 1 |
| Eriksson, B; Holmberg, B; Ingvarsson, P; Johnels, B; Rosengren, L | 1 |
| Jackson, MJ; Jenner, P; Maratos, EC; Pearce, RK | 1 |
| Carta, A; Fenu, S; Morelli, M | 1 |
| Ballermann, M; Farr, T; Metz, GA; Whishaw, IQ | 1 |
| Rajput, AH | 1 |
| Jankovic, J; Tintner, R | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Henry, B | 1 |
| Harbord, M | 1 |
| Becker, G; Beckmann, H; Berg, D; Jabs, B; Merschdorf, U | 1 |
| Abe, K; Miyatake, T; Ren, J; Sano, T; Shinohara, T; Taguchi, K; Utsunomiya, I; Wasai, T | 1 |
| Agid, Y; Bonastre, M; Hirsch, EC; Jiménez, A; Marin, C; Tolosa, E; Vila, M | 1 |
| Charles, KJ; Gray, J; Hunter, AJ; Jenner, P; Medhurst, AD; Reavill, C; Shale, JA; Zeng, BY | 1 |
| Andersson, M; Cenci, MA; Lundblad, M; Westin, JE | 1 |
| Boerman, RH; Hoefnagels, WH; Jansen, RW; Mehagnoul-Schipper, DJ | 1 |
| Groenewegen, HJ; Van De Witte, SV; Voorn, P | 1 |
| Albanese, A; Bentivoglio, AR; Cortelli, P; Elia, A; Ferraris, A; Ialongo, T; Montagna, P; Valente, EM | 1 |
| Lee, SJ; Liao, KK; Liu, RS; Shan, DE; Soong, BW; Sun, CM | 1 |
| Kuroiwa, Y; Momose, T; Okada, M; Yamada, H | 1 |
| Abaul, J; Caparros-Lefebvre, D; Hocquemiller, R; Lannuzel, A; Michel, PP; Ruberg, M | 1 |
| Campos, V; García De Yébenes, J; Mena, MA; Meseguer, E; Sánchez, V; Taboada, R | 1 |
| Evidente, VG; Gwinn-Hardy, K; Hardy, J; Hernandez, D; Singleton, A | 1 |
| Cebeira, M; de Ceballos, ML; Fernández-Ruiz, JJ; Jenner, P; Lastres-Becker, I; Ramos, JA; Zeng, BY | 1 |
| Mellgren, SI; Sjøholm, H; Sundsfjord, J | 1 |
| Mathias, CJ | 1 |
| Earl, J; Fung, VS; Grattan-Smith, PJ; Steenbergen-Spanjers, GC; Wevers, RA; Wilcken, B | 1 |
| Finsterer, J | 1 |
| Cho, JW; Chu, K; Jeon, BS; Song, EC | 1 |
59 review(s) available for levodopa and Parkinsonian Disorders
| Article | Year |
|---|---|
"Parkinson's disease" on the way to progressive supranuclear palsy: a review on PSP-parkinsonism.
Topics: Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Supranuclear Palsy, Progressive; Systematic Reviews as Topic | 2021 |
Parkinsonism and dystonia: Clinical spectrum and diagnostic clues.
Topics: Animals; Dystonia; Dystonic Disorders; Humans; Levodopa; Movement Disorders; Parkinsonian Disorders | 2022 |
Parkinsonism-Hyperpyrexia Syndrome and Dyskinesia-Hyperpyrexia Syndrome in Parkinson's Disease: Two Cases and Literature Review.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Parkinson Disease; Parkinsonian Disorders; Syndrome; Tremor | 2022 |
A Review on the Clinical Diagnosis of Multiple System Atrophy.
Topics: Adult; Diagnosis, Differential; Humans; Levodopa; Magnetic Resonance Imaging; Multiple System Atrophy; Parkinsonian Disorders | 2023 |
Autopallidotomy: From Colloquial Term to Scientific Theory.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesias; Globus Pallidus; Levodopa; Parkinson Disease; Parkinsonian Disorders | 2022 |
Food toxins and the Caribbean Parkinson plus types.
Topics: Annonaceae; Caribbean Region; Dementia; Drug Resistance; Food; Guadeloupe; Humans; Levodopa; Martinique; Parkinson Disease; Parkinsonian Disorders; Teas, Herbal; West Indies | 2019 |
Evolving concepts on bradykinesia.
Topics: Animals; Humans; Hypokinesia; Levodopa; Neural Pathways; Parkinsonian Disorders | 2020 |
Genotype-phenotype correlations of adult-onset PLA2G6-associated Neurodegeneration: case series and literature review.
Topics: Adult; Asian People; Cohort Studies; Female; Genetic Association Studies; Group VI Phospholipases A2; High-Throughput Nucleotide Sequencing; Humans; Levodopa; Male; Middle Aged; Mutation; Neuroaxonal Dystrophies; Parkinson Disease; Parkinsonian Disorders; Phenotype | 2020 |
Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review.
Topics: Genotype; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Phenotype | 2021 |
Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders; Rats | 2018 |
Extrapontine Myelinolysis and Reversible Parkinsonism After Hyponatremia Correction in a Case of Pituitary Adenoma: Hypopituitarism as a Predisposition for Osmotic Demyelination.
Topics: Adenoma; Demyelinating Diseases; Female; Humans; Hydrocortisone; Hyponatremia; Hypopituitarism; Levodopa; Middle Aged; Myelinolysis, Central Pontine; Parkinsonian Disorders; Pituitary Neoplasms; Saline Solution, Hypertonic | 2018 |
Juvenile parkinsonism: Differential diagnosis, genetics, and treatment.
Topics: Adolescent; alpha-Synuclein; Antiparkinson Agents; Child; Child, Preschool; Deep Brain Stimulation; Diagnosis, Differential; DiGeorge Syndrome; Dystonic Disorders; Genetic Diseases, X-Linked; Hepatolenticular Degeneration; Humans; Huntington Disease; Levodopa; Parkinsonian Disorders; Protein Deglycase DJ-1; Protein Kinases; Spinocerebellar Ataxias; Ubiquitin-Protein Ligases; Young Adult | 2019 |
A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Disease Models, Animal; Humans; Levodopa; Mice; Motor Activity; Parkinsonian Disorders; Rats | 2014 |
Effect of nicotine on L-dopa-induced dyskinesia in animal models of Parkinson's disease: a systematic review and meta-analysis.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Ganglionic Stimulants; Levodopa; Nicotine; Parkinsonian Disorders | 2014 |
[Familial progressive external opthalmoplegia, parkinsonism and polyneuropathy associated with POLG1 mutation].
Topics: Aged; DNA Polymerase gamma; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Female; Gene Deletion; Genes, Dominant; Humans; Levodopa; Male; Menopause, Premature; Mitochondrial Diseases; Muscular Diseases; Mutation; Ophthalmoplegia, Chronic Progressive External; Parkinsonian Disorders; Pedigree; Polyneuropathies; Syndrome | 2014 |
POLG1-related levodopa-responsive parkinsonism.
Topics: Aged; Antiparkinson Agents; DNA Polymerase gamma; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Female; Genotype; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinsonian Disorders; Phenotype; Treatment Outcome | 2014 |
Peripheral nervous system involvement in Parkinson's disease: evidence and controversies.
Topics: Antiparkinson Agents; Databases, Bibliographic; Humans; Levodopa; Parkinsonian Disorders; Peripheral Nervous System Diseases | 2014 |
Freezing of Gait in Parkinsonism and its Potential Drug Treatment.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Botulinum Toxins; Droxidopa; Gait Disorders, Neurologic; Humans; Indans; Levodopa; Methylphenidate; Middle Aged; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Selegiline; Treatment Outcome | 2016 |
mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neostriatum; Parkinsonian Disorders; Receptor, Adenosine A2A; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D2 | 2016 |
Topics: Antiparkinson Agents; Articulation Disorders; Corpus Striatum; Deglutition Disorders; Disease Progression; Dopamine Agonists; Dopaminergic Neurons; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Movement; Muscle Hypertonia; Parkinson Disease; Parkinsonian Disorders; Postural Balance; Sensation Disorders; Substantia Nigra; Tremor | 2017 |
Striatal synaptic changes in experimental parkinsonism: role of NMDA receptor trafficking in PSD.
Topics: Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuronal Plasticity; Parkinsonian Disorders; Protein Transport; Receptors, N-Methyl-D-Aspartate; Synapses | 2008 |
Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.
Topics: Animals; Clinical Trials as Topic; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Presynaptic Terminals; Protein Isoforms; Receptors, Dopamine; Receptors, Serotonin; Serotonin | 2008 |
[Synthesis of monoamines by non-monoaminergic neurons: illusion or reality?].
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Brain; Corpus Striatum; Dopamine; Humans; Hypothalamus; Levodopa; Nerve Tissue Proteins; Neurodegenerative Diseases; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Serotonin; Substantia Nigra; Tyrosine; Tyrosine 3-Monooxygenase | 2009 |
Intermittent Dopaminergic stimulation causes behavioral sensitization in the addicted brain and parkinsonism.
Topics: Amphetamine-Related Disorders; Animals; Brain; Dopamine; Humans; Levodopa; Methamphetamine; Parkinsonian Disorders; Receptors, Dopamine D1; Signal Transduction | 2009 |
Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroleptic Malignant Syndrome; Parkinsonian Disorders; Polyneuropathies | 2009 |
[Future standards in diagnosing Parkinson syndrome].
Topics: Antiparkinson Agents; Gait; Humans; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Positron-Emission Tomography; Reference Standards; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2010 |
[Multiple system atrophy].
Topics: Aged; Antiparkinson Agents; Atrophy; Brain; Combined Modality Therapy; Cross-Sectional Studies; Humans; Levodopa; Magnetic Resonance Imaging; Multiple System Atrophy; Neurologic Examination; Palliative Care; Parkinsonian Disorders; Physical Therapy Modalities; Prognosis; Survival Rate | 2010 |
Exercise alleviates Parkinsonism: clinical and laboratory evidence.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Exercise; Exercise Therapy; Humans; Levodopa; Neurotoxins; Parkinsonian Disorders; Quality of Life | 2011 |
Levodopa and Parkinson disease--electrophysiological perspectives in animal models.
Topics: Action Potentials; Animals; Female; Levodopa; Neurons; Parkinsonian Disorders; Substantia Nigra; Subthalamic Nucleus | 2011 |
Pallidoreticular lesion in carbon monoxide intoxication by gradient echo: report of a case with parkinsonism features and review of the literature.
Topics: Antiparkinson Agents; Carbon Monoxide Poisoning; Cerebral Cortex; Female; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Organotechnetium Compounds; Parkinsonian Disorders; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Tropanes | 2012 |
Juvenile parkinsonism as a manifestation of systemic lupus erythematosus: case report and review of the literature.
Topics: Adult; Diagnosis, Differential; Drug Therapy, Combination; Humans; Levodopa; Lupus Erythematosus, Systemic; Lupus Vasculitis, Central Nervous System; Male; Methylprednisolone; Neurologic Examination; Parkinsonian Disorders; Prednisolone; Recurrence | 2002 |
The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities.
Topics: Animals; Caffeine; Disease Models, Animal; Humans; Levodopa; Memory Disorders; Neurons; Parkinsonian Disorders; Rats; Receptors, Dopamine; Receptors, Purinergic P1; Substantia Nigra | 2002 |
Clinical features and laboratory findings for differentiating parkinsonian syndromes.
Topics: Diagnosis, Differential; Humans; Levodopa; Parkinsonian Disorders | 2002 |
The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Dopamine Agonists; Drug Resistance; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinsonian Disorders; Primates | 2003 |
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inhibitors; Clinical Trials as Topic; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Enzyme Inhibitors; Ergot Alkaloids; Family Practice; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease; Parkinson Disease, Secondary; Parkinsonian Disorders; Piperidines | 2003 |
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus Striatum; Disease Models, Animal; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Humans; Levodopa; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Primates; Purines; Rats; Receptor, Adenosine A2A; Receptors, Dopamine D2 | 2003 |
Translating A2A antagonist KW6002 from animal models to parkinsonian patients.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Clinical Trials as Topic; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Humans; Levodopa; Macaca fascicularis; Male; Motor Activity; Neurons; Parkinsonian Disorders; Purines; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 2003 |
Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2).
Topics: Antiparkinson Agents; Brain; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dystonia; Humans; Levodopa; Magnetic Resonance Imaging; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Parkinsonian Disorders; Posture; Spinocerebellar Ataxias; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Tremor | 2004 |
Switching and combining of dopamine agonists.
Topics: Dopamine Agonists; Drug Synergism; Drug Therapy, Combination; Humans; Levodopa; Parkinsonian Disorders; Treatment Outcome | 2004 |
[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].
Topics: Akathisia, Drug-Induced; Animals; Antiparkinson Agents; Carbidopa; Catechols; Clinical Trials as Topic; Dopamine; Drug Therapy, Combination; Humans; Hyperhomocysteinemia; Levodopa; MPTP Poisoning; Neuroprotective Agents; Nitriles; Parkinson Disease; Parkinsonian Disorders; Rats; Treatment Outcome | 2005 |
Parkinson's disease. Diagnosis and the initiation of therapy.
Topics: Antioxidants; Diagnosis, Differential; Dopamine Agonists; Humans; Hypokinesia; Indans; Levodopa; Muscle Rigidity; Nerve Degeneration; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Selegiline; Tremor | 2005 |
L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease.
Topics: Animals; Cell Death; Dopamine; Humans; Levodopa; Mitochondrial Diseases; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders | 2005 |
[Atypical Parkinsonian syndromes, a challenging group of diseases].
Topics: Brain; Diagnosis, Differential; Female; Finland; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease; Parkinsonian Disorders; Prognosis; Risk Factors; Severity of Illness Index; Treatment Failure | 2005 |
The diagnosis of manganese-induced parkinsonism.
Topics: Adult; Diagnosis, Differential; Dopamine Agents; Humans; Levodopa; Male; Manganese Poisoning; Middle Aged; Parkinsonian Disorders | 2006 |
Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
Topics: Alzheimer Disease; Animals; Brain; Delayed-Action Preparations; Diffusion; Disease Models, Animal; Drug Carriers; Drug Stability; Humans; Huntington Disease; Levodopa; Microspheres; Nerve Growth Factor; Neurodegenerative Diseases; Neuroprotective Agents; Parkinsonian Disorders; Polymers; Solubility | 2006 |
How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease?
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Dopamine Agents; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Motor Skills; Parkinsonian Disorders; Stereotyped Behavior | 2006 |
Levodopa responsiveness in disorders with parkinsonism: a review of the literature.
Topics: Antiparkinson Agents; Education, Medical, Continuing; Humans; Levodopa; Parkinsonian Disorders | 2007 |
[Lewy body dementia and Parkinson disease dementia].
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Dementia; Diagnosis, Differential; Disease Progression; Dopamine Agents; Humans; Iatrogenic Disease; Levodopa; Lewy Body Disease; Neuroprotective Agents; Nootropic Agents; Parkinson Disease; Parkinsonian Disorders; Phenylcarbamates; Psychotropic Drugs; Rivastigmine; Serotonin Antagonists | 2007 |
L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinsonian Disorders | 2007 |
Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Glutamic Acid; Humans; Levodopa; Models, Neurological; Neurons, Efferent; Parkinsonian Disorders; Phosphotransferases; Receptors, Dopamine; Receptors, Glutamate; Signal Transduction | 2000 |
[Treatment of Parkinsonism: collaboration between the physician and the neurologist].
Topics: Aged; Antiparkinson Agents; Diagnosis, Differential; Drug Tolerance; Humans; Levodopa; Movement Disorders; Parkinsonian Disorders; Patient Care Team | 2000 |
Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management.
Topics: Disease Progression; Electron Transport; Humans; Levodopa; Mitochondria; Neurodegenerative Diseases; Oxidation-Reduction; Parkinson Disease, Secondary; Parkinsonian Disorders | 2000 |
Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.
Topics: Catechol O-Methyltransferase Inhibitors; Humans; Levodopa; Parkinsonian Disorders | 2000 |
Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials.
Topics: Benzophenones; Catechol O-Methyltransferase Inhibitors; Catechols; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Nitrophenols; Parkinsonian Disorders; Tolcapone | 2000 |
Parkinsonian symptoms as an initial manifestation in a Japanese patient with acquired immunodeficiency syndrome and Toxoplasma infection.
Topics: AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; Carbidopa; Corpus Striatum; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parietal Lobe; Parkinsonian Disorders; Pyrimethamine; Syphilis; Toxoplasmosis, Cerebral | 2000 |
[Physiopathology of parkinsonism and dyskinesias: lessons from surgical observations]].
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Dyskinesia, Drug-Induced; Dyskinesias; Globus Pallidus; Humans; Levodopa; Models, Animal; Models, Neurological; Motor Skills; Neurons; Parkinsonian Disorders; Subthalamic Nucleus; Thalamus | 2001 |
[Parkinson disease: diagnostic and therapeutic criteria].
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Female; Globus Pallidus; Humans; Indoles; Levodopa; Lewy Body Disease; Lisuride; Male; Mental Status Schedule; Neurosurgery; Parkinson Disease; Parkinsonian Disorders; Piribedil; Psychiatric Status Rating Scales; Serotonin Receptor Agonists; Stereotaxic Techniques; Supranuclear Palsy, Progressive; Surveys and Questionnaires; Thalamus | 2001 |
Dystonia and parkinsonism.
Topics: Antiparkinson Agents; Dystonia; Humans; Levodopa; Parkinsonian Disorders; Syndrome | 2001 |
Neurodegeneration, parkinsonian syndromes and autonomic failure.
Topics: Autonomic Nervous System Diseases; Brain; Cardiovascular Physiological Phenomena; Diagnosis, Differential; Humans; Levodopa; Multiple System Atrophy; Parkinsonian Disorders; Shy-Drager Syndrome; Sympathetic Nervous System | 2002 |
12 trial(s) available for levodopa and Parkinsonian Disorders
| Article | Year |
|---|---|
Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients.
Topics: Action Potentials; Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Follow-Up Studies; Gels; Humans; Intestinal Absorption; Levodopa; Male; Middle Aged; Neural Conduction; Parkinsonian Disorders; Peripheral Nervous System Diseases; Prospective Studies; Reaction Time; Vitamin B 12; Vitamin B 12 Deficiency | 2014 |
Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease?
Topics: Aged; Antiparkinson Agents; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Pain; Pain Measurement; Pain Threshold; Parkinsonian Disorders; Severity of Illness Index; Time Factors | 2008 |
Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.
Topics: Aged; Cross-Over Studies; Dopamine Agents; Double-Blind Method; Dyskinesias; Excitatory Amino Acid Antagonists; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Piperidines; Severity of Illness Index | 2008 |
Longitudinal study of the levodopa motor response in Parkinson's disease: relationship between cognitive decline and motor function.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Cognition Disorders; Dementia; Disability Evaluation; Dyskinesias; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Parkinsonian Disorders; Statistics, Nonparametric | 2009 |
Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients.
Topics: Adult; Aged; Animals; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Macaca; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Simvastatin | 2013 |
The dopamine transporter: importance in Parkinson's disease.
Topics: Aged; Analysis of Variance; Blood Pressure; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Routes; Drug Synergism; Dyskinesias; Emotions; Female; Heart Rate; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Methylphenidate; Middle Aged; Motor Activity; Nerve Tissue Proteins; Parkinson Disease; Parkinsonian Disorders; Psychomotor Performance; Time Factors; Walking | 2004 |
Benign tremulous parkinsonism.
Topics: Adult; Aged; Antiparkinson Agents; Essential Tremor; Family Health; Female; Humans; Levodopa; Longitudinal Studies; Male; Medical Records Systems, Computerized; Middle Aged; Parkinsonian Disorders; Treatment Outcome | 2006 |
Laboratory and clinical investigations of the region of the rostral brainstem in motor control.
Topics: Animals; Antiparkinson Agents; Bicuculline; Deep Brain Stimulation; Dose-Response Relationship, Radiation; Female; GABA Antagonists; Humans; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Retrospective Studies | 2006 |
L-Dopa infusion does not improve explicit sequence learning in Parkinson's disease.
Topics: Analysis of Variance; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Neuropsychological Tests; Parkinsonian Disorders; Serial Learning; Severity of Illness Index | 2007 |
Acute challenge with apomorphine and levodopa in Parkinsonism.
Topics: Age of Onset; Aged; Antiparkinson Agents; Apomorphine; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Sensitivity and Specificity | 2000 |
CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antiparkinson Agents; Diagnosis, Differential; Discriminant Analysis; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Nerve Degeneration; Neurofilament Proteins; Parkinsonian Disorders; Spinal Puncture; Supranuclear Palsy, Progressive | 2001 |
Effect of levodopa on orthostatic and postprandial hypotension in elderly Parkinsonian patients.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Autonomic Nervous System; Benserazide; Blood Pressure; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypotension; Hypotension, Orthostatic; Levodopa; Male; Parkinsonian Disorders; Postprandial Period; Posture; Reference Values | 2001 |
781 other study(ies) available for levodopa and Parkinsonian Disorders
| Article | Year |
|---|---|
Highly potent activity of (1R,2R,6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cyclohexanols; Disease Models, Animal; Dopamine Antagonists; Drug Synergism; Haloperidol; Levodopa; Mice; Mice, Inbred C57BL; Molecular Conformation; Motor Activity; Neurotoxins; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Neurotransmitter; Stereoisomerism | 2011 |
The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Medial Forebrain Bundle; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra; Sympatholytics | 2021 |
PLA2G6 mutations cause motor dysfunction phenotypes of young-onset dystonia-parkinsonism type 14 and can be relieved by DHA treatment in animal models.
Topics: Animals; Docosahexaenoic Acids; Group VI Phospholipases A2; Humans; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Parkinsonian Disorders; Phenotype; Treatment Outcome; Zebrafish | 2021 |
Additive effects of mGluR
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Bridged Bicyclo Compounds; Callithrix; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Parkinsonian Disorders; Piperazines; Psychotic Disorders; Pyridines; Receptors, Metabotropic Glutamate; Serotonin 5-HT2 Receptor Antagonists; Sulfonamides | 2021 |
Evaluation of efficiency omega 3 fatty acid improves the behavioural phenotype and protects against oxidative stress against MPP+ induces Parkinson's disease in mice.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Behavior, Animal; Catalase; Fatty Acids, Omega-3; Freezing Reaction, Cataleptic; Frontal Lobe; Glutathione; Glutathione Peroxidase; Levodopa; Male; Mesencephalon; Mice; Open Field Test; Oxidative Stress; Parkinsonian Disorders; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2021 |
How much time is needed in clinical practice to reach a diagnosis of clinically established Parkinson's disease?
Topics: Aged; Diagnosis, Differential; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Symptom Assessment; Time Factors; Tremor | 2021 |
Disruption of mitochondrial complex I induces progressive parkinsonism.
Topics: Animals; Axons; Cell Death; Dendrites; Disease Models, Animal; Disease Progression; Dopamine; Dopaminergic Neurons; Electron Transport Complex I; Female; Levodopa; Male; Mice; Motor Skills; NADH Dehydrogenase; Parkinsonian Disorders; Phenotype; Substantia Nigra | 2021 |
Dopamine D3 receptor ligand suppresses the expression of levodopa-induced dyskinesia in nonhuman primate model of parkinson's disease.
Topics: Animals; Antiparkinson Agents; Callithrix; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; HEK293 Cells; Humans; Levodopa; Ligands; Parkinsonian Disorders; Primates; Protein Structure, Secondary; Quinpirole; Receptors, Dopamine D3 | 2022 |
Modulation of dopamine tone induces frequency shifts in cortico-basal ganglia beta oscillations.
Topics: Action Potentials; Animals; Basal Ganglia; Beta Rhythm; Carbidopa; Cerebral Cortex; Chlorocebus aethiops; Dopamine; Electrodes, Implanted; Eye-Tracking Technology; Female; Humans; Levodopa; Magnetic Resonance Imaging; Nerve Net; Organic Chemicals; Parkinson Disease; Parkinsonian Disorders; Pupil; Stereotaxic Techniques | 2021 |
Spinocerebellar ataxia type 3: response to levodopa infusion in two cases.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Gels; Humans; Infusions, Parenteral; Levodopa; Machado-Joseph Disease; Neurodegenerative Diseases; Parkinson Disease; Parkinsonian Disorders | 2022 |
Radiation-induced Brain Calcification Leads to L-dopa-resistant Parkinsonism and Cerebellar Ataxia.
Topics: Brain; Calcinosis; Cerebellar Ataxia; Corpus Striatum; Female; Humans; Levodopa; Neurodegenerative Diseases; Parkinsonian Disorders; Tomography, Emission-Computed, Single-Photon | 2022 |
L-Dopa response, choreic dyskinesia, and dystonia in Perry syndrome.
Topics: Antiparkinson Agents; Depression; Dyskinesia, Drug-Induced; Dystonia; Dystonic Disorders; Humans; Hypoventilation; Levodopa; Parkinson Disease; Parkinsonian Disorders | 2022 |
Tau-PET and multimodal imaging in clinically atypical multiple system atrophy masquerading as progressive supranuclear palsy.
Topics: Diagnosis, Differential; Fluorodeoxyglucose F18; Humans; Levodopa; Magnetic Resonance Imaging; Multimodal Imaging; Multiple System Atrophy; Parkinson Disease; Parkinsonian Disorders; Supranuclear Palsy, Progressive | 2022 |
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Glycine Plasma Membrane Transport Proteins; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Rats; Sulfones | 2022 |
A case of Lewy body disease and anaplastic astrocytoma presenting with atypical parkinsonism.
Topics: Humans; Levodopa; Lewy Body Disease; Multiple System Atrophy; Parkinson Disease; Parkinsonian Disorders | 2022 |
Long-term efficacy of bilateral subthalamic deep brain stimulation in the parkinsonism of SCA 3: A rare case report.
Topics: Deep Brain Stimulation; Humans; Levodopa; Machado-Joseph Disease; Male; Parkinsonian Disorders; Subthalamic Nucleus; Treatment Outcome | 2022 |
A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats | 2022 |
Amino acid transporter Asc-1 (SLC7A10) expression is altered in basal ganglia in experimental Parkinsonism and L-dopa-induced dyskinesia model mice.
Topics: Amino Acid Transport System ASC; Amino Acid Transport System y+; Animals; Basal Ganglia; Dopamine; Dyskinesias; Levodopa; Mice; Parkinson Disease; Parkinsonian Disorders; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Serine | 2023 |
Deep brain stimulation in dopa-responsive parkinsonism - Look out for red flags.
Topics: Deep Brain Stimulation; Humans; Levodopa; Parkinsonian Disorders | 2023 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Glycine; Levodopa; Macaca fascicularis; Neuroprotective Agents; Parkinsonian Disorders; Pilot Projects; Prodrugs; Receptors, N-Methyl-D-Aspartate | 2022 |
Parkinson disease primer, part 1: diagnosis.
Topics: Canada; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Patients | 2023 |
Striatal Subregion-selective Dysregulated Dopamine Receptor-mediated Intracellular Signaling in a Model of DOPA-responsive Dystonia.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Antagonists; Dystonia; Extracellular Signal-Regulated MAP Kinases; Levodopa; Mice; Parkinsonian Disorders; Receptors, Dopamine D1 | 2023 |
The Dynamics of Dopamine D
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Receptors, Dopamine D2 | 2023 |
Hemiatrophy-hemiparkinsonism and Poland syndrome: A causative or coincidental association?
Topics: Atrophy; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Poland Syndrome | 2023 |
Glycine receptor antibody associated stiff person syndrome with nigrostriatal dopamine loss and levodopa responsiveness.
Topics: Dopamine; Humans; Levodopa; Parkinsonian Disorders; Receptors, Glycine; Stiff-Person Syndrome | 2023 |
7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Parkinsonian Disorders; Primates; Quality of Life | 2023 |
Hippocampal synaptic failure is an early event in experimental parkinsonism with subtle cognitive deficit.
Topics: alpha-Synuclein; Animals; Cognition; Dopamine; Dopaminergic Neurons; Hippocampus; Humans; Levodopa; Neurotransmitter Agents; Parkinson Disease; Parkinsonian Disorders; Pramipexole; Rats | 2023 |
Levodopa responsive asymmetric parkinsonism as clinical presentation of progranulin gene mutation.
Topics: Humans; Levodopa; Mutation; Parkinsonian Disorders; Phenotype; Progranulins | 2023 |
Effect of the mGlu
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Levodopa; Parkinson Disease; Parkinsonian Disorders; Psychotic Disorders; Rats | 2023 |
Brainstem Modulates Parkinsonism-Induced Orofacial Sensorimotor Dysfunctions.
Topics: Animals; Antiparkinson Agents; Brain Stem; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats | 2023 |
Shared GABA transmission pathology in dopamine agonist- and antagonist-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders | 2023 |
Novel RAB39B variant associated intellectual disability and levodopa-responsive young-onset parkinsonism.
Topics: Adult; Child; Humans; Intellectual Disability; Levodopa; Male; Mutation; Parkinson Disease; Parkinsonian Disorders | 2023 |
Stress-induced phospho-ubiquitin formation causes parkin degradation.
Topics: Animals; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cell Differentiation; Cell Line, Tumor; Embryo, Mammalian; Gene Expression Regulation; Humans; Hydrogen Peroxide; Levodopa; Models, Biological; Neurons; Parkinsonian Disorders; PC12 Cells; Phosphorylation; Primary Cell Culture; Proteasome Endopeptidase Complex; Protein Kinases; Proteolysis; Rats; Ubiquitin; Ubiquitin-Protein Ligases | 2019 |
Acute L-DOPA administration reverses changes in firing pattern and low frequency oscillatory activity in the entopeduncular nucleus from long term L-DOPA treated 6-OHDA-lesioned rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus | 2019 |
Cytosolic non-vesicular dopamine accumulation as the predominant mechanism for developing non-DOPA responsive parkinsonism in late-stage Huntington disease.
Topics: Animals; Calcium; Corpus Striatum; Disease Progression; Dopamine; Humans; Huntington Disease; Levodopa; Mitochondria; Movement; Movement Disorders; Neurotransmitter Agents; Parkinsonian Disorders | 2019 |
Levodopa-responsive parkinsonism in a patient with corticobasal degeneration and bilateral choroid plexus xanthogranulomas.
Topics: Aged; Antiparkinson Agents; Basal Ganglia Diseases; Choroid Plexus; Granuloma; Humans; Hydrocephalus; Levodopa; Male; Parkinsonian Disorders; Xanthomatosis | 2020 |
Experimental study of antiparkinsonian action of the harmine hydrochloride original compound.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catalepsy; Haloperidol; Harmine; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Rats | 2019 |
Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; GABAergic Neurons; Glutamic Acid; Levodopa; Locomotion; Male; Medial Forebrain Bundle; Mice; Mice, Knockout; Movement; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Receptors, G-Protein-Coupled; RNA, Messenger; Serotonin; Tacrine; Tremor | 2020 |
Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Camphanes; Cannabinoid Receptor Agonists; Cannabinoids; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Pyrazoles; Receptor, Cannabinoid, CB2 | 2020 |
Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia.
Topics: Adrenergic Uptake Inhibitors; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Motor Disorders; Oxidopamine; Parkinsonian Disorders; Tapentadol | 2020 |
The parthenolide derivative ACT001 synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson's disease in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Apoptosis; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Inflammation; Levodopa; Male; Mice; Mice, Inbred BALB C; Nerve Degeneration; Parkinson Disease; Parkinsonian Disorders; Sesquiterpenes | 2020 |
Which Scale Best Detects Treatment Response of Tremor in Parkinsonism?
Topics: Adult; Aged; Antiparkinson Agents; Carbidopa; Deep Brain Stimulation; Drug Combinations; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinsonian Disorders; Sensitivity and Specificity; Severity of Illness Index; Tremor | 2020 |
Transient parkinsonism associated with acute Legionnaires' disease.
Topics: Adult; Anti-Bacterial Agents; Antiparkinson Agents; Carbidopa; Ciprofloxacin; Drug Combinations; Drug Therapy, Combination; Dysarthria; Humans; Legionella; Legionnaires' Disease; Levodopa; Male; Parkinsonian Disorders; Respiratory Insufficiency | 2020 |
Simultaneous mass spectrometry imaging of multiple neuropeptides in the brain and alterations induced by experimental parkinsonism and L-DOPA therapy.
Topics: Animals; Brain; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Globus Pallidus; Levodopa; Male; Neostriatum; Parkinsonian Disorders; Rats, Wistar | 2020 |
Topics: Administration, Intranasal; Animals; Antiparkinson Agents; Brain; Drug Delivery Systems; Drug Evaluation, Preclinical; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Nanoparticles; Parkinsonian Disorders; PC12 Cells; Rats | 2020 |
Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Dose-Response Relationship, Drug; Excitatory Postsynaptic Potentials; Glutamic Acid; Levodopa; Male; Nerve Net; Organ Culture Techniques; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2020 |
Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
Topics: Administration, Oral; Amantadine; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Rats, Sprague-Dawley | 2020 |
Intraventricular dopamine infusion alleviates motor symptoms in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Infusions, Intraventricular; Levodopa; Macaca; Male; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Pilot Projects | 2020 |
The Bologna motor and non-motor prospective study on parkinsonism at onset (BoProPark): study design and population.
Topics: Aged; Humans; Levodopa; Middle Aged; Neurodegenerative Diseases; Parkinson Disease; Parkinsonian Disorders; Prospective Studies | 2020 |
Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
Topics: Aged; Animals; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nuclear Receptor Subfamily 4, Group A, Member 2; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Inbred F344; Rats, Inbred Lew; Rats, Sprague-Dawley | 2020 |
Dopamine, a key factor of mitochondrial damage and neuronal toxicity on rotenone exposure and also parkinsonic motor dysfunction-Impact of asiaticoside with a probable vesicular involvement.
Topics: Animals; Antiparkinson Agents; bcl-2-Associated X Protein; Cell Death; Corpus Striatum; Dopamine; Dopaminergic Neurons; Levodopa; Neuronal Outgrowth; Neuroprotective Agents; Parkinsonian Disorders; PC12 Cells; Proto-Oncogene Proteins c-bcl-2; Rats; Rotenone; Triterpenes | 2020 |
Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine.
Topics: Amantadine; Animals; Antiparkinson Agents; CHO Cells; Corpus Striatum; Cricetulus; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Potentiation; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Parkinson Disease; Parkinsonian Disorders; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Receptors, N-Methyl-D-Aspartate; Synaptic Potentials | 2020 |
Synergistic action of propolis with levodopa in the management of Parkinsonism in Drosophila melanogaster.
Topics: Animals; Antioxidants; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; Drug Synergism; Drug Therapy, Combination; Ethanol; Levodopa; Longevity; Motor Activity; Oxidative Stress; Parkinsonian Disorders; Plant Extracts; Propolis; Protein Serine-Threonine Kinases | 2020 |
Striatal Nurr1, but not FosB expression links a levodopa-induced dyskinesia phenotype to genotype in Fisher 344 vs. Lewis hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Genotype; Levodopa; Male; Nuclear Receptor Subfamily 4, Group A, Member 2; Parkinsonian Disorders; Phenotype; Proto-Oncogene Proteins c-fos; Rats; Rats, Inbred F344; Rats, Inbred Lew | 2020 |
Deep brain stimulation-guided optogenetic rescue of parkinsonian symptoms.
Topics: Algorithms; Animals; Antiparkinson Agents; Deep Brain Stimulation; Disease Models, Animal; Electrophysiological Phenomena; Female; Humans; Levodopa; Male; Mice, Inbred C57BL; Mice, Transgenic; Motor Cortex; Optogenetics; Oxidopamine; Parkinsonian Disorders; Pyramidal Cells; Somatostatin; Subthalamic Nucleus | 2020 |
Effects of Combined Bushen Zhichan Recipe and Levodopa in a Rodent Model of Parkinson Disease: Potential Mechanisms.
Topics: Animals; Behavior, Animal; Cistanche; Cornus; Corpus Striatum; Dioscorea; Disease Models, Animal; Dopaminergic Neurons; Drugs, Chinese Herbal; Excitatory Amino Acid Transporter 1; Excitatory Amino Acid Transporter 2; Fallopia multiflora; Forelimb; Levodopa; Medial Forebrain Bundle; Mesencephalon; Open Field Test; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Rehmannia | 2020 |
GABA storage and release in the medial globus pallidus in L-DOPA-induced dyskinesia priming.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Male; Neuronal Plasticity; Neurons; Parkinsonian Disorders; Rats; Rats, Wistar; Synaptic Transmission | 2020 |
Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Callithrix; Disease Models, Animal; Female; Levodopa; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders | 2020 |
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Callithrix; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders; Psychoses, Substance-Induced | 2020 |
Caffeine reduces deficits in mechanosensation and locomotion induced by L-DOPA and protects dopaminergic neurons in a transgenic
Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Caenorhabditis elegans; Caffeine; Dopaminergic Neurons; Dose-Response Relationship, Drug; Levodopa; Locomotion; Neuroprotective Agents; Parkinsonian Disorders | 2020 |
Characteristics of Patients with Late-Stage Parkinsonism Who are Nursing Home Residents Compared with those Living at Home.
Topics: Cross-Sectional Studies; Humans; Levodopa; Nursing Homes; Parkinson Disease; Parkinsonian Disorders | 2021 |
Dramatic Response to Pramipexole in Delayed-Onset Parkinsonism from Osmotic Demyelinating Syndrome.
Topics: Adult; Antiparkinson Agents; Deamino Arginine Vasopressin; Demyelinating Diseases; Dystonia; Epistaxis; Hemostatics; Humans; Hyponatremia; Levodopa; Locked-In Syndrome; Male; Myelinolysis, Central Pontine; Osmotic Pressure; Parkinsonian Disorders; Postoperative Hemorrhage; Pramipexole; Pseudobulbar Palsy; Rhinoplasty; Tetrahydronaphthalenes; Thiophenes; Treatment Failure; Treatment Outcome; von Willebrand Disease, Type 1 | 2020 |
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
Topics: Allosteric Regulation; Animals; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Microdialysis; Muscarinic Antagonists; Neostriatum; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Substantia Nigra; Sympatholytics | 2020 |
The selective 5-HT
Topics: Amantadine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Pyridines; Serotonin 5-HT1 Receptor Agonists | 2020 |
Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
Topics: Atrophy; Humans; Levodopa; Multiple System Atrophy; Parkinsonian Disorders | 2020 |
Mitochondrial UQCRC1 mutations cause autosomal dominant parkinsonism with polyneuropathy.
Topics: Age of Onset; Aged; Animals; Antiparkinson Agents; Cell Line; Chromosome Aberrations; Drosophila; Electron Transport Complex III; Exome Sequencing; Female; Frameshift Mutation; Gene Knock-In Techniques; Genes, Dominant; Humans; Levodopa; Male; Mice; Middle Aged; Mitochondria; Mutation; Parkinsonian Disorders; Pedigree; Polyneuropathies | 2020 |
Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Catechol O-Methyltransferase Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Erythrocytes; Female; Levodopa; Locomotion; Macaca fascicularis; Oxadiazoles; Parkinsonian Disorders; Time Factors | 2021 |
Increased emissions of 50-kHz ultrasonic vocalizations in hemiparkinsonian rats repeatedly treated with dopaminomimetic drugs: A potential preclinical model for studying the affective properties of dopamine replacement therapy in Parkinson's disease.
Topics: Affect; Animals; Apomorphine; Desipramine; Disease Models, Animal; Dopamine Agents; Levodopa; Male; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Ultrasonic Waves; Vocalization, Animal | 2021 |
Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats | 2021 |
Is Levodopa Response a Valid Indicator of Parkinson's Disease?
Topics: Humans; Levodopa; Multiple System Atrophy; Parkinson Disease; Parkinsonian Disorders; Supranuclear Palsy, Progressive | 2021 |
L-DOPA regulates α-synuclein accumulation in experimental parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Brain; Dopamine Agents; Female; Levodopa; Macaca mulatta; Neurons; Parkinsonian Disorders | 2021 |
D
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Bromocriptine; Chlorocebus aethiops; Disease Models, Animal; Dopamine Agonists; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Phenanthridines; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2021 |
Early-onset parkinsonism in PPP2R5D-related neurodevelopmental disorder.
Topics: Age of Onset; Antiparkinson Agents; Corpus Striatum; Female; Humans; Levodopa; Mutation, Missense; Parkinsonian Disorders; Phenotype; Protein Phosphatase 2; Young Adult | 2021 |
Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Granisetron; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin 5-HT3 Receptor Antagonists | 2021 |
Involvement of Autophagy in Levodopa-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Autophagy; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders | 2021 |
Exercise decreases aberrant corticostriatal plasticity in an animal model of l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Benserazide; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Dyskinesia, Drug-Induced; Exercise Therapy; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Male; Mice, Inbred C57BL; Motor Activity; Neuronal Plasticity; Parkinsonian Disorders; Running; Time Factors | 2021 |
Subcortical and brainstem hemiatrophy accompanied by iron deposition in a patient with hemiparkinsonism-hemiatrophy syndrome: a case report.
Topics: Antiparkinson Agents; Atrophy; Brain; Functional Laterality; Humans; Iron; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Young Adult | 2021 |
Quantitative Assessment of Motor Response to a Low Subacute Levodopa Dose in the Differential Diagnosis of Parkinsonisms at Disease Onset: Data from the BoProPark Cohort.
Topics: Antiparkinson Agents; Diagnosis, Differential; Humans; Levodopa; Parkinsonian Disorders; Prospective Studies | 2021 |
Levodopa affects spike and local field synchronisation in the pedunculopontine nucleus of a rat model of Parkinson's disease.
Topics: Action Potentials; Animals; Disease Models, Animal; Dopaminergic Neurons; Levodopa; Locomotion; Male; Oxidopamine; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Rats; Rats, Wistar | 2021 |
Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine.
Topics: Analgesics; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gamma Rhythm; Ketamine; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2021 |
Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Inflammation Mediators; Interferon-gamma; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinsonian Disorders | 2021 |
GCH1 mutations in hereditary spastic paraplegia.
Topics: Adult; Canada; Child; Female; GTP Cyclohydrolase; Humans; Levodopa; Male; Middle Aged; Mutation; Parkinsonian Disorders; Pedigree; Phenotype; Spastic Paraplegia, Hereditary; Twins, Monozygotic | 2021 |
Early-Onset Parkinsonism and Early-Onset Parkinson's Disease: A Population-Based Study (2010-2015).
Topics: Adult; Age of Onset; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders | 2021 |
A novel phosphodiesterase 1 inhibitor reverses L-dopa-induced dyskinesia, but not motivation deficits, in monkeys.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Antagonists; Dyskinesia, Drug-Induced; Levodopa; Macaca mulatta; Male; Motivation; Motor Activity; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases | 2021 |
Pediatric autoimmune Parkinsonism and response to deep brain stimulation.
Topics: Adolescent; Child; Deep Brain Stimulation; Female; Globus Pallidus; Humans; Levodopa; Parkinsonian Disorders; Treatment Outcome; Tremor | 2022 |
Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinsonian Disorders | 2021 |
Reply to: "Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism".
Topics: Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinsonian Disorders | 2021 |
Early suspicion of progressive supranuclear palsy using dopamine transporter imaging: an illustrative case presenting with levodopa-responsive parkinsonism.
Topics: Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Supranuclear Palsy, Progressive | 2021 |
Clinical Outcome and Striatal Dopaminergic Function After Shunt Surgery in Patients With Idiopathic Normal Pressure Hydrocephalus.
Topics: Aged; Aged, 80 and over; Cerebrospinal Fluid Shunts; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Female; Follow-Up Studies; Gait Disorders, Neurologic; Humans; Hydrocephalus, Normal Pressure; Levodopa; Male; Neostriatum; Outcome Assessment, Health Care; Parkinsonian Disorders; Phenotype; Postural Balance; Tomography, Emission-Computed, Single-Photon | 2021 |
Older-onset levodopa-responsive parkinsonism with normal DAT-SPECT and pterin hypometabolism.
Topics: Adult; Aged; Dopamine Plasma Membrane Transport Proteins; GTP Cyclohydrolase; Humans; Levodopa; Parkinsonian Disorders; Pterins; Tomography, Emission-Computed, Single-Photon | 2021 |
Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Female; Levodopa; Male; Parkinsonian Disorders; Psychotic Disorders | 2021 |
The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease.
Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Growth Factor | 2021 |
Locomotor activity and resting local field potential oscillatory rhythms of 6-OHDA mouse model of Parkinson's disease in response to acute and repeated treatments with L-dopa.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Levodopa; Locomotion; Male; Membrane Potentials; Mice; Mice, Inbred ICR; Parkinsonian Disorders | 2021 |
Subregion-Specific Regulation of Dopamine D1 Receptor Signaling in the Striatum: Implication for L-DOPA-Induced Dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Receptors, Dopamine D1; Signal Transduction | 2021 |
Discrimination of idiopathic Parkinson's disease and vascular parkinsonism based on gait time series and the levodopa effect.
Topics: Antiparkinson Agents; Gait; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders | 2021 |
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Calcium-Binding Proteins; Caudate Nucleus; Dyskinesia, Drug-Induced; Glial Fibrillary Acidic Protein; Interleukin-10; Interleukin-1beta; Levodopa; Microfilament Proteins; Neuroinflammatory Diseases; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Piperazines; Putamen; Pyrimidines; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Serotonin 5-HT1 Receptor Agonists; Triazoles; Tumor Necrosis Factor-alpha | 2021 |
Pediatric Gaucher disease with intermediate type 2-3 phenotype associated with parkinsonian features and levodopa responsiveness.
Topics: Antiparkinson Agents; Child, Preschool; Diseases in Twins; Female; Gaucher Disease; Humans; Infant; Levodopa; Male; Parkinsonian Disorders; Phenotype; Twins | 2021 |
Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.
Topics: Animals; Antiparkinson Agents; Armadillo Domain Proteins; Catechol O-Methyltransferase; Cell Adhesion Molecules; Corpus Striatum; Disease Models, Animal; Disease Susceptibility; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphoproteins; Proto-Oncogene Proteins c-fos; Serotonin; Thioredoxin Reductase 2 | 2017 |
Parkinson's patients can rely on perspective cues to perceive 3D space.
Topics: Aged; Aged, 80 and over; Cues; Depth Perception; Evoked Potentials, Visual; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Photic Stimulation; Vision, Binocular; Vision, Monocular; Visual Cortex; Visual Perception | 2017 |
A polysomnographic study in parkinsonian patients treated with intestinal levodopa infusion.
Topics: Aged; Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Gels; Humans; Intestines; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinsonian Disorders; Polysomnography; Severity of Illness Index; Sleep Wake Disorders; Statistics, Nonparametric; Surveys and Questionnaires; Treatment Outcome | 2017 |
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.
Topics: Acetylcholine; Administration, Oral; Animals; Antiparkinson Agents; Benserazide; Choline O-Acetyltransferase; Colon; Gastrointestinal Transit; Inflammation; Interleukin-1beta; Levodopa; Male; Muscle, Smooth; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Synaptic Transmission; Tissue Culture Techniques; Tumor Necrosis Factor-alpha | 2017 |
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Benzothiazoles; Blood-Brain Barrier; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Drug Combinations; Levodopa; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Parkinsonian Disorders; Pramipexole; Selegiline | 2017 |
Chronic asymmetric tremor and levodopa-responsive parkinsonism due to a vein of Galen aneurysmal malformation.
Topics: Antiparkinson Agents; Chronic Disease; Female; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Tremor; Vein of Galen Malformations | 2017 |
Choreiform dyskinesias following levodopa treatment of parkinsonism due to osmotic demyelination syndrome.
Topics: Aged; Antiparkinson Agents; Demyelinating Diseases; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Osmosis; Parkinsonian Disorders | 2017 |
β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Topics: Allylbenzene Derivatives; Animals; Anisoles; Antiparkinson Agents; Behavior, Animal; Benserazide; Catechol O-Methyltransferase; Corpus Striatum; Dopa Decarboxylase; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Drug Combinations; Drug Therapy, Combination; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2017 |
Rabphilin 3A: A novel target for the treatment of levodopa-induced dyskinesias.
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca mulatta; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Post-Synaptic Density; Protein Binding; Rabphilin-3A; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Synapses; Tissue Culture Techniques; Vesicular Transport Proteins | 2017 |
Pain processing in atypical Parkinsonisms and Parkinson disease: A comparative neurophysiological study.
Topics: Aged; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Pain; Pain Measurement; Parkinson Disease; Parkinsonian Disorders; Supranuclear Palsy, Progressive | 2017 |
Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; Gynostemma; Levodopa; Male; Maze Learning; Memory Disorders; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Plant Extracts; Spatial Memory | 2017 |
DNAJC12 and dopa-responsive nonprogressive parkinsonism.
Topics: Adult; alpha-Synuclein; Amyloid beta-Peptides; Antiparkinson Agents; Biogenic Amines; Brain; DNA Mutational Analysis; DNA-Binding Proteins; Family Health; Female; Humans; Levodopa; Male; Middle Aged; Mutation; Parkinsonian Disorders; Phenylalanine; Repressor Proteins; Sequestosome-1 Protein; tau Proteins; Young Adult | 2017 |
Differential effects of levodopa and apomorphine on neuronal population oscillations in the cortico-basal ganglia loop circuit in vivo in experimental parkinsonism.
Topics: Animals; Apomorphine; Basal Ganglia; Cerebral Cortex; Dose-Response Relationship, Drug; Levodopa; Male; Nerve Net; Neurons; Parkinsonian Disorders; Rats; Rats, Wistar | 2017 |
Parkinsonism without dopamine neuron degeneration in aged l-dopa-responsive dystonia knockin mice.
Topics: Aging; Analysis of Variance; Animals; Antiparkinson Agents; Dopamine Agents; Dopamine beta-Hydroxylase; Dopamine Plasma Membrane Transport Proteins; Dystonic Disorders; Female; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Parkinsonian Disorders; Tyrosine 3-Monooxygenase | 2017 |
Differential effects of dopaminergic drugs on spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine.
Topics: Animals; Apomorphine; Area Under Curve; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopaminergic Neurons; Dose-Response Relationship, Drug; Immunohistochemistry; Levodopa; Male; Methamphetamine; Motor Activity; Oxidopamine; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2017 |
Biallelic mutations in mitochondrial tryptophanyl-tRNA synthetase cause Levodopa-responsive infantile-onset Parkinsonism.
Topics: Adolescent; Age of Onset; Alleles; Biopsy; DNA Mutational Analysis; Fibroblasts; Genetic Association Studies; Genotype; Humans; Levodopa; Magnetic Resonance Imaging; Male; Mutation; Parkinsonian Disorders; Phenotype; Polymorphism, Single Nucleotide; Precision Medicine; Tryptophan-tRNA Ligase | 2018 |
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Topics: Adrenergic Agents; Analgesics, Opioid; Animals; Benzamides; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Guinea Pigs; Levodopa; Macaca; Male; Mice; Mice, Inbred C57BL; Movement; Narcotic Antagonists; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Rats, Sprague-Dawley; Receptors, Opioid, delta; Receptors, Opioid, mu; Vas Deferens | 2018 |
SPG7 with parkinsonism responsive to levodopa and dopaminergic deficit.
Topics: ATPases Associated with Diverse Cellular Activities; Brain; Dopamine; Dopamine Agents; Female; Humans; Levodopa; Metalloendopeptidases; Middle Aged; Organotechnetium Compounds; Parkinsonian Disorders; Tomography, Emission-Computed, Single-Photon; Tropanes | 2018 |
Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Behavior, Animal; Callithrix; Disorders of Excessive Somnolence; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; MPTP Poisoning; Parkinsonian Disorders; Serotonin Receptor Agonists; Trazodone | 2018 |
Cortical stimulation relieves parkinsonian pathological activity in vitro.
Topics: Animals; Corpus Striatum; Dopamine; Levodopa; Mice; Neurons; Oxidopamine; Parkinsonian Disorders | 2019 |
Zonisamide for DLB parkinsonism: An old drug used in a new context.
Topics: Double-Blind Method; Humans; Levodopa; Lewy Body Disease; Parkinsonian Disorders; Zonisamide | 2018 |
Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Glucagon-Like Peptide 1; Levodopa; Linagliptin; Mice; Mice, Inbred BALB C; NF-kappa B; Parkinsonian Disorders; Toll-Like Receptor 4; Transforming Growth Factor beta1 | 2018 |
Quantitative Analysis of Catecholamines in the Pink1 -/- Rat Model of Early-onset Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Brain; Catecholamines; Female; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Protein Kinases; Rats, Long-Evans; Rats, Transgenic; RNA, Messenger; Ultrasonics; Vocalization, Animal | 2018 |
Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
Topics: Animals; Antiparkinson Agents; Benserazide; Cytoskeletal Proteins; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Male; Movement; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger; Selegiline; Time Factors | 2018 |
Genetic disruption of the nuclear receptor Nur77 (Nr4a1) in rat reduces dopamine cell loss and l-Dopa-induced dyskinesia in experimental Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Gene Knockout Techniques; Levodopa; Mice; Nuclear Receptor Subfamily 4, Group A, Member 1; Parkinsonian Disorders; Rats | 2018 |
Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
Topics: Animals; Antiparkinson Agents; Apomorphine; Arachidonic Acids; Biomarkers; Cannabinoid Receptor Agonists; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Endocannabinoids; Glycerides; Levodopa; Male; Metabolome; Metabolomics; Motor Activity; Oxidopamine; Parkinsonian Disorders; Polyunsaturated Alkamides; Rats, Sprague-Dawley | 2018 |
Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Inflammation; Levodopa; Male; Nociceptive Pain; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Rats, Wistar | 2018 |
Anticataleptic activity of Zamzam water in chlorpromazine induced animal model of Parkinson disease.
Topics: Animals; Brain; Carbidopa; Catalepsy; Chlorpromazine; Disease Models, Animal; Drug Combinations; Hydrogen-Ion Concentration; Levodopa; Parkinsonian Disorders; Rats; Water | 2018 |
Restorative effect of l-Dopa treatment against Ochratoxin A induced neurotoxicity.
Topics: Animals; Antiparkinson Agents; Carcinogens; Levodopa; Male; Mice; Mice, Inbred BALB C; Motor Activity; Ochratoxins; Parkinsonian Disorders; Random Allocation; Treatment Outcome | 2018 |
Haloperidol-induced parkinsonism is attenuated by varenicline in mice.
Topics: Animals; Catalepsy; Disease Models, Animal; Dopamine; Female; Haloperidol; Levodopa; Male; Mice; Neurons; Parkinsonian Disorders; Varenicline | 2018 |
Diametric neural ensemble dynamics in parkinsonian and dyskinetic states.
Topics: Animals; Calcium Signaling; Dopamine; Dyskinesias; Female; Levodopa; Male; Mice; Models, Biological; Movement; Neostriatum; Neurons; Parkinsonian Disorders; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2018 |
Zinc and linoleic acid pre-treatment attenuates biochemical and histological changes in the midbrain of rats with rotenone-induced Parkinsonism.
Topics: Animals; Antioxidants; Disease Models, Animal; Female; Glutathione; Levodopa; Linoleic Acid; Lipid Peroxidation; Parkinsonian Disorders; Rats, Wistar; Rotenone; Zinc | 2018 |
Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental parkinsonism.
Topics: Administration, Inhalation; Animals; Antiparkinson Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Green Fluorescent Proteins; Levodopa; Mice; Mice, Transgenic; MPTP Poisoning; Oxidopamine; Parkinsonian Disorders; Rats; Sensation Disorders; Sympatholytics; Time Factors; Xenon | 2018 |
Osmotic Demyelination Syndrome With Evolving Movement Disorders.
Topics: Acute Disease; Adult; Akinetic Mutism; Athetosis; Benserazide; Chorea; Demyelinating Diseases; Dopamine Agents; Drug Combinations; Fluid Therapy; Gastroenteritis; Humans; Hyponatremia; Levodopa; Male; Myelinolysis, Central Pontine; Parkinsonian Disorders; Saline Solution; Time Factors | 2018 |
Aberrant Striatal Activity in Parkinsonism and Levodopa-Induced Dyskinesia.
Topics: Action Potentials; Animals; Behavior, Animal; Corpus Striatum; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Neurons; Optogenetics; Parkinsonian Disorders; Receptors, Dopamine | 2018 |
Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain; Central Nervous System Stimulants; Dopamine; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Functional Laterality; Levodopa; Male; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Neurodegenerative Diseases; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine; Receptors, Nicotinic; RNA, Messenger | 2018 |
Jaw tremor: a manifestation of vascular parkinsonism? - a case report.
Topics: Aged; Brain; Female; Humans; Levodopa; Parkinsonian Disorders; Tremor; Vascular Diseases | 2018 |
Expanding the Spectrum of Dopa-Responsive Dystonia (DRD) and Proposal for New Definition: DRD, DRD-plus, and DRD Look-alike.
Topics: Carrier Proteins; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dystonic Disorders; Group VI Phospholipases A2; Humans; Levodopa; Mitochondrial Proteins; Molecular Chaperones; Parkinsonian Disorders; Proteins | 2018 |
Effects of histone acetyltransferase inhibitors on L-DOPA-induced dyskinesia in a murine model of Parkinson's disease.
Topics: Anacardic Acids; Animals; Antiparkinson Agents; Curcumin; Cytoskeletal Proteins; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Fos-Related Antigen-2; Gene Expression Regulation; Histone Acetyltransferases; Histone Code; Levodopa; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Specific Pathogen-Free Organisms; Substantia Nigra; Terpenes | 2018 |
Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Parkinsonian Disorders; Piperazines; Psychoses, Substance-Induced; Triazoles | 2018 |
Modulation of Beta Bursts in the Subthalamic Nucleus Predicts Motor Performance.
Topics: Aged; Antiparkinson Agents; Beta Rhythm; Deep Brain Stimulation; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinsonian Disorders; Psychomotor Performance; Subthalamic Nucleus | 2018 |
An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
Topics: Allosteric Regulation; Animals; Antiparkinson Agents; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Positron-Emission Tomography; Receptors, Metabotropic Glutamate; Time Factors | 2018 |
Severe acute colitis related to levodopa treatment.
Topics: Acute Disease; Aged, 80 and over; Antiparkinson Agents; Colitis; Colon; Colonoscopy; Humans; Levodopa; Male; Parkinsonian Disorders; Treatment Outcome | 2018 |
Interactions of the tricyclic antidepressant drug amitriptyline with L-DOPA in the striatum and substantia nigra of unilaterally 6-OHDA-lesioned rats. Relevance to motor dysfunction in Parkinson's disease.
Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Drug Interactions; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Substantia Nigra | 2018 |
Dramatic improvement by levodopa treatment in a patient with vascular parkinsonism.
Topics: Antiparkinson Agents; Brain; Cerebrovascular Disorders; Diagnosis, Differential; Female; Humans; Levodopa; Middle Aged; Parkinsonian Disorders | 2019 |
SPG11-related parkinsonism: Clinical profile, molecular imaging and l-dopa response.
Topics: Adult; Antiparkinson Agents; Brain; Cognition Disorders; Cohort Studies; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Mutation; Neuropsychological Tests; Organotechnetium Compounds; Parkinsonian Disorders; Proteins; Single-Blind Method; Statistics, Nonparametric; Tomography Scanners, X-Ray Computed; Tomography, Emission-Computed, Single-Photon; Tropanes; Young Adult | 2018 |
Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation, Missense; Neurons; Parkinsonian Disorders; Protein Conformation | 2018 |
Treatment response in osmotic demyelination syndrome presenting as severe parkinsonism, ptosis and gaze palsy.
Topics: Blepharoptosis; Diagnosis, Differential; Humans; Hyponatremia; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Myelinolysis, Central Pontine; Parkinsonian Disorders; Syndrome | 2018 |
A case of Perry Syndrome responding to intestinal infusion of carbidopa/levodopa.
Topics: Antiparkinson Agents; Carbidopa; Depression; Drug Combinations; Female; Gels; Humans; Hypoventilation; Infusions, Parenteral; Jejunostomy; Levodopa; Middle Aged; Parkinsonian Disorders | 2019 |
Earlier onset of motor complications in Parkinson's patients with comorbid diabetes mellitus.
Topics: Aged; Antiparkinson Agents; Diabetes Complications; Diabetes Mellitus; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Parkinsonian Disorders | 2018 |
Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Protein Precursors; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; RNA, Messenger; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Time Factors; Vilazodone Hydrochloride | 2018 |
Dyskinesia and brain-derived neurotrophic factor levels after long-term levodopa and nicotinic receptor agonist treatments in female mice with near-total unilateral dopaminergic denervation.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Brain; Brain-Derived Neurotrophic Factor; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Furans; Levodopa; Mice, Inbred C57BL; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Quinuclidines; Random Allocation | 2018 |
The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice.
Topics: Animals; Anticonvulsants; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred ICR; Oxidopamine; Parkinsonian Disorders; Treatment Outcome; Zonisamide | 2019 |
Differential Expression of Striatal ΔFosB mRNA and FosB mRNA After Different Levodopa Treatment Regimens in a Rat Model of Parkinson's Disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Functional Laterality; Gene Expression; Levodopa; Male; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats, Sprague-Dawley; RNA, Messenger; Time Factors | 2019 |
Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Dopamine; Drug Combinations; Dyskinesia, Drug-Induced; Levodopa; Liraglutide; Male; Motor Activity; Parkinsonian Disorders; Pars Compacta; Random Allocation; Rats, Wistar; Rotenone; Sitagliptin Phosphate | 2019 |
Craniocervical dystonia with levodopa-responsive parkinsonism co-segregating with a pathogenic ANO3 mutation in a Taiwanese family.
Topics: Anoctamins; Cervical Vertebrae; Dystonia; Female; Genetic Variation; Humans; Levodopa; Male; Middle Aged; Mutation; Parkinsonian Disorders; Pedigree; Skull; Taiwan; Young Adult | 2019 |
Spike and Local Field Synchronization Between the Pedunculopontine Nucleus and Primary Motor Cortex in a Rat Model of Parkinson's Disease.
Topics: Action Potentials; Animals; Disease Models, Animal; Levodopa; Male; Motor Cortex; Oxidopamine; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Rats; Rats, Wistar | 2019 |
Striatal spreading depolarization: Possible implication in levodopa-induced dyskinetic-like behavior.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiparkinson Agents; Corpus Striatum; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Levodopa; Neurons; Nitrogen Mustard Compounds; Parkinsonian Disorders; Prednisolone; Procarbazine; Rats; Rats, Wistar; Synaptic Transmission; Vincristine | 2019 |
Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia.
Topics: Activins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Mice, Inbred C57BL; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Random Allocation; Treatment Failure | 2019 |
Fact-finding survey on diagnostic procedures and therapeutic interventions for parkinsonism accompanying dementia with Lewy bodies.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Lewy Body Disease; Middle Aged; Muscle Rigidity; Neurologists; Parkinsonian Disorders; Physicians; Postural Balance; Psychiatry; Psychotropic Drugs; Tremor | 2019 |
Parkinsonism Caused by Viral Encephalitis Affecting the Bilateral Substantia Nigra.
Topics: Acyclovir; Benserazide; Drug Combinations; Drug Therapy, Combination; Encephalitis, Viral; Female; Humans; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Substantia Nigra; Young Adult | 2019 |
Optostimulation of striatonigral terminals in substantia nigra induces dyskinesia that increases after L-DOPA in a mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Lasers; Levodopa; Mice, Inbred C57BL; Optogenetics; Oxidopamine; Parkinsonian Disorders; Photic Stimulation; Substantia Nigra | 2019 |
Baicalein enhances the effect of low dose Levodopa on the gait deficits and protects dopaminergic neurons in experimental Parkinsonism.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopaminergic Neurons; Flavanones; Gait; Levodopa; Male; Mice; Neuroprotective Agents; Parkinsonian Disorders; Plant Extracts; Scutellaria baicalensis | 2019 |
Late-onset presentation of POLG1-associated mitochondrial disease.
Topics: Age of Onset; Aged; Antiparkinson Agents; Blepharoptosis; Disease Progression; DNA Polymerase gamma; Humans; Levodopa; Male; Mitochondrial Diseases; Ophthalmoplegia, Chronic Progressive External; Parkinsonian Disorders; Point Mutation; Treatment Outcome | 2019 |
Multiple system atrophy mimicked by multi-organ pathology.
Topics: Aged; Diagnosis, Differential; Humans; Levodopa; Male; Multiple Organ Failure; Multiple System Atrophy; Parkinsonian Disorders | 2019 |
Dopamine drives binge-like consumption of a palatable food in experimental Parkinsonism.
Topics: Animals; Dopamine Agents; Eating; Feeding Behavior; Food Preferences; Levodopa; Long-Term Potentiation; Male; Nucleus Accumbens; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Weight Gain | 2019 |
Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Calcium Channels; Disease Models, Animal; Dyskinesia, Drug-Induced; Green Fluorescent Proteins; Levodopa; Luminescent Agents; Medial Forebrain Bundle; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; RNA Interference; RNA, Small Interfering; Substantia Nigra; Tyrosine 3-Monooxygenase | 2019 |
Brain state-dependent alterations of corticostriatal synchronized oscillations in awake and anesthetized parkinsonian rats.
Topics: Anesthesia; Animals; Basal Ganglia; Beta Rhythm; Brain; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Motor Cortex; Neural Pathways; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Wakefulness | 2019 |
Acute parkinsonism as an unexpected consequence of pituitary adenoma resection: A case report.
Topics: Adenoma; Adult; Carbidopa; Drug Combinations; Female; Humans; Hyponatremia; Levodopa; Magnetic Resonance Imaging; Myelinolysis, Central Pontine; Parkinsonian Disorders; Pituitary Neoplasms | 2019 |
l-Dopa-free learned dyskinetic behavior in a Parkinson's primate model.
Topics: Animals; Antiparkinson Agents; Conditioning, Psychological; Disease Models, Animal; Dyskinesia, Drug-Induced; Dyskinesias; Levodopa; Macaca; Parkinsonian Disorders | 2019 |
Video-based assessments of the hind limb stepping in a mouse model of hemi-parkinsonism.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Gait; Hindlimb; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Tyrosine 3-Monooxygenase | 2020 |
Gait stride-to-stride variability and foot clearance pattern analysis in Idiopathic Parkinson's Disease and Vascular Parkinsonism.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Female; Foot; Gait Disorders, Neurologic; Humans; Kinetics; Levodopa; Longitudinal Studies; Male; Parkinsonian Disorders; Walking | 2019 |
Residual signs of dopa-responsive dystonia with GCH1 mutation following levodopa treatment are uncommon in Korean patients.
Topics: Adolescent; Adult; Child; Child, Preschool; Dopamine Agents; Dystonic Disorders; Female; GTP Cyclohydrolase; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Republic of Korea; Young Adult | 2019 |
Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dependovirus; Drug Evaluation, Preclinical; Female; Genes, Reporter; Genes, Synthetic; Genetic Vectors; GTP Cyclohydrolase; Humans; Levodopa; Macaca mulatta; Male; Motor Activity; Parkinsonian Disorders; Pars Compacta; Proof of Concept Study; Putamen; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Tyrosine 3-Monooxygenase | 2019 |
Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Treatment Outcome | 2013 |
Parkinsonism is a late, not rare, feature of CADASIL: a study on Italian patients carrying the R1006C mutation.
Topics: Aged; Brain; CADASIL; Exons; Female; Genetic Predisposition to Disease; Humans; Italy; Leukoencephalopathies; Levodopa; Magnetic Resonance Imaging; Male; Mutation; Parkinsonian Disorders; Receptor, Notch3; Receptors, Notch; Tomography, Emission-Computed, Single-Photon | 2013 |
Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Berberine; Dopamine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Levodopa; Male; Neurons; Neurotoxicity Syndromes; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Time Factors | 2013 |
Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
Topics: Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Physical Conditioning, Animal | 2013 |
The effect of dopamine on MPTP-induced rotarod disability.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Parkinsonian Disorders; Receptors, Dopamine D1; Rotarod Performance Test; Time Factors | 2013 |
Transcortical motor aphasia and unilateral parkinsonism in a case of hyperostosis frontalis.
Topics: Aged; Antiparkinson Agents; Aphasia, Broca; Dopamine Antagonists; Female; Functional Laterality; Handwriting; Humans; Hyperostosis Frontalis Interna; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Speech Disorders; Tiapride Hydrochloride | 2013 |
Degradation of stored movement representations in the Parkinsonian brain and the impact of levodopa.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Brain; Female; Humans; Imaging, Three-Dimensional; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement; Oxygen; Parkinsonian Disorders; Photic Stimulation; Reaction Time; Severity of Illness Index | 2013 |
Behavioral characterization of the 6-hydroxidopamine model of Parkinson's disease and pharmacological rescuing of non-motor deficits.
Topics: Adrenergic Agents; Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Bupropion; Disease Models, Animal; Immunohistochemistry; Levodopa; Mood Disorders; Motor Activity; Oxidopamine; Parkinsonian Disorders; Paroxetine; Rats; Rats, Wistar | 2013 |
The K(V)7.2/3 preferring channel opener ICA 27243 attenuates L-DOPA-induced dyskinesia in hemiparkinsonian rats.
Topics: Animals; Benzamides; Dyskinesia, Drug-Induced; Female; Ion Channel Gating; KCNQ2 Potassium Channel; KCNQ3 Potassium Channel; Levodopa; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2013 |
Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Topics: 2-Amino-5-phosphonovalerate; Amino Acids; Animals; Basal Ganglia; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Imidazoles; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Phenols; Piperidines; Pyridines; Quinazolines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Tritium; Xanthenes | 2013 |
L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Cerebral Cortex; Corpus Striatum; Dendritic Spines; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Male; Membrane Potentials; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2014 |
Transplantation of melanocytes obtained from the skin ameliorates apomorphine-induced abnormal behavior in rodent hemi-parkinsonian models.
Topics: Analysis of Variance; Animals; Apomorphine; Corpus Striatum; Dopamine; Immunohistochemistry; Levodopa; Melanocytes; Mice; Monophenol Monooxygenase; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation | 2013 |
Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism.
Topics: Adolescent; Adult; Age of Onset; Auxilins; Child; Cognition Disorders; Consanguinity; Dystonia; Exome; Female; Genes, Recessive; Genetic Variation; Homozygote; Humans; Italy; Levodopa; Male; Middle Aged; Mutation; Parkinsonian Disorders; Pedigree; Phosphoric Monoester Hydrolases; Radiography; Sequence Analysis, DNA; Young Adult | 2013 |
Commentary.
Topics: Antiparkinson Agents; Dyskinesia, Drug-Induced; Humans; Levodopa; Male; Parkinsonian Disorders; Substantia Nigra | 2013 |
Wearing-off phenomena and levodopa-induced dyskinesias in posttraumatic hemiparkinsonism.
Topics: Aged; Antiparkinson Agents; Craniocerebral Trauma; Dyskinesia, Drug-Induced; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Radiography; Substantia Nigra; Tomography Scanners, X-Ray Computed | 2013 |
Therapeutic response to pramipexole in a patient with multiple system atrophy with predominant parkinsonism: positron emission tomography and pharmacokinetic assessments.
Topics: Antiparkinson Agents; Benzothiazoles; Brain; Comorbidity; Dose-Response Relationship, Drug; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Multiple System Atrophy; Parkinsonian Disorders; Positron-Emission Tomography; Pramipexole; Treatment Outcome | 2013 |
The discriminating properties of an optoelectronic movement analysis method in patients with parkinsonism.
Topics: Aged; Antiparkinson Agents; Diagnosis, Differential; Female; Humans; Levodopa; Linear Models; Logistic Models; Male; Middle Aged; Movement; Multiple System Atrophy; Parkinsonian Disorders; Posture; Reproducibility of Results; ROC Curve; Supranuclear Palsy, Progressive | 2013 |
5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Topics: 5-Hydroxytryptophan; Adrenergic Agents; Animals; Caudate Nucleus; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin | 2013 |
Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Dopamine Agonists; Drug Synergism; Dyskinesia, Drug-Induced; Levodopa; Parkinsonian Disorders; Pyridines; Rats; Receptor, Metabotropic Glutamate 5; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Receptors, Dopamine D1; Serotonin Receptor Agonists; Thiazoles | 2013 |
Levodopa induces long-lasting modification in the functional activity of the nigrostriatal pathway.
Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Corpus Striatum; Dihydroxyphenylalanine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Neural Pathways; Parkinsonian Disorders; Positron-Emission Tomography; Substantia Nigra | 2014 |
Alterations in the expression of nNOS in the substantia nigra and subthalamic nucleus of 6-OHDA-lesioned rats: the effects of chronic treatment with l-DOPA and the nitric oxide donor, molsidomine.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Blotting, Western; Immunohistochemistry; Levodopa; Male; Molsidomine; NADPH Dehydrogenase; Neurons; Nitric Oxide Donors; Nitric Oxide Synthase Type I; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra; Subthalamic Nucleus | 2013 |
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
Topics: Amphetamine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzazepines; Buspirone; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Mesencephalon; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides; Serotonin Receptor Agonists | 2014 |
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Pyridines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT1 Receptor Agonists | 2013 |
Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; In Situ Hybridization; Levodopa; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus | 2013 |
Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Enkephalins; Female; Globus Pallidus; Levodopa; Macaca mulatta; Neuropeptides; Parkinsonian Disorders; Protein Precursors; Putamen; Tachykinins | 2014 |
D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Electrocardiography; Electroencephalography; Electromyography; Female; Levodopa; Macaca fascicularis; Macaca mulatta; Parkinsonian Disorders; Quinpirole; Sleep; Sleep Disorders, Circadian Rhythm; Telemetry; Time Factors; Wakefulness | 2014 |
An 85-year old male with levodopa-responsive parkinsonism followed by dementia and supranuclear ophthalmoplegia caused by alzheimer-type pathology without Lewy bodies.
Topics: Aged, 80 and over; Alzheimer Disease; Amphetamine; Dementia; Humans; Imaging, Three-Dimensional; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Radiopharmaceuticals; Supranuclear Palsy, Progressive; Tomography, Emission-Computed, Single-Photon | 2014 |
L-DOPA-treatment in primates disrupts the expression of A(2A) adenosine-CB(1) cannabinoid-D(2) dopamine receptor heteromers in the caudate nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Caudate Nucleus; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Levodopa; Macaca fascicularis; Male; Parkinsonian Disorders; Putamen; Receptor, Adenosine A2A; Receptor, Cannabinoid, CB1; Receptors, Dopamine D2 | 2014 |
Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cell Count; Cell Survival; Dopamine Agents; Dopaminergic Neurons; Hippocampus; Levodopa; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Neural Stem Cells; Neurogenesis; Neuroprotective Agents; Olfactory Bulb; Oxidopamine; Parkinsonian Disorders; Selegiline | 2014 |
Thalamic stimulation alleviates levodopa-resistant rigidity in a patient with non-Parkinson's disease parkinsonian syndrome.
Topics: Aged; Deep Brain Stimulation; Humans; Levodopa; Male; Muscle Rigidity; Parkinsonian Disorders; Thalamus | 2014 |
Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Buspirone; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Mitogen-Activated Protein Kinase 1; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D3; Serotonin 5-HT1 Receptor Agonists; Severity of Illness Index; Signal Transduction | 2014 |
Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study.
Topics: Adult; Age Factors; Aged; Chi-Square Distribution; Disease Progression; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinsonian Disorders; Predictive Value of Tests; Protein Binding; Schizophrenia; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Tropanes | 2014 |
Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Benserazide; Benzothiazoles; Corpus Striatum; Hippocampus; Levodopa; Male; Motor Activity; Neurogenesis; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D3; Substantia Nigra; Time Factors | 2014 |
Effect of Tianqi antitremor granules on behavioral manifestations and expression of G protein-coupled receptor kinase 6 and β-arrestin1 in levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Arrestins; Behavior, Animal; beta-Arrestins; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Dyskinesia, Drug-Induced; Female; G-Protein-Coupled Receptor Kinases; Immunohistochemistry; Levodopa; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2013 |
Parkinsonian syndrome and ataxia as a presenting finding of acquired hepatocerebral degeneration.
Topics: Antiparkinson Agents; Ataxia; Atrophy; Brain; Diagnosis, Differential; Female; Hepatic Encephalopathy; Humans; Levodopa; Liver Cirrhosis, Alcoholic; Magnetic Resonance Imaging; Middle Aged; Parkinsonian Disorders; Wine | 2014 |
Morphological and electrophysiological changes in intratelencephalic-type pyramidal neurons in the motor cortex of a rat model of levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Dendritic Spines; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Levodopa; Male; Motor Cortex; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Pyramidal Cells; Rats; Rats, Wistar; Telencephalon | 2014 |
Asymmetric postural tremor preceding DOPA-responsive Parkinsonism - the transition disease.
Topics: Aged; Brain; Disease Progression; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Posture; Prospective Studies; Tremor | 2014 |
Antioxidant potential of melatonin enhances the response to L-dopa in 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine-parkinsonian mice.
Topics: Animals; Antioxidants; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Carbidopa; Catalase; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Synergism; Glutathione; Glutathione Peroxidase; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Melatonin; Mice; Motor Activity; Oxidative Stress; Parkinsonian Disorders; Superoxide Dismutase | 2013 |
The effects of the β-lactam antibiotic, ceftriaxone, on forepaw stepping and L-DOPA-induced dyskinesia in a rodent model of Parkinson's disease.
Topics: Animals; Anti-Bacterial Agents; Antiparkinson Agents; Ceftriaxone; Central Nervous System Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Transporter 2; Forelimb; Kainic Acid; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats, Long-Evans | 2014 |
L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Cannabinoid Receptor Antagonists; Cholinesterase Inhibitors; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Functional Laterality; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperidines; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Rimonabant; Tacrine; Time Factors; Tremor | 2014 |
UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Benzodioxoles; Callithrix; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Mental Disorders; Methylamines; Molecular Structure; Motor Activity; Parkinsonian Disorders; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Time Factors | 2014 |
Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Levodopa; Macaca fascicularis; MAP Kinase Signaling System; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D1; Receptors, Dopamine D2; RNA, Messenger | 2014 |
Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in Parkinsonian mice.
Topics: Adenoviridae; Animals; Antiparkinson Agents; Behavior, Animal; Denervation; Diphtheria Toxin; DNA, Complementary; Dyskinesia, Drug-Induced; Hydroxydopamines; Image Processing, Computer-Assisted; Immunohistochemistry; Levodopa; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neostriatum; Parasympathetic Nervous System; Parkinsonian Disorders | 2014 |
The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Functional Laterality; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Time Factors; Tryptophan; Tyrosine 3-Monooxygenase | 2014 |
Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Gastrodia; Levodopa; Male; MAP Kinase Signaling System; Mice, Inbred C57BL; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos | 2014 |
Adenosine A₂A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Callithrix; Drug Synergism; Dyskinesias; Female; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Purines | 2014 |
Walther Birkmayer, Co-describer of L-Dopa, and his Nazi connections: victim or perpetrator?
Topics: Austria; History, 20th Century; Humans; Levodopa; National Socialism; Neurology; Nobel Prize; Parkinsonian Disorders; Pharmacology; World War II | 2014 |
Sustained increase of PKA activity in the postcommissural putamen of dyskinetic monkeys.
Topics: Animals; Corpus Striatum; Cyclic AMP-Dependent Protein Kinases; Levodopa; Macaca fascicularis; Male; Parkinsonian Disorders; Phosphorylation; Putamen; Receptors, Dopamine; Signal Transduction | 2014 |
Effects of 6-hydroxydopamine exposure on motor activity and biochemical expression in zebrafish (Danio rerio) larvae.
Topics: Animals; Antiparkinson Agents; Anxiety; Biomarkers; Blotting, Western; Carbidopa; Disease Models, Animal; Drug Combinations; Levodopa; Minocycline; Motor Activity; Oxidopamine; Parkinsonian Disorders; Real-Time Polymerase Chain Reaction; Sympatholytics; Vitamin E; Zebrafish; Zebrafish Proteins | 2014 |
Toxicity and metabolism of layered double hydroxide intercalated with levodopa in a Parkinson's disease model.
Topics: Aluminum; Animals; Cell Line; Cell Survival; Homovanillic Acid; Hydroxides; Levodopa; Nanocomposites; Nanoconjugates; Nanoparticles; Parkinsonian Disorders; PC12 Cells; Rats; Zinc | 2014 |
Effects of gypenosides on anxiety disorders in MPTP-lesioned mouse model of Parkinson's disease.
Topics: Animals; Anti-Anxiety Agents; Antiparkinson Agents; Anxiety Disorders; Behavior, Animal; Brain; Dopamine; Dopaminergic Neurons; Ethanol; Gynostemma; Levodopa; Male; Maze Learning; Mice, Inbred C57BL; Neuroprotective Agents; Neuropsychological Tests; Parkinsonian Disorders; Phytotherapy; Plant Extracts; Serotonin; Water | 2014 |
Noradrenergic terminals regulate L-DOPA-derived dopamine extracellular levels in a region-dependent manner in Parkinsonian rats.
Topics: Adrenergic Neurons; Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Extracellular Fluid; Levodopa; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2014 |
Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Butadienes; Cerebral Cortex; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Mice, Knockout; Neuronal Plasticity; Neurons; Nitriles; Oxidopamine; Parkinsonian Disorders; Protein Kinase Inhibitors; ras-GRF1; Tissue Culture Techniques | 2015 |
Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome.
Topics: Antiparkinson Agents; Epilepsies, Myoclonic; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Parkinsonian Disorders; Sensation Disorders; Statistics, Nonparametric; Videotape Recording | 2014 |
Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
Topics: Acetylation; Animals; Antiparkinson Agents; Blotting, Western; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Endorphins; Histones; Immunohistochemistry; Kv Channel-Interacting Proteins; Levodopa; Mice, Knockout; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Receptors, AMPA; Repressor Proteins; Rotarod Performance Test | 2015 |
NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Excitatory Amino Acid Antagonists; Extracellular Space; Functional Laterality; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Subthalamic Nucleus | 2014 |
Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Catechol O-Methyltransferase; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Levodopa; Male; Methylation; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Parkinsonian Disorders; Time Factors | 2014 |
RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Cells, Cultured; Corpus Striatum; Dyskinesia, Drug-Induced; Enkephalins; Functional Laterality; Gene Expression; Genetic Therapy; Levodopa; Male; Oligonucleotides, Antisense; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RGS Proteins; RNA, Messenger; Up-Regulation | 2014 |
Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism.
Topics: Animals; Basal Ganglia; Cannabinoids; Levodopa; Macaca; Male; Neurons; Parkinsonian Disorders; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2015 |
Sleep disorders in Parkinsonian macaques: effects of L-dopa treatment and pedunculopontine nucleus lesion.
Topics: Animals; Benserazide; Cholinergic Neurons; Diphtheria Toxin; Drug Combinations; Levodopa; Macaca fascicularis; Male; MPTP Poisoning; Muscle Tonus; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Polysomnography; Recombinant Fusion Proteins; Sleep Deprivation; Sleep Disorders, Intrinsic; Sleep, REM; Urotensins; Wakefulness | 2014 |
Cortico-striatal-thalamic network functional connectivity in hemiparkinsonism.
Topics: Aged; Corpus Striatum; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neural Pathways; Parkinsonian Disorders; Temporal Lobe; Thalamus | 2014 |
[Influence of hemantane in injectable dosage form on levodopa-induced dyskinesia in rats with model parkinsonian syndrome].
Topics: Adamantane; Adrenergic Agents; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats | 2014 |
Effect of a chronic treatment with an mGlu5 receptor antagonist on brain serotonin markers in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Benserazide; Brain; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Combinations; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Homovanillic Acid; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Protein Binding; Pyridines; Serotonin | 2015 |
l-DOPA reverses the impairment of Dentate Gyrus LTD in experimental parkinsonism via β-adrenergic receptors.
Topics: Animals; Antiparkinson Agents; Benzazepines; Dentate Gyrus; Disease Models, Animal; Dopamine; Dopamine Antagonists; Electric Stimulation; Functional Laterality; Levodopa; Long-Term Synaptic Depression; Male; Microdialysis; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Sulpiride | 2014 |
Functional correlates of exaggerated oscillatory activity in basal ganglia output in hemiparkinsonian rats.
Topics: Action Potentials; Adrenergic Agents; Animals; Antiparkinson Agents; Basal Ganglia; Brain Waves; Disease Models, Animal; Dopamine Antagonists; Functional Laterality; Levodopa; Male; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Piperazines; Pyridines; Rats; Rats, Long-Evans; Salicylamides; Serotonin Antagonists; Substantia Nigra | 2014 |
Inhibition of adenylyl cyclase type 5 prevents L-DOPA-induced dyskinesia in an animal model of Parkinson's disease.
Topics: Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Animals; Antiparkinson Agents; Blotting, Western; Disease Models, Animal; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Parkinsonian Disorders; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
A new quantitative rating scale for dyskinesia in nonhuman primates.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Macaca mulatta; Male; Observer Variation; Parkinsonian Disorders; Reproducibility of Results; Severity of Illness Index; Video Recording | 2015 |
Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.
Topics: Animals; Animals, Newborn; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Functional Laterality; Green Fluorescent Proteins; In Vitro Techniques; Levodopa; Mice; Mice, Transgenic; Neural Pathways; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Purinergic Agents; Receptor, Adenosine A2A; Receptors, Dopamine D1 | 2014 |
Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism.
Topics: Aged; Aged, 80 and over; Brain; Carbon Isotopes; Dopamine Agents; Family Health; Fluorodeoxyglucose F18; Humans; Levodopa; Middle Aged; Molecular Chaperones; Mutation; Parkinsonian Disorders; Positron-Emission Tomography; Tetrabenazine | 2014 |
Dopamine signaling leads to loss of Polycomb repression and aberrant gene activation in experimental parkinsonism.
Topics: Animals; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Female; Gene Expression Regulation; Genetic Loci; Histones; Levodopa; Mice; Mice, Knockout; Parkinsonian Disorders; Phosphorylation; Polycomb-Group Proteins; Protein Binding; Ribosomal Protein S6 Kinases, 90-kDa; RNA, Messenger; Signal Transduction; Transcriptional Activation | 2014 |
Older treatment may be best overall for treating new Parkinson's.
Topics: Antiparkinson Agents; Controlled Clinical Trials as Topic; Humans; Levodopa; Male; Parkinsonian Disorders; Psychomotor Performance; Task Performance and Analysis | 2014 |
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinsonian Disorders; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Species Specificity | 2015 |
Effects of dopamine uptake inhibitor MRZ-9547 in animal models of Parkinson's disease.
Topics: Acetamides; Animals; Brain; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Haloperidol; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pyrrolidinones; Rats, Sprague-Dawley | 2015 |
New ghrelin agonist, HM01 alleviates constipation and L-dopa-delayed gastric emptying in 6-hydroxydopamine rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Brain; Constipation; Gastrointestinal Transit; Ghrelin; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2014 |
Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Corpus Striatum; Dimerization; Dominance, Cerebral; Dopamine; Dopamine Agonists; Dyskinesia, Drug-Induced; Gene Expression Regulation; Levodopa; Macaca fascicularis; Male; Oxidopamine; Parkinsonian Disorders; Putamen; Radioligand Assay; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Dopamine D3 | 2015 |
Chronic levodopa treatment alters expression and function of dopamine D3 receptor in the MPTP/p mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Green Fluorescent Proteins; Levodopa; Mice, Mutant Strains; Motor Activity; Parkinsonian Disorders; Receptors, Dopamine D3 | 2015 |
Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Dyskinesia Agents; Cell Death; Cytosol; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Levodopa; Mesencephalon; Mice, Inbred C57BL; Mice, Transgenic; Motor Skills; Movement Disorders; Oxidative Stress; Parkinsonian Disorders; Vesicular Monoamine Transport Proteins | 2015 |
L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Random Allocation | 2014 |
Levodopa-induced dyskinesias are associated with transient down-regulation of cAMP and cGMP in the caudate-putamen of hemiparkinsonian rats: reduced synthesis or increased catabolism?
Topics: Animals; Antiparkinson Agents; Caudate Nucleus; Cyclic AMP; Cyclic GMP; Down-Regulation; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Putamen; Rats; Rats, Wistar | 2014 |
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Dopamine; Dynorphins; Dyskinesia, Drug-Induced; Early Growth Response Protein 1; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; PPAR gamma; Rats, Sprague-Dawley; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2015 |
Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dopaminergic Neurons; Drug Synergism; Levodopa; Male; Melatonin; Mice; Mice, Inbred BALB C; Neuroprotective Agents; Parkinsonian Disorders; Substantia Nigra | 2015 |
Dopamine-dependent corticostriatal synaptic filtering regulates sensorimotor behavior.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Dopamine; Dopamine Agents; Levodopa; Mice, Inbred C57BL; Motor Activity; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Dopamine D2; Synapses; Tissue Culture Techniques | 2015 |
Nitrosative and cognitive effects of chronic L-DOPA administration in rats with intra-nigral 6-OHDA lesion.
Topics: Animals; Antiparkinson Agents; Astrocytes; Carbidopa; Corpus Striatum; Gliosis; Levodopa; Male; Maze Learning; Memory Disorders; Memory, Short-Term; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Prefrontal Cortex; Rats, Wistar; Spatial Memory | 2015 |
The NR2B antagonist, ifenprodil, corrects the l-DOPA-induced deficit of bilateral movement and reduces c-Fos expression in the subthalamic nucleus of hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Brain; Forelimb; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Piperidines; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Subthalamic Nucleus | 2015 |
Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist.
Topics: Aminobutyrates; Animals; Antiparkinson Agents; Catalepsy; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Haloperidol; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphinic Acids; Picolinic Acids; Random Allocation; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate | 2015 |
Plasmalogen precursor analog treatment reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: Animals; Anti-Dyskinesia Agents; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Phosphatidylethanolamines; Plasmalogens | 2015 |
Effect of simvastatin on L-DOPA-induced abnormal involuntary movements of hemiparkinsonian rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Levodopa; Male; MAP Kinase Signaling System; Oncogene Proteins v-fos; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Simvastatin; Time Factors | 2015 |
Deep brain stimulation of different pedunculopontine targets in a novel rodent model of parkinsonism.
Topics: Animals; Cell Survival; Cholinergic Neurons; Deep Brain Stimulation; Disease Models, Animal; Dopaminergic Neurons; Gait; Ibotenic Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Postural Balance; Rats | 2015 |
Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Cocaine; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Transgenic; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Protein Binding; Receptors, Nicotinic | 2015 |
Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Clonidine; Dyskinesia, Drug-Induced; Imidazoles; Levodopa; Locus Coeruleus; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2 | 2015 |
Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Anxiety; Benzothiazoles; Depression; Hippocampus; Levodopa; Male; Mice, Inbred C57BL; Neurogenesis; Neurons; Olfactory Bulb; Oxidopamine; Parkinsonian Disorders; Pramipexole; Random Allocation | 2015 |
Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.
Topics: Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Microdialysis; Motor Activity; Parkinsonian Disorders; Propranolol; Rats; Rats, Sprague-Dawley | 2015 |
Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ethanol; Gynostemma; Levodopa; Locomotion; Male; MAP Kinase Signaling System; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Solvents | 2015 |
Subthalamic nucleus activity in the awake hemiparkinsonian rat: relationships with motor and cognitive networks.
Topics: Action Potentials; Adrenergic Agents; Animals; Antiparkinson Agents; Benzazepines; Cognition Disorders; Disease Models, Animal; Dopamine Antagonists; Evoked Potentials; Functional Laterality; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Long-Evans; Subthalamic Nucleus; Time Factors; Tyrosine 3-Monooxygenase; Wakefulness | 2015 |
Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca; Parkinsonian Disorders; Receptors, Glutamate; Subthalamic Nucleus | 2015 |
Similar L-dopa-stimulated motor activity in mice with adult-onset 6-hydroxydopamine-induced symmetric dopamine denervation and in transcription factor Pitx3 null mice with perinatal-onset symmetric dopamine denervation.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Homeodomain Proteins; Levodopa; Male; Mice; Mice, Knockout; Motor Activity; Oxidopamine; Parkinsonian Disorders; Transcription Factors | 2015 |
Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.
Topics: Adenine; Animals; Drug Delivery Systems; Drug Synergism; Levodopa; Male; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Pyridines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Rotation; Treatment Outcome; Xanthines | 2015 |
Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA?
Topics: Animals; Calbindins; Cyclooxygenase 2; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Nitric Oxide; Nitric Oxide Synthase; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2015 |
From unilateral to bilateral parkinsonism: Effects of lateralization on dyskinesias and associated molecular mechanisms.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Functional Laterality; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats, Sprague-Dawley; RNA, Messenger | 2015 |
Dissociative disorder manifesting for underlying adolescent hemi-parkinsonism: New chronology for old mummies.
Topics: Adult; Age of Onset; Antiparkinson Agents; Carbidopa; Dissociative Disorders; Drug Combinations; Female; Humans; Levodopa; Parkinsonian Disorders; Young Adult | 2015 |
The 5-HT4 Agonist Prucalopride Stimulates L-DOPA-Induced Dopamine Release in Restricted Brain Regions of the Hemiparkinsonian Rat In Vivo.
Topics: Animals; Benzofurans; Brain; Dopamine; Dopamine Agents; Functional Laterality; Indoles; Levodopa; Microdialysis; Oxidopamine; Parkinsonian Disorders; Rats; Serotonin 5-HT4 Receptor Agonists; Serotonin 5-HT4 Receptor Antagonists; Sulfonamides | 2015 |
Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia.
Topics: AIDS-Related Complex; Animals; Benzazepines; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression; Levodopa; Male; Medial Forebrain Bundle; Motor Cortex; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Synaptic Transmission | 2015 |
Effects of fibroblast transplantation into the internal pallidum on levodopa-induced dyskinesias in parkinsonian non-human primates.
Topics: Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Fibroblasts; Globus Pallidus; Levodopa; Macaca mulatta; Parkinsonian Disorders | 2015 |
Delayed chorea after recovery from severe akinetic-rigid parkinsonism caused by extrapontine myelinolysis.
Topics: Carbidopa; Chorea; Disease Progression; Dopamine Agonists; Drug Combinations; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Muscle Rigidity; Myelinolysis, Central Pontine; Parkinsonian Disorders | 2015 |
Amelioration of L-Dopa-Associated Dyskinesias with Triterpenoic Acid in a Parkinsonian Rat Model.
Topics: Adrenergic Agents; Age Factors; Animals; Animals, Newborn; Antiparkinson Agents; Catalase; Disease Models, Animal; Dyskinesia, Drug-Induced; Extremities; Female; Glutathione; Levodopa; Male; Movement; Oleanolic Acid; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric | 2016 |
Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.
Topics: Adrenergic Agents; Akathisia, Drug-Induced; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Glutamic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligodeoxyribonucleotides, Antisense; Oxidopamine; Parkinsonian Disorders; Radiopharmaceuticals; Receptors, G-Protein-Coupled; Stereotyped Behavior; Synaptic Transmission; Time Factors; Tyrosine 3-Monooxygenase | 2015 |
Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling.
Topics: Animals; Corpus Striatum; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Mice; Mice, Knockout; Parkinsonian Disorders; Receptors, Dopamine D1; Receptors, Dopamine D3 | 2017 |
Brain dopamine-serotonin vesicular transport disease presenting as a severe infantile hypotonic parkinsonian disorder.
Topics: Brain; Brain Diseases; Carbidopa; Child; Dopamine; Humans; Levodopa; Male; Parkinsonian Disorders; Polymorphism, Single Nucleotide; Serotonin | 2016 |
Loss of VGLUT3 Produces Circadian-Dependent Hyperdopaminergia and Ameliorates Motor Dysfunction and l-Dopa-Mediated Dyskinesias in a Model of Parkinson's Disease.
Topics: Amino Acid Transport Systems, Acidic; Animals; Circadian Rhythm; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Motor Skills Disorders; Parkinsonian Disorders | 2015 |
α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha7 Nicotinic Acetylcholine Receptor; Animals; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Nicotinic Agonists; Parkinsonian Disorders; Saimiri; Substantia Nigra | 2015 |
Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzazepines; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Gamma Rhythm; Levodopa; Male; Motor Activity; Motor Cortex; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists | 2016 |
Bridging the Gap: Muscarinic M4 Receptors Promote Striatal Plasticity in Health and Disease.
Topics: Animals; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Neostriatum; Neuronal Plasticity; Parkinsonian Disorders; Receptor, Muscarinic M4; RGS Proteins | 2015 |
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.
Topics: Allosteric Regulation; Animals; Cerebral Cortex; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Glutamic Acid; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Macaca mulatta; Mice; Mice, Transgenic; Neostriatum; Neuronal Plasticity; Neurons; Parkinsonian Disorders; Receptor, Muscarinic M4; RGS Proteins; Signal Transduction | 2015 |
Levodopa-Induced Motor and Dopamine Receptor Changes in Caenorhabditis elegans Overexpressing Human Alpha-Synuclein.
Topics: Actigraphy; alpha-Synuclein; Animals; Animals, Genetically Modified; Antiparkinson Agents; Caenorhabditis elegans; Dyskinesia, Drug-Induced; Humans; Levodopa; Microscopy, Confocal; Motor Activity; Motor Neurons; Parkinsonian Disorders; Pattern Recognition, Automated; Receptors, Dopamine | 2016 |
A patient with 41 CAG repeats in SCA17 presenting with parkinsonism and chorea.
Topics: Amantadine; Antiparkinson Agents; Benzothiazoles; Brain; Chorea; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Positron-Emission Tomography; Pramipexole; Spinocerebellar Ataxias; TATA-Box Binding Protein; Trinucleotide Repeats | 2016 |
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dyskinesia, Drug-Induced; Levodopa; Male; MAP Kinase Signaling System; Motor Activity; Neuronal Plasticity; Neurons; Oxidopamine; Parkinsonian Disorders; Piperazines; Rats; Rats, Wistar; Serotonin Receptor Agonists; Synapses; Synaptic Transmission; TOR Serine-Threonine Kinases | 2016 |
Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia.
Topics: Amino Acid Transport Systems, Acidic; Animals; Antiparkinson Agents; Cell Count; Cell Size; Choline O-Acetyltransferase; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mice, Inbred C57BL; Mice, Transgenic; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Receptors, AMPA; Ribosomal Protein S6; Vesicular Acetylcholine Transport Proteins | 2016 |
Coherence of neuronal firing of the entopeduncular nucleus with motor cortex oscillatory activity in the 6-OHDA rat model of Parkinson's disease with levodopa-induced dyskinesias.
Topics: Action Potentials; Animals; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Levodopa; Male; Motor Cortex; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2016 |
CART modulates the effects of levodopa in rat model of Parkinson's disease.
Topics: Animals; Antibodies; Antiparkinson Agents; Apomorphine; Brain; Dopamine Agonists; Dose-Response Relationship, Drug; Fluorescent Antibody Technique; Levodopa; Male; Movement; Nerve Tissue Proteins; Neurons; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Rotarod Performance Test; Tyrosine 3-Monooxygenase | 2016 |
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cross-Over Studies; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyridines; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists | 2016 |
p11 modulates L-DOPA therapeutic effects and dyskinesia via distinct cell types in experimental Parkinsonism.
Topics: Animals; Annexin A2; Dyskinesias; Levodopa; Mice; Mice, Knockout; Parkinsonian Disorders; S100 Proteins | 2016 |
Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats.
Topics: Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Dopamine; Dyskinesias; Levodopa; Male; Norepinephrine Plasma Membrane Transport Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins | 2016 |
Chronic L-DOPA administration increases the firing rate but does not reverse enhanced slow frequency oscillatory activity and synchronization in substantia nigra pars reticulata neurons from 6-hydroxydopamine-lesioned rats.
Topics: Action Potentials; Animals; Brain; Brain Waves; Cerebral Cortex; Disease Models, Animal; Dyskinesia, Drug-Induced; GABAergic Neurons; Levodopa; Neurons; Oxidopamine; Parkinsonian Disorders; Pars Reticulata; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus | 2016 |
Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
Topics: Animals; Antigens, Differentiation; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; MAP Kinase Signaling System; Mice; Mice, Knockout; Motor Activity; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine D1; RNA, Messenger; Substantia Nigra | 2016 |
Targeting the D1-N-methyl-D-aspartate receptor complex reduces L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.
Topics: Animals; Dyskinesia, Drug-Induced; Female; Levodopa; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate | 2016 |
Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
Topics: Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Cytoskeleton; Drug Combinations; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Random Allocation; Rats, Wistar; RNA, Messenger; Tyrosine 3-Monooxygenase | 2016 |
β-asarone and levodopa co-administration increase striatal dopamine level in 6-hydroxydopamine induced rats by modulating P-glycoprotein and tight junction proteins at the blood-brain barrier and promoting levodopa into the brain.
Topics: Allylbenzene Derivatives; Animals; Anisoles; ATP Binding Cassette Transporter, Subfamily B; Blood-Brain Barrier; Corpus Striatum; Dopamine; Drug Therapy, Combination; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Tight Junction Proteins | 2016 |
Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Cyclic AMP-Dependent Protein Kinases; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Glycogen Synthase Kinase 3 beta; Levodopa; Mitogen-Activated Protein Kinase 3; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Rats; Receptors, Dopamine D1; tau Proteins; Thiadiazoles; Tyrosine 3-Monooxygenase | 2016 |
Ibuprofen or piroxicam protects nigral neurons and delays the development of l-dopa induced dyskinesia in rats with experimental Parkinsonism: Influence on angiogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dyskinesia, Drug-Induced; Female; Ibuprofen; Levodopa; Neovascularization, Physiologic; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Piroxicam; Random Allocation; Rats; Substantia Nigra; Time Factors | 2016 |
Parkinsonism and cognitive impairment due to a giant frontal arachnoid cyst and improving after shunting.
Topics: Aged; Antiparkinson Agents; Arachnoid Cysts; Cerebrospinal Fluid Shunts; Cognition Disorders; Female; Humans; Levodopa; Mental Status Schedule; Parkinsonian Disorders; Postoperative Complications; Tomography Scanners, X-Ray Computed | 2017 |
Mystery Case: Parkinsonism in a diabetic uremic patient.
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Diabetes Mellitus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Renal Dialysis; Steroids | 2016 |
L-DOPA treatment in MPTP-mouse model of Parkinson's disease potentiates homocysteine accumulation in substantia nigra.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Homocysteine; Levodopa; Male; Mice; Motor Activity; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2016 |
Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action.
Topics: Animals; Anti-Dyskinesia Agents; Arachidonic Acids; Brain; Cannabidiol; Capsaicin; Cyclooxygenase 2; Dyskinesia, Drug-Induced; Endocannabinoids; Extracellular Signal-Regulated MAP Kinases; Histones; Levodopa; Male; Mice, Inbred C57BL; NF-kappa B; Oxidopamine; Parkinsonian Disorders; Polyunsaturated Alkamides; PPAR gamma; Receptor, Cannabinoid, CB1; TRPV Cation Channels; Tyrosine 3-Monooxygenase | 2016 |
Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats.
Topics: Animals; Dopamine Plasma Membrane Transport Proteins; Levodopa; Male; Norepinephrine Plasma Membrane Transport Proteins; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins | 2016 |
Facial tremors in patients with and without parkinsonism.
Topics: Aged; Aged, 80 and over; Dopamine Agents; Face; Female; Humans; Levodopa; Male; Parkinsonian Disorders; Retrospective Studies; Sensitivity and Specificity; Tremor | 2016 |
Small (autonomic) and large fiber neuropathy in Parkinson disease and parkinsonism.
Topics: Age Factors; Aged; Antiparkinson Agents; Autonomic Nervous System Diseases; Autonomic Pathways; Diabetes Complications; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Neural Conduction; Neuromuscular Junction; Parkinson Disease; Parkinsonian Disorders; Peripheral Nervous System Diseases; Skin | 2016 |
Medication use in people with late stage Parkinson's disease and parkinsonism living at home and in institutional care in north-east England: A balance of symptoms and side-effects?
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; England; Female; Home Care Services; Humans; Levodopa; Male; Nursing Homes; Parkinson Disease; Parkinsonian Disorders; Postural Balance; Quality of Life; Retrospective Studies; Sensation Disorders | 2016 |
The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Agents; GABA Agents; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Motor Cortex; Movement; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Signal Transduction; Sympatholytics; Tardive Dyskinesia | 2016 |
Continuous MPTP intoxication in the Göttingen minipig results in chronic parkinsonian deficits.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drinking; Drug Administration Schedule; Drug Delivery Systems; Eating; Female; Injections, Intramuscular; Levodopa; Neurotoxins; Parkinsonian Disorders; Severity of Illness Index; Swine; Swine, Miniature; Time Factors | 2016 |
Beneficial anti-Parkinson effects of camel milk in Chlorpromazineinduced animal model: Behavioural and histopathological study.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Brain; Camelus; Carbidopa; Catalepsy; Chlorpromazine; Drug Combinations; Female; Levodopa; Male; Milk; Parkinsonian Disorders; Rats, Wistar; Time Factors | 2016 |
Contribution of the nitric oxide donor molsidomine and the antiparkinsonian drug l-DOPA to the modulation of the blood pressure in unilaterally 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Blood Pressure; Levodopa; Male; Molsidomine; Nitric Oxide Donors; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2017 |
Intrastriatal injection of ionomycin profoundly changes motor response to l-DOPA and its underlying molecular mechanisms.
Topics: Animals; Antiparkinson Agents; Calcineurin; Calcium Ionophores; Corpus Striatum; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Glutamic Acid; Ionomycin; Levodopa; Male; MAP Kinase Signaling System; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2017 |
Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
Topics: Animals; Antiparkinson Agents; Avoidance Learning; Corpus Striatum; Dioxoles; Dopamine; Dose-Response Relationship, Drug; Levodopa; Lignans; Male; Memory; Memory Disorders; Mice, Inbred C57BL; Motor Activity; Nootropic Agents; Parkinsonian Disorders; RNA, Messenger; Substantia Nigra | 2016 |
Pallidal Deep Brain Stimulation for the Treatment of Levodopa-Responsive Juvenile Dystonia and Parkinsonism Secondary to SPG11 Mutation.
Topics: Action Potentials; Antiparkinson Agents; Deep Brain Stimulation; Dystonia; Female; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Mutation; Neurons; Parkinsonian Disorders; Proteins; Treatment Outcome; Young Adult | 2017 |
Novel compound heterozygous synaptojanin-1 mutation causes l-dopa-responsive dystonia-parkinsonism syndrome.
Topics: Antiparkinson Agents; Corpus Striatum; Dystonic Disorders; Humans; Levodopa; Male; Mutation; Nerve Tissue Proteins; Parkinsonian Disorders; Pedigree; Phosphoric Monoester Hydrolases; Tomography, Emission-Computed, Single-Photon | 2017 |
Three Cases of Levodopa-Resistant Parkinsonism After Radiation Therapy.
Topics: Adult; Aged; Antiparkinson Agents; Brain Neoplasms; Child; Drug Resistance; Female; Humans; Leukoencephalopathies; Levodopa; Male; Parkinsonian Disorders; Radiotherapy, Adjuvant; Treatment Failure | 2016 |
Octogenarian parkinsonism - Clinicopathological observations.
Topics: Aged, 80 and over; Aging; Antiparkinson Agents; Autopsy; Brain; Disease Progression; Female; Humans; Levodopa; Longitudinal Studies; Male; Parkinsonian Disorders | 2017 |
The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.
Topics: Animals; Antidepressive Agents, Tricyclic; Antiparkinson Agents; Behavior, Animal; Callithrix; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Mianserin; Mirtazapine; Motor Activity; MPTP Poisoning; Parkinsonian Disorders; Psychoses, Substance-Induced | 2017 |
Asymmetric dopaminergic degeneration and levodopa alter functional corticostriatal connectivity bilaterally in experimental parkinsonism.
Topics: Animals; Corpus Striatum; Diffusion Tensor Imaging; Disease Models, Animal; Dopamine; Levodopa; Male; Medial Forebrain Bundle; Parkinsonian Disorders; Rats, Sprague-Dawley; Substantia Nigra | 2017 |
Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
Topics: Animals; Antiparkinson Agents; Channelrhodopsins; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Female; Gene Expression Regulation; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Oxidopamine; Parkinsonian Disorders; Receptors, Dopamine D1; Sympatholytics | 2017 |
Anti-Parkinsonian L-Dopa can also act as anti-systemic amyloidosis-A mechanistic exploration.
Topics: Amyloidosis; Cell Line, Tumor; Cell Survival; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Levodopa; Molecular Docking Simulation; Muramidase; Parkinsonian Disorders; Protein Multimerization; Protein Structure, Secondary | 2017 |
Dysregulation of BET proteins in levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Azepines; Chromatin Immunoprecipitation; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Domains; Proteins; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Triazoles | 2017 |
Reuptake of L-DOPA-derived extracellular DA in the striatum of a rodent model of Parkinson's disease via norepinephrine transporter.
Topics: Animals; Antidepressive Agents, Tricyclic; Corpus Striatum; Denervation; Desipramine; Disease Models, Animal; Dopamine; Extracellular Matrix; Levodopa; Male; Microdialysis; Neurons; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Synapses; Synaptic Transmission | 2008 |
Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Corpus Striatum; Dizocilpine Maleate; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Hydroxyindoleacetic Acid; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Motor Skills; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, N-Methyl-D-Aspartate; Serotonin; Serotonin Receptor Agonists; Stereotyped Behavior | 2008 |
6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat.
Topics: 1-Methyl-3-isobutylxanthine; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Cyclic AMP; Disease Models, Animal; Dopamine Agents; Functional Laterality; gamma-Aminobutyric Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Rats; Rats, Wistar; Receptors, Dopamine D1; Substantia Nigra; Time Factors; Tritium | 2008 |
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2008 |
Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements.
Topics: Action Potentials; Analysis of Variance; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesias; Female; Levodopa; Macaca mulatta; Neurons; Parkinsonian Disorders | 2008 |
Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
Topics: Animals; Anti-Inflammatory Agents; Corpus Striatum; Corticosterone; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Encephalitis; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Levodopa; Male; Medial Forebrain Bundle; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Sympatholytics; Up-Regulation | 2008 |
L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antiparkinson Agents; Antipsychotic Agents; Benzazepines; Berberine; CHO Cells; Corpus Striatum; Cricetinae; Cricetulus; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Drug Interactions; Dyskinesias; Gene Expression Regulation; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; RNA, Messenger; Serotonin Receptor Agonists; Transfection; Tritium | 2010 |
Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.
Topics: Animals; Animals, Newborn; Brain; Cerebral Cortex; Cyclic AMP; Cyclic GMP; Dopamine; Dopamine Agents; Down-Regulation; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Neostriatum; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Phosphorylation; Purinones; Rats; Rats, Sprague-Dawley; Second Messenger Systems; Substantia Nigra; Sympatholytics; Synaptic Transmission | 2008 |
Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Female; Functional Laterality; Gene Expression; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger; Synaptotagmins; Time Factors | 2008 |
Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.
Topics: Animals; Antiparkinson Agents; Apomorphine; Brain; Catechols; Corpus Striatum; Dynorphins; Electron Transport Complex IV; Enkephalins; Gene Expression; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Nitriles; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Subthalamus | 2008 |
Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Interactions; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor-Like Protein Tyrosine Phosphatases, Class 5; RNA, Messenger; Up-Regulation | 2008 |
Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Creatine; Dietary Supplements; Disease Models, Animal; Dyskinesia, Drug-Induced; Energy Metabolism; Enkephalins; Female; In Vitro Techniques; Levodopa; Neostriatum; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Phosphocreatine; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Statistics, Nonparametric | 2009 |
Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism.
Topics: Adenosine Triphosphate; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Levodopa; Mitochondria; NAD; Neurons; Parkinsonian Disorders; Proto-Oncogene Proteins c-bcl-2; Psychomotor Performance; Rats; Rotenone; Spectrophotometry; Ubiquinone; Ultrasonography; Vitamins | 2008 |
Levodopa affects functional brain networks in Parkinsonian resting tremor.
Topics: Antiparkinson Agents; Brain; Brain Mapping; Cerebellum; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Motor Cortex; Nerve Net; Parietal Lobe; Parkinsonian Disorders; Somatosensory Cortex; Thalamus; Tremor | 2009 |
Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia.
Topics: Animals; Axonal Transport; Dementia; Disease Models, Animal; Frontal Lobe; Humans; Levodopa; Mice; Mice, Transgenic; Motor Skills Disorders; Mutation, Missense; Parkinsonian Disorders; Phenotype; Sciatic Nerve; Substantia Nigra; tau Proteins; Temporal Lobe | 2008 |
Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Benzazepines; Biperiden; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Female; Levodopa; Macaca nemestrina; Muscarinic Antagonists; Parkinsonian Disorders; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Tetrahydronaphthalenes; Thiophenes | 2008 |
Parkinsonism during cyclosporine treatment in liver transplantation: an unusual case report.
Topics: Adult; Cyclosporine; Hepatitis C; Humans; Immunosuppressive Agents; Levodopa; Liver Cirrhosis; Liver Transplantation; Male; Parkinsonian Disorders; Treatment Outcome | 2008 |
Pseudo-orthostatic and resting leg tremor in a large Spanish family with homozygous truncating parkin mutation.
Topics: Adult; Age of Onset; Antiparkinson Agents; Codon, Nonsense; Consanguinity; DNA Mutational Analysis; Exons; Female; Genotype; Humans; Levodopa; Male; Parkinsonian Disorders; Pedigree; Spain; Tremor; Ubiquitin-Protein Ligases | 2009 |
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Pyridines; Receptors, N-Methyl-D-Aspartate; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Treatment Outcome | 2008 |
The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Motor Activity; Narcotic Antagonists; Neural Pathways; Nociceptin Receptor; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Substantia Nigra; Thalamus; Time Factors | 2008 |
[Case of a 30-year history of PARK6 --findings from functional imaging of the brain].
Topics: Antiparkinson Agents; Benzothiazoles; Diagnostic Imaging; Female; Humans; Levodopa; Middle Aged; Mutation, Missense; Parkinsonian Disorders; Pramipexole; Protein Kinases; Receptors, Dopamine D2; Time Factors | 2008 |
Should 3,4-dihydroxy-L-phenylalanine be used routinely in vascular Parkinson?
Topics: Aged, 80 and over; Antiparkinson Agents; Humans; Levodopa; Male; Parkinsonian Disorders; Positron-Emission Tomography; Tomography, Emission-Computed, Single-Photon | 2008 |
Clinical features of dystonia in atypical parkinsonism.
Topics: Adult; Aged; Antiparkinson Agents; Cerebral Cortex; Dystonia; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Multiple System Atrophy; Nerve Degeneration; Parkinsonian Disorders; Supranuclear Palsy, Progressive | 2008 |
Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Corpus Striatum; Dynorphins; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Piperazines; Protein Precursors; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; RNA, Messenger; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists | 2009 |
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzopyrans; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Antagonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger | 2009 |
Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Caffeine; Catalepsy; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glutathione; Haloperidol; Levodopa; Male; Mice; Motor Activity; Parkinsonian Disorders; Posture; Superoxide Dismutase; Swimming | 2009 |
Deep brain stimulation of the globus pallidus internus in the parkinsonian primate: local entrainment and suppression of low-frequency oscillations.
Topics: Action Potentials; Algorithms; Animals; Antiparkinson Agents; Deep Brain Stimulation; Disease Models, Animal; Elbow; Electric Stimulation; Female; Globus Pallidus; Levodopa; Macaca fascicularis; Neural Inhibition; Neurons; Parkinsonian Disorders; Periodicity; Time Factors | 2009 |
L-dopa-induced desensitization depends on 5-hydroxytryptamine imbalance in hemiparkinsonian rats.
Topics: Animals; Brain; Brain Chemistry; Corpus Striatum; Dopamine Agents; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Movement Disorders; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Serotonin; Sympatholytics; Tryptophan Hydroxylase | 2009 |
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Organic Chemicals; Ovariectomy; Parkinsonian Disorders; Serotonin Receptor Agonists | 2009 |
De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat.
Topics: Animals; Cell Proliferation; Corpus Striatum; Dopamine Agents; Drug Administration Schedule; Gene Expression Profiling; Gene Expression Regulation; In Situ Hybridization; Levodopa; Male; Nerve Regeneration; Neurogenesis; Neuronal Plasticity; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2009 |
Metabotropic glutamate receptor II in the brains of Parkinsonian patients.
Topics: Aged; Aged, 80 and over; Amino Acids; Antiparkinson Agents; Brain; Cocaine; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Parkinsonian Disorders; Postmortem Changes; Radioligand Assay; Receptors, Metabotropic Glutamate; Tritium; Xanthenes | 2009 |
Spinal cord stimulation restores locomotion in animal models of Parkinson's disease.
Topics: Afferent Pathways; alpha-Methyltyrosine; Animals; Combined Modality Therapy; Corpus Striatum; Dopamine; Electric Stimulation Therapy; Electrodes, Implanted; Electrophysiological Phenomena; Humans; Levodopa; Locomotion; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Cortex; Neurons; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Rats; Spinal Cord | 2009 |
Cyclosporine-induced parkinsonism.
Topics: Antiparkinson Agents; Brain; Carbidopa; Cyclosporine; Fatal Outcome; Hematoma, Subdural; Humans; Immunosuppressive Agents; Leukemia, Lymphoid; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinsonian Disorders; Stem Cell Transplantation | 2009 |
Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia.
Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Neurons; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Receptors, Dopamine D1; Receptors, Dopamine D3 | 2009 |
Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
Topics: Amphetamine; Animals; Antiparkinson Agents; Brain Tissue Transplantation; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Stem Cell Transplantation; Sympatholytics | 2009 |
Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Brain; Brain Tissue Transplantation; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Graft Survival; Levodopa; Male; Neurons; Parkinsonian Disorders; Rats; Rats, Inbred F344; Treatment Outcome | 2009 |
Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism.
Topics: Animals; Antiparkinson Agents; Cell Count; Disease Models, Animal; Forelimb; Hypokinesia; Lameness, Animal; Levodopa; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurologic Examination; Parkinsonian Disorders; Predictive Value of Tests; Sensitivity and Specificity; Substantia Nigra | 2009 |
Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benzylamines; Brain; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Levodopa; Male; Movement; Neurotoxins; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Recovery of Function; Synaptic Transmission; Time; Treatment Outcome | 2009 |
D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Antiparkinson Agents; Apomorphine; Benserazide; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2009 |
The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Blood-Brain Barrier; Brain; Dyskinesia, Drug-Induced; Gadolinium DTPA; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Time Factors | 2009 |
Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Topics: Acetylation; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Functional Laterality; Gene Expression Regulation; Histones; Levodopa; Mice; Mice, Knockout; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Receptors, Dopamine D1; Receptors, Dopamine D2; Statistics as Topic; Tyrosine 3-Monooxygenase | 2009 |
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cocaine; Corpus Striatum; Disease Models, Animal; Docosahexaenoic Acids; Dopamine; Dopamine Uptake Inhibitors; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; Naltrexone; Neuropeptides; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Precursors; RNA, Messenger; Sulfonamides; Tachykinins; Thiazoles; Time Factors | 2010 |
Evaluation of the effects of deep brain stimulation of the subthalamic nucleus and levodopa treatment on parkinsonian voice using perturbation, nonlinear dynamic, and perceptual analysis.
Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Nonlinear Dynamics; Parkinsonian Disorders; Phonation; Phonetics; Speech Production Measurement; Subthalamic Nucleus; Treatment Outcome; Voice; Voice Disorders | 2009 |
Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aminoacetonitrile; Animals; Antiparkinson Agents; Basal Ganglia; Benzazepines; Bromocriptine; Disease Models, Animal; Dopamine Agents; Dopamine D2 Receptor Antagonists; Extracellular Signal-Regulated MAP Kinases; Female; Levodopa; Neovascularization, Pathologic; Oxidopamine; Parkinsonian Disorders; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides | 2009 |
Different functional basal ganglia subcircuits associated with anti-akinetic and dyskinesiogenic effects of antiparkinsonian therapies.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Electric Stimulation; Electrodes, Implanted; Electron Transport Complex IV; Gene Expression Regulation; Levodopa; Male; Nerve Net; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Protein Subunits; Rats; Rats, Wistar; RNA, Messenger | 2009 |
Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Carrier Proteins; Dyskinesia, Drug-Induced; Levodopa; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Parkinsonian Disorders; Phosphotransferases (Alcohol Group Acceptor); Proteins; Receptors, Dopamine D1; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors | 2009 |
Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Benzazepines; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Severity of Illness Index; Time Factors | 2009 |
Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Carrier Proteins; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Homer Scaffolding Proteins; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Pyridines; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2009 |
Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents.
Topics: Animals; Corpus Striatum; Dendrites; Dopamine; Dopamine Agents; Fluorescent Antibody Technique; Glutamine; Haplorhini; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Microscopy, Electron, Transmission; Neurons, Afferent; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, G-Protein-Coupled | 2009 |
The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benzopyrans; Disability Evaluation; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Hypokinesia; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Time Factors; Treatment Outcome | 2010 |
Acute L: -DOPA effect on hydroxyl radical- and DOPAC-levels in striatal microdialysates of parkinsonian rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Female; Hydroxyindoleacetic Acid; Hydroxyl Radical; Injections, Intraventricular; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Sympatholytics; Time Factors | 2010 |
Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Topics: Animals; Antiparkinson Agents; bcl-2-Associated X Protein; Benzothiazoles; Cell Count; Disease Models, Animal; Dopamine; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Glutathione; Levodopa; Male; Mice; Mice, Inbred C57BL; Neurons; Parkinsonian Disorders; Pramipexole; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Statistics, Nonparametric; Substantia Nigra; Tyrosine 3-Monooxygenase | 2009 |
Hemibody mirror movements in hemiparkinsonism-hemiatrophy syndrome.
Topics: Antiparkinson Agents; Arm; Electromyography; Facial Muscles; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Contraction; Muscle, Skeletal; Muscular Atrophy; Parkinsonian Disorders; Peripheral Nervous System Diseases; Syndrome; Treatment Outcome | 2009 |
The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebrospinal Fluid; Disease Models, Animal; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Plasma; Propranolol; Random Allocation; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-1; Tetralones | 2010 |
Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Ascorbic Acid; Brain; Central Nervous System Depressants; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Ferrous Compounds; Levodopa; Male; Melatonin; Mice; Mice, Inbred BALB C; Oxidopamine; Parkinsonian Disorders | 2009 |
The effect of levodopa treatment on cerebral hemodynamics in patients with Parkinson's disease: serial transcranial Doppler studies.
Topics: Aged; Antiparkinson Agents; Cerebrovascular Circulation; Female; Hemodynamics; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Prospective Studies; Retrospective Studies; Statistics, Nonparametric; Ultrasonography, Doppler, Transcranial | 2010 |
Conjugal Parkinsonism and Parkinson disease: a case series with environmental risk factor analysis.
Topics: Age of Onset; Aged; Cognition Disorders; Disease Progression; Environment; Environmental Exposure; Female; Humans; Levodopa; Male; Marriage; Middle Aged; Parkinsonian Disorders; Retrospective Studies; Risk Assessment; Risk Factors; Surveys and Questionnaires | 2010 |
Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cell Membrane; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Neostriatum; Neurons; Parkinsonian Disorders; Receptors, AMPA; Synapses; Synaptic Vesicles | 2010 |
Cavernous hemangioma: a rare cause for secondary parkinsonism: a case report.
Topics: Aged; Antiparkinson Agents; Basal Ganglia Diseases; Carbidopa; Female; Globus Pallidus; Hemangioma, Cavernous, Central Nervous System; Humans; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Putamen; Tomography, X-Ray Computed; Treatment Failure | 2009 |
Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Basal Ganglia; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Dopa Decarboxylase; Dopamine; Drug Combinations; Drug Synergism; Encephalitis Virus, Japanese; Encephalitis, Japanese; Enzyme Inhibitors; Levodopa; Nitriles; Parkinsonian Disorders; Rats; Rats, Inbred F344; Treatment Outcome | 2010 |
HIV-associated Parkinsonism with levodopa-induced dyskinesia and response to highly-active antiretroviral therapy.
Topics: Adult; Akathisia, Drug-Induced; Antiparkinson Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Tomography, Emission-Computed, Single-Photon; Tropanes | 2009 |
L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation.
Topics: Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Electrochemistry; Levodopa; Male; Mice; Mice, Inbred BALB C; MPTP Poisoning; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2010 |
Sustained dopaminergic response of parkinsonism and depression in POLG-associated parkinsonism.
Topics: Affect; Depression; DNA Polymerase gamma; DNA-Directed DNA Polymerase; Dopamine Agents; Female; Humans; Indoles; Levodopa; Middle Aged; Parkinsonian Disorders; Radionuclide Imaging; Treatment Outcome | 2010 |
Functional enhancement and protection of dopaminergic terminals by RAB3B overexpression.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Cell Line; Corpus Striatum; Dopamine; Female; Gene Expression; Gene Expression Profiling; Humans; In Vitro Techniques; Leupeptins; Levodopa; Models, Neurological; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Presynaptic Terminals; rab3 GTP-Binding Proteins; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Synaptic Vesicles; Ventral Tegmental Area | 2009 |
Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Ergolines; Female; Glycogen Synthase Kinase 3; Levodopa; Macaca fascicularis; Oncogene Protein v-akt; Parkinsonian Disorders; Phosphorylation; Piperidines; Serine; Signal Transduction; Statistics as Topic | 2010 |
Behavioral and electrophysiological effects of 5-HT in globus pallidus of 6-hydroxydopamine lesioned rats.
Topics: Action Potentials; Animals; Behavior, Animal; Dopamine Agents; Drug Combinations; Functional Laterality; Globus Pallidus; Levodopa; Male; Microinjections; Neural Inhibition; Neurons; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Serotonin | 2010 |
Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.
Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Cohort Studies; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Glutamic Acid; Humans; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Up-Regulation | 2011 |
Frequency-velocity mismatch: a fundamental abnormality in parkinsonian gait.
Topics: Acoustic Stimulation; Aged; Algorithms; Antiparkinson Agents; Biomechanical Phenomena; Feedback, Physiological; Female; Foot; Gait; Gait Disorders, Neurologic; Humans; In Vitro Techniques; Levodopa; Male; Middle Aged; Models, Neurological; Movement; Parkinsonian Disorders; Walking | 2010 |
Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.
Topics: Animals; Behavior, Animal; Biomarkers; Corpus Striatum; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Gait Disorders, Neurologic; Infusion Pumps, Implantable; Levodopa; Locomotion; Male; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Signal Transduction; Thionucleotides | 2010 |
Levodopa-induced dyskinesias in spinocerebellar ataxia type 2.
Topics: Antiparkinson Agents; Atrophy; Depressive Disorder; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Parkinsonian Disorders; Rhombencephalon; Spinocerebellar Ataxias | 2010 |
Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Locomotion; Macaca fascicularis; Parkinsonian Disorders; Pyridines; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Severity of Illness Index; Thiazoles; Time Factors; Treatment Outcome | 2010 |
MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dizocilpine Maleate; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Time Factors | 2010 |
Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease.
Topics: 5,7-Dihydroxytryptamine; Animals; Antiparkinson Agents; Brain; Citalopram; Cobra Neurotoxin Proteins; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Extracellular Fluid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Raphe Nuclei; Rats; Selective Serotonin Reuptake Inhibitors; Serotonin; Sympatholytics; Synaptic Transmission | 2010 |
Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
Topics: Amisulpride; Animals; Antiparkinson Agents; Benzimidazoles; Benzothiazoles; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Interactions; Drug Synergism; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neural Inhibition; Nociceptin; Opioid Peptides; Parkinsonian Disorders; Piperidines; Pramipexole; Pyridines; Reaction Time; Receptors, Dopamine D3; Sulpiride | 2010 |
Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavioral Symptoms; Callithrix; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Hyperkinesis; Levodopa; Parkinsonian Disorders; Reproducibility of Results | 2010 |
Familial paroxysmal exercise-induced dystonia: atypical presentation of autosomal dominant GTP-cyclohydrolase 1 deficiency.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Child; Codon, Nonsense; Depressive Disorder; Dystonia; Exercise; Exons; Family; Female; GTP Cyclohydrolase; Humans; Levodopa; Male; Parkinsonian Disorders; Pedigree; Restless Legs Syndrome | 2010 |
Age of Parkinson's disease onset as a predictor for the development of dyskinesia.
Topics: Adult; Age Factors; Age of Onset; Aged; Aged, 80 and over; Dyskinesia, Drug-Induced; Female; Humans; Kaplan-Meier Estimate; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinsonian Disorders; Predictive Value of Tests; Proportional Hazards Models; Risk Factors | 2010 |
Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Dose-Response Relationship, Drug; Dyskinesias; Endocytosis; G-Protein-Coupled Receptor Kinases; Gene Knockdown Techniques; Genetic Therapy; Humans; Lentivirus; Levodopa; Macaca; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Signal Transduction | 2010 |
Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Antiparkinson Agents; Cell Count; Disease Models, Animal; Dopamine; Drug Interactions; Gene Expression Regulation; Homovanillic Acid; Levodopa; Male; Movement; Neurons; Neurotoxins; Parkinsonian Disorders; Rats; Rats, Wistar; Reaction Time; Substantia Nigra; Tyrosine 3-Monooxygenase | 2009 |
Pre-treatment with dopamine agonists influence L-dopa mediated rotations without affecting abnormal involuntary movements in the 6-OHDA lesioned rat.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Corpus Striatum; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Oxidopamine; Parkinsonian Disorders; Piribedil; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotation; Time Factors | 2010 |
Perry syndrome due to the DCTN1 G71R mutation: a distinctive levodopa responsive disorder with behavioral syndrome, vertical gaze palsy, and respiratory failure.
Topics: Arginine; Behavioral Symptoms; DNA Mutational Analysis; Dopamine Agents; Dynactin Complex; Glycine; Humans; Levodopa; Male; Microtubule-Associated Proteins; Middle Aged; Neuropsychological Tests; Optic Nerve Diseases; Parkinsonian Disorders; Respiratory Insufficiency | 2010 |
[Rapidly progressive parkinsonism that developed one year after ventriculoperitoneal shunting for idiopathic aqueductal stenosis: a case report].
Topics: Acute Disease; Cerebral Aqueduct; Constriction, Pathologic; Disease Progression; Female; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Postoperative Complications; Syndrome; Treatment Outcome; Ventriculoperitoneal Shunt | 2010 |
Dopaminergic neuronal integrity in parkinsonism associated with liver cirrhosis.
Topics: Aged; Basal Ganglia; Dopamine Plasma Membrane Transport Proteins; Drug Resistance; Female; Humans; Levodopa; Liver Cirrhosis; Male; Middle Aged; Neurons; Parkinsonian Disorders; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Tropanes | 2010 |
Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Male; Medial Forebrain Bundle; Mice; Mice, Inbred BALB C; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Salicylates | 2010 |
Effect of cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease.
Topics: Animals; Antiparasitic Agents; Corpus Striatum; Cyclin-Dependent Kinase 5; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Kinase Inhibitors; Purines; Random Allocation; Rats; Rats, Sprague-Dawley; Roscovitine; Severity of Illness Index; Treatment Outcome | 2010 |
Neuronal intranuclear inclusion disease: two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia.
Topics: Adolescent; Antiparkinson Agents; Child; Dyskinesia, Drug-Induced; Female; Humans; Intranuclear Inclusion Bodies; Levodopa; Male; Neurons; Parkinsonian Disorders; Peptides; Taiwan; Ubiquitin | 2010 |
Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Biocompatible Materials; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Synergism; Dyskinesia, Drug-Induced; Female; Lameness, Animal; Levodopa; Microspheres; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2010 |
Juvenile levodopa-responsive Parkinsonism with early orobuccolingual dyskinesias and cognitive impairment.
Topics: Adolescent; Brain; Cognition Disorders; Deep Brain Stimulation; Dyskinesia, Drug-Induced; Female; Humans; Intranuclear Inclusion Bodies; Levodopa; Magnetic Resonance Imaging; Neurodegenerative Diseases; Parkinsonian Disorders; Young Adult | 2010 |
Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations.
Topics: Adult; Brain; F-Box Proteins; Female; Genetic Association Studies; Genotype; Group VI Phospholipases A2; Humans; Levodopa; Male; Parkinsonian Disorders; Pedigree; Proteins; Proton-Translocating ATPases | 2010 |
Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release.
Topics: Animals; Benzothiazoles; Biomarkers; Brain; Dopamine; Dopamine Agonists; Levodopa; Male; Parkinsonian Disorders; Positron-Emission Tomography; Pramipexole; Presynaptic Terminals; Rats; Rats, Sprague-Dawley | 2010 |
Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia.
Topics: Animals; Antiparkinson Agents; Callithrix; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Immunohistochemistry; Levodopa; Male; Neurites; Parkinsonian Disorders; Serotonin; Tryptophan Hydroxylase | 2010 |
Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Medial Forebrain Bundle; Nerve Fibers; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2011 |
L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata.
Topics: Adenylyl Cyclases; Animals; Dyskinesia, Drug-Induced; Enzyme Inhibitors; gamma-Aminobutyric Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Severity of Illness Index; Substantia Nigra; Up-Regulation | 2011 |
Drug-induced cranial myoclonus.
Topics: Aged; Antidepressive Agents; Antiparkinson Agents; Depression; Female; Humans; Levodopa; Male; Middle Aged; Myoclonus; Parkinsonian Disorders | 2010 |
Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia.
Topics: Animals; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesias; Extracellular Signal-Regulated MAP Kinases; Female; Levodopa; Macaca mulatta; MAP Kinase Signaling System; Parkinsonian Disorders; ras Proteins | 2010 |
Metabolic activity of the subthalamic nucleus in a primate model of L-dopa-unresponsive parkinsonism.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Energy Metabolism; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Substantia Nigra; Subthalamic Nucleus | 2010 |
Expanding phenotype and clinical analysis of tyrosine hydroxylase deficiency.
Topics: Adolescent; Adult; Child; Child, Preschool; Deficiency Diseases; Dopamine Agents; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Parkinsonian Disorders; Phenotype; Prolactin; Selegiline; Severity of Illness Index; Treatment Outcome; Tyrosine 3-Monooxygenase | 2011 |
The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.
Topics: Adrenergic alpha-2 Receptor Antagonists; Analysis of Variance; Animals; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Imidazoles; Indans; Levodopa; Macaca fascicularis; Male; Motor Activity; Parkinsonian Disorders; Time Factors | 2010 |
The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dronabinol; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant | 2010 |
Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry.
Topics: Age of Onset; Antiparkinson Agents; Cerebellar Ataxia; Europe; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Multiple System Atrophy; Parkinsonian Disorders; Registries; Shy-Drager Syndrome | 2010 |
Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.
Topics: Animals; Autoradiography; Caudate Nucleus; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Cortex; Parkinsonian Disorders; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Agonists | 2012 |
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Biological Assay; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Drug Administration Schedule; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Placebos; Purines; Random Allocation; Rats; Reproducibility of Results; Rotation; Sample Size; Single-Blind Method; Sympatholytics | 2011 |
BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Topics: Animals; Area Under Curve; Behavior, Animal; Chromatography, High Pressure Liquid; Corpus Striatum; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiazoles | 2011 |
The effects of chronic levodopa treatments on the neuronal firing properties of the subthalamic nucleus and substantia nigra reticulata in hemiparkinsonian rhesus monkeys.
Topics: Action Potentials; Animals; Female; Levodopa; Macaca mulatta; Neurons; Parkinsonian Disorders; Substantia Nigra; Subthalamic Nucleus; Treatment Outcome | 2011 |
Nigrostriatal dysfunction in patients with amyotrophic lateral sclerosis and parkinsonism.
Topics: Aged; Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Corpus Striatum; Fluorine Radioisotopes; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Positron-Emission Tomography; Presynaptic Terminals; Putamen; Radiopharmaceuticals; Substantia Nigra; Tremor; Tropanes | 2011 |
Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia.
Topics: Animals; Corpus Striatum; Cyclic GMP; Dyskinesia, Drug-Induced; Levodopa; Long-Term Synaptic Depression; Male; Microinjections; Neurons; Oxidopamine; Parkinsonian Disorders; Phosphodiesterase Inhibitors; Piperazines; Purinones; Pyrimidinones; Rats; Rats, Wistar | 2011 |
Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats.
Topics: Analysis of Variance; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Functional Laterality; Gene Expression Profiling; Gene Expression Regulation; Levodopa; Male; Nerve Tissue Proteins; Neurotrophin 3; Oligonucleotide Array Sequence Analysis; Oxidopamine; Parkinsonian Disorders; Pulsatile Flow; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2011 |
CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Blotting, Western; Brain; Caffeine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Levodopa; Male; Microscopy, Electron, Transmission; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Synapses | 2011 |
Context-driven changes in L-DOPA-induced behaviours in the 6-OHDA lesioned rat.
Topics: Animals; Conditioning, Psychological; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2011 |
Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Organic Chemicals; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D3; Serotonin 5-HT1 Receptor Agonists; Time Factors | 2011 |
The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate | 2011 |
BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice.
Topics: Animals; Behavior, Animal; Brain; Cell Survival; Drug Combinations; gamma-Aminobutyric Acid; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Neurons; Neuroprotective Agents; Parkinsonian Disorders | 2011 |
Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.
Topics: Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Benzoxazines; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Molecular Targeted Therapy; Motor Activity; Oxazines; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Time Factors | 2011 |
Decades of delayed diagnosis in 4 levodopa-responsive young-onset monogenetic parkinsonism patients.
Topics: Adult; Age of Onset; Antiparkinson Agents; Delayed Diagnosis; Diagnosis, Differential; Dystonic Disorders; Fatigue Syndrome, Chronic; Female; Gait Disorders, Neurologic; Humans; Levodopa; Parkinsonian Disorders; Time Factors; Ubiquitin-Protein Ligases; Young Adult | 2011 |
The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Receptors, Opioid, mu | 2011 |
The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Down-Regulation; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Vesicular Glutamate Transport Protein 2 | 2011 |
Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Biogenic Amines; Brain; Cabergoline; Dopamine Agents; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Ketanserin; Levodopa; Macaca; Parkinsonian Disorders; Receptor, Serotonin, 5-HT2A | 2011 |
Differential expression of FosB, c-Fos, and Zif268 in forebrain regions after acute or chronic L-DOPA treatment in a rat model of Parkinson's disease.
Topics: Acute Disease; Animals; Chronic Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Gene Expression Regulation; Levodopa; Male; Parkinsonian Disorders; Prosencephalon; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Tissue Distribution; Treatment Outcome | 2011 |
Pallidothalamic-projecting neurons in Macaca fascicularis co-express GABAergic and glutamatergic markers as seen in control, MPTP-treated and dyskinetic monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Colorimetry; DNA Primers; Dopamine; Dyskinesia, Drug-Induced; Fluorescent Antibody Technique; GABAergic Neurons; Globus Pallidus; Glutamate Decarboxylase; Immunohistochemistry; In Situ Hybridization; In Situ Hybridization, Fluorescence; Levodopa; Macaca fascicularis; Male; Neurons, Efferent; Parkinsonian Disorders; Polymerase Chain Reaction; Statistics, Nonparametric; Thalamus; Vesicular Glutamate Transport Protein 1 | 2011 |
Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Locus Coeruleus; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; RNA, Messenger | 2012 |
[Levodopa-responsive parkinsonism-dystonia due to a traumatic injury of the substantia nigra].
Topics: Antiparkinson Agents; Brain; Brain Injuries; Dystonia; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinsonian Disorders; Substantia Nigra; Tomography, X-Ray Computed | 2012 |
Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Cell Count; Combined Modality Therapy; Dopamine; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Recovery of Function; Serotonin; Sympatholytics | 2011 |
Antidepressant-like properties of sarizotan in experimental Parkinsonism.
Topics: Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Benserazide; Cell Proliferation; Dentate Gyrus; Depression; Disease Models, Animal; Doublecortin Protein; Drug Combinations; Levodopa; Locomotion; Male; Organic Chemicals; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Swimming | 2011 |
[2011: not just PRAXIS, also dopa turns 100 years old...].
Topics: Antiparkinson Agents; History, 20th Century; History, 21st Century; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Periodicals as Topic; Publishing; Switzerland | 2011 |
A case of parkinsonism and dopa-induced severe dyskinesia associated with novel mutation in the GTP cyclohydrolase I gene.
Topics: Adult; Aged; Base Sequence; Dopamine Agonists; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; GTP Cyclohydrolase; Humans; Levodopa; Male; Mutation; Parkinsonian Disorders; Pedigree | 2011 |
Endogenous morphine-like compound immunoreactivity increases in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; alpha-Methyltyrosine; Analysis of Variance; Animals; Brain; Choline O-Acetyltransferase; Chromatography, High Pressure Liquid; Dendrites; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Functional Laterality; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Glutamate Decarboxylase; Humans; Levodopa; Macaca fascicularis; Male; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Immunoelectron; Middle Aged; Nerve Growth Factors; Organic Chemicals; Oxidopamine; Parkinsonian Disorders; Postmortem Changes; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Tandem Mass Spectrometry | 2011 |
Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Animals; Antigens, CD; Antigens, Surface; Antiparkinson Agents; Astrocytes; Behavior, Animal; Benserazide; Blood Vessels; Blood-Brain Barrier; Brain; Bromodeoxyuridine; Cell Count; Cells, Cultured; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Embryo, Mammalian; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Laminin; Levodopa; Male; Neovascularization, Pathologic; Nerve Tissue Proteins; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA, Messenger; Time Factors; Up-Regulation; Vascular Endothelial Growth Factor A | 2011 |
Deep brain stimulation in benign tremulous parkinsonism.
Topics: Adult; Aged; Cohort Studies; Deep Brain Stimulation; Disease Progression; Drug Resistance; Essential Tremor; Female; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Patient Selection; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome; Tremor; Ventral Thalamic Nuclei | 2011 |
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; Dopamine; Glutamic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Triazines; Triazoles | 2012 |
Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Delayed-Action Preparations; Disease Models, Animal; Dopamine Agents; Drug Combinations; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Reaction Time | 2011 |
Parkinsonism and dropped head: dystonia, myopathy or both?
Topics: Aged; Carbidopa; Drug Combinations; Dystonic Disorders; Electromyography; Female; Head Movements; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Muscular Diseases; Parkinsonian Disorders; Retrospective Studies | 2012 |
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra | 2011 |
Experimental Models of l-DOPA-Induced Dyskinesia.
Topics: Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Parkinsonian Disorders | 2011 |
The locus coeruleus is directly implicated in L-DOPA-induced dyskinesia in parkinsonian rats: an electrophysiological and behavioural study.
Topics: Amphetamine; Animals; Behavior, Animal; Dyskinesias; Electrophysiology; Female; Ibotenic Acid; Levodopa; Locus Coeruleus; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2011 |
Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
Topics: Action Potentials; Animals; Antiparkinson Agents; Corpus Striatum; D-Aspartate Oxidase; D-Aspartic Acid; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; N-Methylaspartate; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Sympatholytics; Synapses | 2011 |
Parkinsonism with multiple cysts in the bilateral striata.
Topics: 3-Iodobenzylguanidine; Aged; Antiparkinson Agents; Antipsychotic Agents; Brain Ischemia; Delirium; Delusions; Diagnosis, Differential; Dibenzothiazepines; Dominance, Cerebral; Drug Therapy, Combination; Encephalomalacia; Hallucinations; Humans; Levodopa; Magnetic Resonance Imaging; Male; Neostriatum; Neurologic Examination; Organophosphate Poisoning; Parkinsonian Disorders; Psychoses, Substance-Induced; Quetiapine Fumarate; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2011 |
A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice.
Topics: alpha-Synuclein; Animals; Brain; Dopaminergic Neurons; Levodopa; Male; Mice; Mice, Knockout; Nerve Regeneration; Parkinsonian Disorders | 2012 |
Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Antiparkinson Agents; Buspirone; Catalepsy; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Serotonin 5-HT1 Receptor Agonists; Time Factors | 2011 |
Automated gait analysis in bilateral parkinsonian rats and the role of L-DOPA therapy.
Topics: Animals; Cell Count; Corpus Striatum; Dopamine; Gait; Humans; Levodopa; Male; Medial Forebrain Bundle; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Inbred Strains; Substantia Nigra; Tyrosine 3-Monooxygenase | 2012 |
Levodopa-responsive parkinsonism in probable extrapontine myelinolysis of the mesencephalon.
Topics: Adult; Antiparkinson Agents; Female; Humans; Levodopa; Mesencephalon; Myelinolysis, Central Pontine; Parkinsonian Disorders; Tomography, Emission-Computed, Single-Photon; Tropanes | 2011 |
Do levodopa treatments modify the morphology of the parkinsonian brain?
Topics: Animals; Antiparkinson Agents; Brain; Humans; Levodopa; Parkinsonian Disorders | 2012 |
Intranasally applied L-DOPA alleviates parkinsonian symptoms in rats with unilateral nigro-striatal 6-OHDA lesions.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Benserazide; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Dopamine; Electrochemistry; Exploratory Behavior; Forelimb; Functional Laterality; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Motor Activity; Motor Skills; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra; Sympatholytics | 2012 |
Loss of dopaminoreceptive neuron causes L-dopa resistant parkinsonism in tauopathy.
Topics: Animals; Antiparkinson Agents; Apoptosis; Caspase 3; Corpus Striatum; Dopaminergic Neurons; Hippocampus; Humans; Immunohistochemistry; Levodopa; Male; Mice; Mice, Transgenic; Mutation; Neurofibrils; Neuropsychological Tests; Parkinsonian Disorders; Putamen; tau Proteins; Tauopathies | 2012 |
Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-dopa in a Parkinson's animal model.
Topics: Analysis of Variance; Animals; Basal Ganglia; CD11b Antigen; Disease Models, Animal; Dopamine; Drug Evaluation, Preclinical; Gene Expression; Glial Fibrillary Acidic Protein; Glutathione; Heme Oxygenase-1; Levodopa; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; NF-E2-Related Factor 2; NF-kappa B; Nitric Oxide Synthase Type II; Oligopeptides; Oxidative Stress; Parkinsonian Disorders; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase | 2012 |
Selective IGT decision-making impairment in a patient with juvenile Parkinson's disease and pathological gambling: a role for dopaminergic therapy?
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Case-Control Studies; Compulsive Behavior; Decision Making; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Gambling; Humans; Levodopa; Matched-Pair Analysis; Neuropsychological Tests; Parkinsonian Disorders; Pramipexole; Reference Values | 2012 |
L-DOPA impairs proteasome activity in parkinsonism through D1 dopamine receptor.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Organ Culture Techniques; Parkinsonian Disorders; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1 | 2012 |
Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Indazoles; Levodopa; Male; Neostriatum; Nerve Tissue Proteins; Neurons; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type I; Parkinsonian Disorders; Protein Subunits; Proto-Oncogene Proteins c-fos; Random Allocation; Rats; Rats, Wistar; Receptors, AMPA; Signal Transduction | 2012 |
Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Biomarkers; Catecholamines; Dopamine Agents; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Levodopa; Male; Methoxyhydroxyphenylglycol; Middle Aged; Multiple System Atrophy; Parkinsonian Disorders; Positron-Emission Tomography; Pure Autonomic Failure; ROC Curve | 2012 |
Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat.
Topics: Animals; Behavior, Animal; Corpus Striatum; Dopamine; Drug Synergism; Dyskinesias; Exenatide; Glucagon-Like Peptide 1; Levodopa; Lizards; Male; Oxidopamine; Parkinsonian Disorders; Peptides; Rats; Rats, Wistar; Venoms | 2012 |
The relationship between cerebral vascular disease and parkinsonism: The VADO study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cerebrovascular Disorders; Cohort Studies; Corpus Striatum; Cross-Sectional Studies; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon | 2012 |
Influence of corticostriatal δ-opioid receptors on abnormal involuntary movements induced by L-DOPA in hemiparkinsonian rats.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Enkephalin, D-Penicillamine (2,5)-; Levodopa; Male; Neurons; Parkinsonian Disorders; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta | 2012 |
Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice.
Topics: Animals; Antiparkinson Agents; Autoradiography; Benserazide; Cotinine; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Hydroxydopamines; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Receptors, Nicotinic | 2012 |
L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson's disease patients.
Topics: Animals; Brain; Dopaminergic Neurons; Humans; Levodopa; Models, Neurological; Neurodegenerative Diseases; Oxidopamine; Parkinsonian Disorders | 2012 |
L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Anxiety; Behavior, Animal; Brain; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin | 2012 |
L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benserazide; Biological Availability; Caudate Nucleus; Chromatography, High Pressure Liquid; Dopamine Agents; Drug Combinations; Dyskinesia, Drug-Induced; Female; Half-Life; Levodopa; Macaca fascicularis; Metabolic Clearance Rate; Parkinsonian Disorders; Severity of Illness Index; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tissue Distribution | 2012 |
Clinical and neuroimaging characteristics in neurodegenerative overlap syndrome.
Topics: Aged; Aged, 80 and over; Functional Laterality; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Neuron Disease; Parkinsonian Disorders; Positron-Emission Tomography; Tremor; Tropanes | 2013 |
Dopamine- and cAMP-regulated phosphoprotein of 32-kDa (DARPP-32)-dependent activation of extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) signaling in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Cyclic AMP; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Levodopa; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Transgenic; Multiprotein Complexes; Nerve Tissue Proteins; Neurons; Parkinsonian Disorders; Proteins; TOR Serine-Threonine Kinases | 2012 |
Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease.
Topics: Animals; Basal Ganglia; Deep Brain Stimulation; Dopamine Agents; Dyskinesias; Electrodes, Implanted; Immunohistochemistry; Levodopa; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Subthalamic Nucleus | 2012 |
Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Apomorphine; Biogenic Monoamines; Citalopram; Corpus Striatum; Dyskinesia, Drug-Induced; Fluoxetine; Levodopa; Male; Parkinsonian Disorders; Paroxetine; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors | 2012 |
L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function.
Topics: Animals; Corpus Striatum; Dopamine; Dopamine Agents; Immunohistochemistry; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Activity; Neurons; Parkinsonian Disorders; Receptors, Dopamine D1; Receptors, Dopamine D2; Tyrosine 3-Monooxygenase | 2012 |
DYT16: the original cases.
Topics: Adolescent; Adult; Age of Onset; Anti-Dyskinesia Agents; Antiparkinson Agents; Baclofen; Biperiden; Botulinum Toxins; Carbidopa; Child; Child, Preschool; Cholinergic Antagonists; Drug Combinations; Drug Resistance; Dystonia; Dystonic Disorders; Female; Humans; Levodopa; Male; Middle Aged; Muscle Relaxants, Central; Mutation; Parkinsonian Disorders; Pedigree; Phenotype; RNA-Binding Proteins; Speech Disorders; Trihexyphenidyl; Young Adult | 2012 |
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.
Topics: Amantadine; Animals; Antiparkinson Agents; Cycloserine; Dextromethorphan; Dopamine Agents; Dyskinesias; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Serotonin, 5-HT1A; Receptors, N-Methyl-D-Aspartate; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT1 Receptor Antagonists | 2012 |
MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Administration Schedule; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Oximes; Parkinsonian Disorders; Putamen; Pyridines; Radioligand Assay; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate | 2013 |
Clinical variability and L-Dopa responsive Parkinsonism in hereditary spastic paraplegia 11.
Topics: Adult; Humans; Levodopa; Male; Parkinsonian Disorders; Pedigree; Spastic Paraplegia, Hereditary | 2012 |
RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study.
Topics: Animals; Antiparkinson Agents; Callithrix; Dyskinesia, Drug-Induced; Female; Histone Deacetylase Inhibitors; Levodopa; Parkinsonian Disorders | 2013 |
Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain.
Topics: Animals; Behavior, Animal; Brain; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Receptors, Serotonin, 5-HT1 | 2012 |
New algorithm for the diagnosis of hereditary dystonia.
Topics: Algorithms; Antiparkinson Agents; Dystonic Disorders; Genetic Testing; Humans; Levodopa; Parkinsonian Disorders | 2012 |
Gait patterns in Parkinsonian patients with or without mild cognitive impairment.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Cognition Disorders; Executive Function; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Memory; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinsonian Disorders; Psychomotor Performance; Severity of Illness Index | 2012 |
Eppendorf finalist. Striatal interneurons: causes of or cures for movement disorders?
Topics: Adamantane; Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Humans; Interneurons; Levodopa; Mice; Mice, Transgenic; Movement Disorders; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Receptors, AMPA; Receptors, Kainic Acid; Treatment Failure | 2012 |
Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat.
Topics: Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2013 |
Levodopa-responsive Parkinsonism following bilateral putaminal hemorrhages.
Topics: Antiparkinson Agents; Female; Functional Laterality; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Putaminal Hemorrhage; Stroke | 2013 |
Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
Topics: Animals; Antiparkinson Agents; Benserazide; Blotting, Western; Delayed-Action Preparations; Disease Models, Animal; Down-Regulation; Drug Carriers; Drug Combinations; Dyskinesia, Drug-Induced; Female; Lactic Acid; Levodopa; Microspheres; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, AMPA | 2012 |
Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease.
Topics: Animals; Benzothiazoles; Corpus Striatum; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Receptors, AMPA; Receptors, Dopamine D3; Receptors, N-Methyl-D-Aspartate | 2012 |
Subthalamic lesion or levodopa treatment rescues giant GABAergic currents of PINK1-deficient striatum.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Electric Conductivity; Excitatory Amino Acid Agonists; Female; gamma-Aminobutyric Acid; Immunohistochemistry; Kainic Acid; Levodopa; Male; Mice; Mice, Knockout; Neurons; Parkinsonian Disorders; Patch-Clamp Techniques; Protein Kinases; Subthalamic Nucleus | 2012 |
Drebrin immunoreactivity in the striatum of a rat model of levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dendritic Spines; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Microscopy, Immunoelectron; Neuropeptides; Parkinsonian Disorders; Rats; Rats, Wistar | 2013 |
An electromyographic study of parkinsonian swallowing and its response to levodopa.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Deglutition; Electromyography; Humans; Laryngeal Muscles; Levodopa; Middle Aged; Parkinsonian Disorders; Treatment Outcome | 2012 |
A common optimization principle for motor execution in healthy subjects and parkinsonian patients.
Topics: Acceleration; Aged; Algorithms; Antiparkinson Agents; Biomechanical Phenomena; Data Interpretation, Statistical; Deep Brain Stimulation; Executive Function; Female; Humans; Hypokinesia; Individuality; Isotonic Contraction; Levodopa; Male; Middle Aged; Models, Neurological; Motor Skills; Parkinsonian Disorders; Reaction Time | 2013 |
Persistent activation of the D1R/Shp-2/Erk1/2 pathway in l-DOPA-induced dyskinesia in the 6-hydroxy-dopamine rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Blotting, Western; Dyskinesia, Drug-Induced; Immunoprecipitation; Levodopa; Male; MAP Kinase Signaling System; Oxidopamine; Parkinsonian Disorders; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Rats; Rats, Wistar; Receptors, Dopamine D1 | 2013 |
Antimicrobial surveillance in idiopathic parkinsonism: indication-specific improvement in hypokinesia following Helicobacter pylori eradication and non-specific effect of antimicrobials for other indications in worsening rigidity.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antiparkinson Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hypokinesia; Intestine, Small; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinsonian Disorders; Treatment Outcome | 2013 |
The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.
Topics: Animals; Antiparkinson Agents; Autoradiography; Corpus Striatum; Disease Models, Animal; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic | 2013 |
Levodopa-induced dyskinesia in a patient who has normal presynaptic dopaminergic neurons.
Topics: Antiparkinson Agents; Brain; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Positron-Emission Tomography; Tropanes | 2013 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Medial Forebrain Bundle; Motor Activity; Oxidopamine; Parkinson Disease; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Serotonin Receptor Agonists; Time Factors; Tyrosine 3-Monooxygenase | 2013 |
Paradoxical response to apomorphine in a case of atypical parkinsonism.
Topics: Antiparkinson Agents; Apomorphine; Dopamine Agonists; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinsonian Disorders; Tomography, Emission-Computed, Single-Photon; Treatment Failure | 2002 |
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Topics: Afferent Pathways; Animals; Bacterial Proteins; Behavior, Animal; Biomarkers; Brain Mapping; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Enkephalins; Female; Image Processing, Computer-Assisted; Levodopa; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Putamen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Severity of Illness Index; Substantia Nigra; Sympathectomy, Chemical; Transcription Factors | 2002 |
Behavioural and immunohistochemical changes following supranigral administration of sonic hedgehog in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
Topics: Animals; Behavior, Animal; Body Weight; Callithrix; Cell Count; Dopamine; Drug Interactions; Female; Glial Fibrillary Acidic Protein; Hedgehog Proteins; Immunohistochemistry; Levodopa; Male; Motor Activity; Nerve Growth Factors; Nerve Regeneration; Neurons; Parkinsonian Disorders; Recovery of Function; Substantia Nigra; Trans-Activators; Treatment Outcome; Tyrosine 3-Monooxygenase | 2002 |
Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Disability Evaluation; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Multiple System Atrophy; Neurologic Examination; Parkinsonian Disorders; Reproducibility of Results | 2002 |
Presynaptic parkinsonism in multiple system atrophy mimicking Parkinson's disease: a clinicopathological case study.
Topics: Brain; Combined Modality Therapy; Diagnosis, Differential; Electric Stimulation Therapy; Electrodes, Implanted; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Neurologic Examination; Parkinson Disease; Parkinsonian Disorders; Receptors, Presynaptic; Subthalamic Nucleus | 2002 |
Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Chlorocebus aethiops; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Electrodes, Implanted; Female; Globus Pallidus; Levodopa; Neurons; Organic Chemicals; Parkinsonian Disorders | 2002 |
A site-specific mutation of tyrosine hydroxylase reduces feedback inhibition by dopamine in genetically modified cells grafted in parkinsonian rats.
Topics: Amino Acid Substitution; Animals; Aromatic-L-Amino-Acid Decarboxylases; Catecholamines; Cells, Cultured; Coculture Techniques; Corpus Striatum; Disease Models, Animal; Dopamine; Extracellular Space; Feedback, Physiological; Female; Fibroblasts; Genetic Therapy; Graft Survival; GTP Cyclohydrolase; Levodopa; Microdialysis; Mutagenesis, Site-Directed; Parkinsonian Disorders; Rats; Rats, Inbred F344; Transduction, Genetic; Tyrosine 3-Monooxygenase | 2002 |
Dopa-responsive parkinsonism phenotype of spinocerebellar ataxia type 2.
Topics: Aged; Atrophy; Cerebellum; Corpus Striatum; Dopamine Agonists; Genotype; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Organotechnetium Compounds; Parkinsonian Disorders; Pedigree; Pons; Radiopharmaceuticals; Spinocerebellar Ataxias; Substantia Nigra; Tomography, Emission-Computed, Single-Photon; Tropanes | 2002 |
Restorative effects of glutamate antagonists in experimental parkinsonism.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Dopamine; Excitatory Amino Acid Antagonists; Glutamic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Parkinsonian Disorders; Receptors, N-Methyl-D-Aspartate | 2002 |
Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression Regulation; Levodopa; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Sympatholytics; Transcription Factors | 2002 |
Functional alteration by NMDA antagonist: effects of L-Dopa, neuroleptics drug and postnatal administration.
Topics: Age Factors; Animals; Animals, Newborn; Antiparkinson Agents; Antipsychotic Agents; Excitatory Amino Acid Antagonists; Female; Humans; Levodopa; Male; Maze Learning; Mice; Mice, Inbred C57BL; Motor Activity; N-Methylaspartate; Oxidopamine; Parkinsonian Disorders; Pregnancy; Rats; Rats, Sprague-Dawley; Sympatholytics | 2002 |
Systemic administration of dizocilpine maleate (MK-801) or L-dopa reverses the increases in GAD65 and GAD67 mRNA expression in the globus pallidus in a rat hemiparkinsonian model.
Topics: Animals; Dizocilpine Maleate; Female; Globus Pallidus; Glutamate Decarboxylase; Injections, Subcutaneous; Isoenzymes; Levodopa; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger | 2002 |
Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats.
Topics: Animals; Caffeine; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1 | 2002 |
Lesioning the thalamus for dyskinesia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Electrocoagulation; Haloperidol; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Parkinsonian Disorders; Reoperation; Retrospective Studies; Schizophrenia; Stereotaxic Techniques; Sulpiride; Torticollis; Treatment Outcome; Tremor; Ventral Thalamic Nuclei | 2001 |
Growth-hormone release to clonidine and the clinical response to levodopa in parkinsonism.
Topics: Aged; Antiparkinson Agents; Benserazide; Clonidine; Female; Growth Hormone; Humans; Levodopa; Male; Parkinsonian Disorders | 2002 |
Reversal of akinesia in experimental parkinsonism by GABA antagonist microinjections in the pedunculopontine nucleus.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bicuculline; Cholinergic Fibers; Female; GABA Antagonists; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Levodopa; Macaca mulatta; Male; Motor Activity; Neural Inhibition; Neural Pathways; Parkinsonian Disorders; Pons; Receptors, GABA-A; Recovery of Function; Tegmentum Mesencephali; Treatment Outcome | 2002 |
Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antipsychotic Agents; Behavior, Animal; Dibenzothiazepines; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Quetiapine Fumarate; Rats; Receptor, Serotonin, 5-HT2A; Receptor, Serotonin, 5-HT2C; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Serotonin; Serotonin Antagonists | 2002 |
Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system.
Topics: Animals; Corpus Striatum; Dyskinesias; Genes, fos; Injections, Intraventricular; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra | 2002 |
Striatal metabotropic glutamate receptor function following experimental parkinsonism and chronic levodopa treatment.
Topics: Animals; Corpus Striatum; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; In Vitro Techniques; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate | 2002 |
Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Male; Mazindol; Neostriatum; Neural Pathways; Neuropeptides; Parkinsonian Disorders; Protein Precursors; Receptors, Purinergic P1; RNA, Messenger; Tachykinins | 2002 |
Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dystonia; Female; Levodopa; Macaca fascicularis; Neurotoxins; Nitro Compounds; Parkinsonian Disorders; Propionates; Putamen; Striatonigral Degeneration; Substantia Nigra | 2002 |
Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Forelimb; Homovanillic Acid; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Motor Activity; Nerve Tissue Proteins; Neuropeptides; Parkinsonian Disorders; Postural Balance; Recovery of Function; Tyrosine 3-Monooxygenase; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins; Walking | 2002 |
Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Carbidopa; Corpus Striatum; Cytoplasm; Drug Combinations; Indoles; Levodopa; Male; Microscopy, Immunoelectron; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Synaptic Membranes; Tyrosine 3-Monooxygenase | 2002 |
Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Callithrix; Corpus Striatum; Dose-Response Relationship, Drug; Dronabinol; Drug Combinations; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Globus Pallidus; Levodopa; Male; Motor Skills; Parkinsonian Disorders; Receptors, Cannabinoid; Receptors, Drug | 2002 |
Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Motor Skills; Neurologic Examination; Parkinsonian Disorders; Recurrence | 2002 |
AMPA receptor antagonist LY293558 reverses preproenkephalin mRNA overexpression in the striatum of 6-OHDA-lesioned-rats treated with L-dopa.
Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Gene Expression Regulation; Isoquinolines; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tetrazoles | 2002 |
Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Levodopa; Motor Activity; Parkinsonian Disorders; Pergolide; Receptors, Dopamine D1; Receptors, Dopamine D2; Severity of Illness Index | 2003 |
Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism.
Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Electroencephalography; Humans; Levodopa; Male; Mianserin; Mirtazapine; Neuropsychological Tests; Parkinsonian Disorders; Polysomnography; REM Sleep Behavior Disorder | 2003 |
Frequency of apraxia of eyelid opening in the general population and in patients with extrapyramidal disorders.
Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Apomorphine; Apraxias; Blepharospasm; Dystonia; Eyelids; Female; Humans; Italy; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Supranuclear Palsy, Progressive | 2002 |
ALS-plus: 5 cases of concomitant amyotrophic lateral sclerosis and parkinsonism.
Topics: Aged; Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Dementia; Female; Humans; Levodopa; Male; Parkinsonian Disorders | 2002 |
Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors.
Topics: Acetylcholine; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Drug Therapy, Combination; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Levodopa; Male; N-Methylaspartate; Neuronal Plasticity; Parkinsonian Disorders; Potassium; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Synaptosomes | 2003 |
Reversal of parkinsonism following liver transplantation.
Topics: Acute Disease; Aged; Antiparkinson Agents; Carbidopa; Disease Progression; Gait Disorders, Neurologic; Humans; Immunosuppressive Agents; Levodopa; Liver Cirrhosis; Liver Transplantation; Male; Parkinsonian Disorders; Remission Induction; Treatment Outcome; Tremor | 2003 |
An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Clonidine; Dopamine; Dopamine Agonists; Drug Interactions; Drug Therapy, Combination; Guanfacine; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Neostriatum; Neurons; Parkinsonian Disorders; Prazosin; Receptors, Adrenergic, alpha-2; Synaptic Transmission; Yohimbine | 2003 |
Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Binding, Competitive; Chronic Disease; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Enkephalins; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neural Pathways; Neurons; Parkinsonian Disorders; Protein Precursors; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Substantia Nigra; Tachykinins; Tyrosine 3-Monooxygenase | 2003 |
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; RNA, Messenger; Treatment Outcome | 2003 |
Two large Polish kindreds with levodopa-responsive Parkinsonism not linked to known Parkinsonian genes and loci.
Topics: Activities of Daily Living; Adult; Age of Onset; Aged; Antiparkinson Agents; Dementia; Disease Progression; Female; Genetic Linkage; Humans; Levodopa; Male; Middle Aged; Molecular Biology; Parkinsonian Disorders; Pedigree; Phenotype; Poland; Urinary Incontinence | 2003 |
Chemotherapy-induced parkinsonism responsive to levodopa: an underrecognized entity.
Topics: Aged; Antineoplastic Agents; Antiparkinson Agents; Female; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Treatment Outcome | 2003 |
Decreased striatal dopamine transporter binding in a patient with extrapontine myelinolysis.
Topics: Antiparkinson Agents; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Hyponatremia; Isotonic Solutions; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Myelinolysis, Central Pontine; Nerve Tissue Proteins; Parkinsonian Disorders; Protein Binding; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tropanes | 2003 |
[Current preclinical findings on substances against Parkinson's disease].
Topics: Animals; Antiparkinson Agents; Caenorhabditis elegans; Corpus Striatum; Dopamine Agonists; Drug Evaluation, Preclinical; Drugs, Investigational; Dyskinesia, Drug-Induced; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders | 2003 |
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia.
Topics: Animals; Corpus Striatum; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Excitatory Postsynaptic Potentials; In Vitro Techniques; Levodopa; Male; Nerve Tissue Proteins; Neuronal Plasticity; Parkinsonian Disorders; Phosphoproteins; Phosphorylation; Rats; Rats, Wistar; Synaptic Transmission | 2003 |
SCA2 may present as levodopa-responsive parkinsonism.
Topics: Adult; Aged; Alleles; Anticipation, Genetic; Antiparkinson Agents; Ataxins; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Genotype; Humans; Levodopa; Male; Middle Aged; Nerve Tissue Proteins; Neurologic Examination; Parkinson Disease; Parkinsonian Disorders; Pedigree; Phenotype; Proteins; Treatment Outcome; Trinucleotide Repeats | 2003 |
Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Blotting, Western; Corpus Striatum; Enzyme Inhibitors; Gene Transfer, Horizontal; Genetic Vectors; Herpesvirus 1, Human; Immunohistochemistry; Levodopa; Male; Models, Animal; Motor Activity; Neurons; Parkinsonian Disorders; Phosphorylation; Piperidines; Protein Kinase C; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Time Factors | 2003 |
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism.
Topics: Amidohydrolases; Animals; Antiparkinson Agents; Arachidonic Acids; Binding, Competitive; Cannabinoid Receptor Modulators; Cerebellum; Corpus Striatum; Cyclohexanols; Disease Models, Animal; Endocannabinoids; Excitatory Postsynaptic Potentials; Fatty Acids, Unsaturated; Glutamic Acid; Glycerides; In Vitro Techniques; Levodopa; Oxidopamine; Parkinsonian Disorders; Patch-Clamp Techniques; Phospholipase D; Polyunsaturated Alkamides; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug | 2003 |
Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Carbidopa; Catechols; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Locomotion; Male; Nitriles; Parkinsonian Disorders; Pulse Therapy, Drug; Substantia Nigra; Time Factors | 2003 |
Parkin disease: a phenotypic study of a large case series.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Dystonia; Female; Genetic Predisposition to Disease; Humans; Levodopa; Ligases; Male; Mental Disorders; Middle Aged; Mutation; Parkinsonian Disorders; Pedigree; Phenotype; Polymerase Chain Reaction; Ubiquitin-Protein Ligases | 2003 |
Characterization of freezing of gait subtypes and the response of each to levodopa in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Female; Gait Disorders, Neurologic; Humans; Leg; Levodopa; Male; Middle Aged; Motion; Parkinsonian Disorders; Prevalence; Psychomotor Performance; Regression Analysis; Reproducibility of Results; Surveys and Questionnaires; Time Factors; Videotape Recording | 2003 |
D3 receptors and levodopa-induced dyskinesia.
Topics: Animals; Dyskinesia, Drug-Induced; Levodopa; Parkinsonian Disorders; Piperazines; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2003 |
Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Binding, Competitive; Callithrix; Dyskinesia, Drug-Induced; Female; Imidazoles; Indans; Levodopa; Male; Parkinsonian Disorders; Radioligand Assay; Rats; Receptors, Adrenergic; Receptors, AMPA; Receptors, Dopamine; Receptors, GABA; Receptors, Histamine; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin | 2003 |
Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile parkinsonism.
Topics: Adult; Antiparkinson Agents; DNA Mutational Analysis; GTP Cyclohydrolase; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Pedigree; Point Mutation; Severity of Illness Index; Ubiquitin-Protein Ligases | 2003 |
Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca mulatta; Magnesium Sulfate; Motor Activity; Parkinsonian Disorders | 2003 |
Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Disease Models, Animal; Ditiocarb; Dopamine; Drug Synergism; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Motor Activity; Parkinsonian Disorders; Reaction Time; Recovery of Function; Selegiline; Serotonin | 2003 |
[A patient with multiple system atrophy presenting prolonged levodopa-responsive parkinsonism and off-dystonia of the trunk].
Topics: Brain; Diagnosis, Differential; Dystonia; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Multiple System Atrophy; Olivopontocerebellar Atrophies; Parkinsonian Disorders; Time Factors | 2003 |
SCA2 and SCA3 mutations in young-onset dopa-responsive parkinsonism.
Topics: Adult; Age of Onset; Female; Humans; Levodopa; Machado-Joseph Disease; Male; Middle Aged; Mutation; Parkinsonian Disorders; Spinocerebellar Ataxias; Yugoslavia | 2003 |
Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Basal Ganglia; Corpus Striatum; Disease Models, Animal; Electron Transport Complex IV; Enkephalins; Entopeduncular Nucleus; Globus Pallidus; Glutamate Decarboxylase; In Situ Hybridization; Isoenzymes; Levodopa; Male; Motor Activity; Neurons; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus | 2003 |
Effect of acute and chronic administration of U50,488, a kappa opioid receptor agonist, in 6-OHDA-lesioned rats chronically treated with levodopa.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Administration Schedule; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Time; Treatment Outcome | 2003 |
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.
Topics: Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Autoradiography; Behavior, Animal; Benzothiazoles; Binding, Competitive; Corpus Striatum; Disease Models, Animal; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Sprague-Dawley; Substantia Nigra; Thiazoles; Treatment Outcome; Tritium; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins | 2003 |
Denervation and repeated L-DOPA induce a coordinate expression of the transcription factor NGFI-B in striatal projection pathways in hemi-parkinsonian rats.
Topics: Animals; Corpus Striatum; Denervation; DNA-Binding Proteins; Enkephalins; Gene Expression Regulation; Levodopa; Male; Neural Pathways; Nuclear Receptor Subfamily 4, Group A, Member 1; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA, Messenger; Transcription Factors | 2003 |
[EXPERIENCES WITH L-DOPA IN THE THERAPY OF PARKINSONISM].
Topics: Dihydroxyphenylalanine; Humans; Levodopa; Parkinsonian Disorders | 1963 |
[THE EFFICACY OF L-DOPA IN PARKINSON PATIENTS WITH AND WITHOUT STEREOTACTIC BRAIN SURGERY].
Topics: Brain; Dihydroxyphenylalanine; Levodopa; Neurosurgery; Neurosurgical Procedures; Parkinsonian Disorders; Psychosurgery; Stereotaxic Techniques | 1964 |
[ON THE CONTROL OF AKINESIA AND OTHER EXTRAPYRAMIDAL MOTOR DISORDERS WITH L-DOPA (L-DIHYDROXYPHENYLALANINE)].
Topics: Chorea; Dihydroxyphenylalanine; Electromyography; Extrapyramidal Tracts; Humans; Levodopa; Monoamine Oxidase Inhibitors; Movement Disorders; Neurosurgery; Neurosurgical Procedures; Parkinsonian Disorders; Stereotaxic Techniques; Torticollis; Tremor | 1964 |
[ELECTROENCEPHALOGRAMS DURING ADMINISTRATION OF L-DOPA BEFORE, IN (DEPTH LEADS AND STIMULATION EFFECTS) AND AFTER STEREOTACTIC BRAIN OPERATIONS IN PARKINSON PATIENTS].
Topics: Brain; Dihydroxyphenylalanine; Electroencephalography; Levodopa; Neurosurgery; Neurosurgical Procedures; Parkinsonian Disorders; Stereotaxic Techniques | 1964 |
[ADDITIONAL EXPERIMENTAL STUDIES ON L-DOPA IN PARKINSON'S SYNDROME AND RESERPINE PARKINSONISM].
Topics: Biomedical Research; Brain; Catecholamines; Dihydroxyphenylalanine; Levodopa; Metabolism; Parkinson Disease; Parkinsonian Disorders; Pharmacology; Reserpine; Toxicology | 1964 |
Multiple system atrophy: an update.
Topics: alpha-Synuclein; Animals; Brain; Clinical Trials as Topic; Humans; Inclusion Bodies; Levodopa; Multiple System Atrophy; Nerve Tissue Proteins; Neurologic Examination; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Synucleins | 2003 |
Basal ganglia neuronal discharge in primary and secondary dystonia.
Topics: Action Potentials; Adolescent; Adult; Aged; Carrier Proteins; Child; Dystonic Disorders; Electric Stimulation; Electrophysiology; Female; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Chaperones; Neurons; Parkinsonian Disorders; Putamen; Treatment Outcome | 2004 |
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Parkinsonian Disorders; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists | 2003 |
Unclassifiable parkinsonism in two European tertiary referral centres for movement disorders.
Topics: Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Sectional Studies; Demography; Diagnosis, Differential; Ethnicity; Europe; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neurologic Examination; Outpatient Clinics, Hospital; Parkinsonian Disorders; Prevalence; Prospective Studies; Referral and Consultation; Retrospective Studies; Statistics, Nonparametric | 2003 |
Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy.
Topics: Aged; Antiparkinson Agents; Brain Mapping; Case-Control Studies; Demography; Functional Laterality; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Multiple System Atrophy; Parkinsonian Disorders | 2003 |
Persistent hemiballism after subthalamotomy: the size of the lesion matters more than the location.
Topics: Antiparkinson Agents; Corpus Striatum; Dyskinesias; Female; Functional Laterality; Humans; Levodopa; Middle Aged; Neurosurgical Procedures; Parkinsonian Disorders; Postoperative Complications; Thalamus | 2003 |
The parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) mediates release of l-3,4-dihydroxyphenylalanine (l-DOPA) and inhibition of l-DOPA decarboxylase in the rat striatum: a microdialysis study.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antioxidants; Aromatic Amino Acid Decarboxylase Inhibitors; Body Temperature; Chromatography, High Pressure Liquid; Dopa Decarboxylase; Hydroxyindoleacetic Acid; Levodopa; Male; Mannitol; Microdialysis; Neostriatum; Parkinsonian Disorders; Perfusion; Rats; Rats, Sprague-Dawley; Salicylates; Serotonin; Time Factors | 2003 |
A paradoxical acute effect of levodopa in de novo parkinsonian patients: worsening of some bradykinetic components.
Topics: Acoustic Stimulation; Aged; Antiparkinson Agents; Choice Behavior; Drug Administration Schedule; Electromyography; Female; Humans; Hypokinesia; Levodopa; Male; Parkinsonian Disorders; Reaction Time | 2003 |
Awakenings from persistent vegetative state: report of three cases with parkinsonism and brain stem lesions on MRI.
Topics: Adolescent; Adult; Antiparkinson Agents; Brain Stem; Craniocerebral Trauma; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinsonian Disorders; Persistent Vegetative State; Receptors, Dopamine; Treatment Outcome | 2003 |
Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesias; Functional Laterality; Levodopa; Male; Motor Activity; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Stereotyped Behavior; Subthalamic Nucleus; Time Factors | 2004 |
Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process.
Topics: Administration, Oral; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Female; Immunohistochemistry; Injections, Intraventricular; Levodopa; Mesencephalon; Nerve Degeneration; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Time Factors; Tyrosine 3-Monooxygenase | 2003 |
Clinical and [99mTc]TRODAT-1/[123I]IBZM SPECT imaging findings in dopa-responsive dystonia.
Topics: Adult; Benzamides; Brain; Contrast Media; Diagnosis, Differential; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dystonia; Female; Humans; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Organotechnetium Compounds; Parkinsonian Disorders; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon; Tropanes | 2004 |
Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Antiparkinson Agents; Callithrix; Dopamine Agents; Drug Synergism; Drug Therapy, Combination; Female; Indoles; Levetiracetam; Levodopa; Male; Parkinsonian Disorders; Piracetam | 2003 |
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Denervation; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Gene Expression; Glutamate Decarboxylase; Isoenzymes; Levodopa; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Pyrimidines; Rats; Receptor, Adenosine A2A; Receptors, Dopamine; RNA, Messenger; Time; Triazoles | 2003 |
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Synapses; Triazoles | 2003 |
Genetically modified human embryonic stem cells relieve symptomatic motor behavior in a rat model of Parkinson's disease.
Topics: Animals; Blotting, Western; Cells, Cultured; Disease Models, Animal; Embryo, Mammalian; Genetic Therapy; Graft Survival; GTP Cyclohydrolase; Humans; Immunohistochemistry; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Stem Cells; Transfection; Tyrosine 3-Monooxygenase | 2003 |
Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Enkephalins; Gene Expression; In Situ Hybridization; Indoles; Levodopa; Male; Motor Activity; Opioid Peptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Synaptic Transmission | 2004 |
The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Topics: Animals; Antiparkinson Agents; Callithrix; Carbidopa; Chlorobenzenes; Cyclobutanes; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Levodopa; Locomotion; Male; Motor Activity; Motor Skills; Neurologic Examination; Parkinsonian Disorders; Postural Balance; Stereotyped Behavior | 2004 |
Exercise-induced dystonia as a preceding symptom of familial Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Disease Progression; DNA Mutational Analysis; Drug Combinations; Dystonic Disorders; Exercise; Female; Genotype; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinsonian Disorders; Phenotype; Semen; Ubiquitin-Protein Ligases; Videotape Recording | 2004 |
L-DOPA-induced modulation of GABA and glutamate release in substantia nigra pars reticulata in a rodent model of Parkinson's disease.
Topics: Animals; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2004 |
Parkinsonism following anterior choroidal artery stroke.
Topics: Adult; Angiography; Antiparkinson Agents; Benserazide; Cerebral Infarction; Female; Humans; Levodopa; Magnetic Resonance Imaging; Mesencephalon; Parkinsonian Disorders; Putamen; Tomography, Emission-Computed, Single-Photon | 2004 |
Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Synergism; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phenols; Piperidines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate | 2004 |
Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.
Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Disease Progression; Dopamine Plasma Membrane Transport Proteins; Heterozygote; Homozygote; Islands of Calleja; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Nucleus Accumbens; Olfactory Pathways; Oxidative Stress; Parkinsonian Disorders; Prosencephalon; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Receptor, trkB; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Tyrosine 3-Monooxygenase | 2004 |
The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Brain Chemistry; Catalepsy; Chromatography, High Pressure Liquid; Dopamine; Levodopa; Male; Medial Forebrain Bundle; Motor Activity; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Reaction Time; Rotenone; Statistics, Nonparametric; Time Factors | 2004 |
Measurements of transcallosally mediated cortical inhibition for differentiating parkinsonian syndromes.
Topics: Aged; Antiparkinson Agents; Basal Ganglia Diseases; Corpus Callosum; Diagnosis, Differential; Electromyography; Humans; Levodopa; Magnetic Resonance Imaging; Magnetoencephalography; Middle Aged; Motor Cortex; Multiple System Atrophy; Muscle, Skeletal; Nerve Degeneration; Nerve Net; Neural Inhibition; Parkinsonian Disorders; Supranuclear Palsy, Progressive | 2004 |
Arg(184)His mutant GTP cyclohydrolase I, causing recessive hyperphenylalaninemia, is responsible for dopa-responsive dystonia with parkinsonism: a case report.
Topics: Antiparkinson Agents; Arginine; Brain; Dystonia; Genes, Recessive; GTP Cyclohydrolase; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinsonian Disorders; Pedigree; Phenylketonurias; Point Mutation; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2004 |
SCA2 presenting as levodopa-responsive parkinsonism in a young patient from the United Kingdom: a case report.
Topics: Adult; Alleles; Antiparkinson Agents; Ataxins; Female; Humans; Levodopa; Nerve Tissue Proteins; Parkinsonian Disorders; Phenotype; Proteins; Spinocerebellar Ataxias; Trinucleotide Repeat Expansion | 2004 |
Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism.
Topics: Animals; Benzylamines; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Corpus Striatum; Denervation; Disease Models, Animal; Disks Large Homolog 4 Protein; Enzyme Inhibitors; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Membrane Proteins; Motor Activity; Nerve Tissue Proteins; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Peptides; Phosphorylation; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Sulfonamides; Synaptic Transmission | 2004 |
Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzopyrans; Brain; Callithrix; Disease Models, Animal; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Indoles; Levodopa; Parkinsonian Disorders; Pyrroles; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2004 |
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
Topics: Animals; Callithrix; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Piperidines; Range of Motion, Articular; Receptors, N-Methyl-D-Aspartate; Treatment Failure | 2004 |
Spinocerebellar ataxia type 2 with Levodopa-responsive parkinsonism culminating in motor neuron disease.
Topics: Alleles; Antiparkinson Agents; Atrophy; Brain Stem; Female; Humans; Levodopa; Magnetic Resonance Imaging; Middle Aged; Motor Neuron Disease; Parkinsonian Disorders; Pedigree; Phenotype; Spinocerebellar Ataxias | 2004 |
Markedly asymmetrical parkinsonism as a leading feature of adult-onset Huntington's disease.
Topics: Adult; Alleles; Antiparkinson Agents; Carbidopa; Cognition Disorders; Diagnosis, Differential; Drug Combinations; Humans; Huntington Disease; Levodopa; Male; Neuropsychological Tests; Parkinsonian Disorders; Pedigree; Severity of Illness Index | 2004 |
L-DOPA reverses the hypokinetic behaviour and rigidity in rotenone-treated rats.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Corpus Striatum; Dopamine; Drug Synergism; Electron Transport Complex I; Levodopa; Male; Motor Activity; Motor Skills; Muscle Rigidity; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra; Uncoupling Agents | 2004 |
Case study: cerebrovascular parkinsonism with levodopa addiction.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cerebrovascular Disorders; Female; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Substance Withdrawal Syndrome; Substance-Related Disorders | 2004 |
High titer retroviral gene transduction to neural progenitor cells for establishment of donor cells for neural transplantation to parkinsonian model rats.
Topics: Animals; Cells, Cultured; Corpus Striatum; Fetal Tissue Transplantation; Gene Expression Regulation, Enzymologic; Gene Transfer Techniques; Humans; Levodopa; Mesencephalon; Neurons; Parkinsonian Disorders; Rats; Rats, Wistar; Retroviridae; Stem Cell Transplantation; Transduction, Genetic; Transformation, Genetic; Tyrosine 3-Monooxygenase | 2004 |
[Increase in regional cerebral blood flow of striatum induced by low dose levodopa in a patient with hemiparkinsonism].
Topics: Antiparkinson Agents; Cerebrovascular Circulation; Corpus Striatum; Female; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Stimulation, Chemical | 2004 |
Chronic bilateral subthalamic deep brain stimulation in a patient with homozygous deletion in the parkin gene.
Topics: Antiparkinson Agents; Deep Brain Stimulation; Disability Evaluation; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Exons; Female; Gene Deletion; Genomic Imprinting; Homozygote; Humans; Levodopa; Male; Parkinsonian Disorders; Polymerase Chain Reaction; Severity of Illness Index; Subthalamic Nucleus; Ubiquitin-Protein Ligases | 2004 |
Prolongation of levodopa responses by glycineB antagonists in parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Glycine Agents; Levodopa; Macaca mulatta; Motor Activity; Parkinsonian Disorders; Pilot Projects; Psychomotor Performance; Receptors, Glycine | 2004 |
Pathophysiology of parkinsonism due to hydrocephalus.
Topics: Adult; Antiparkinson Agents; Brain Mapping; Carbidopa; Caudate Nucleus; Cerebral Ventricles; Drug Combinations; Equipment Failure; Humans; Hydrocephalus; Hypokinesia; Levodopa; Magnetic Resonance Imaging; Male; Neurologic Examination; Parkinsonian Disorders; Positron-Emission Tomography; Postoperative Complications; Putamen; Ventriculoperitoneal Shunt | 2004 |
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Blotting, Western; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinases; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Guanosine 5'-O-(3-Thiotriphosphate); Immunohistochemistry; In Situ Hybridization; Isotopes; Levodopa; Macaca fascicularis; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Nerve Tissue Proteins; Nortropanes; Parkinsonian Disorders; Phosphoproteins; Radioligand Assay; Receptors, Dopamine D1; Receptors, Dopamine D2; Signal Transduction; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2005 |
[Dose levodopa decrease the right and left difference of the striatal blood flow in patients with hemiparkinsonism?].
Topics: Animals; Antiparkinson Agents; Cerebrovascular Circulation; Corpus Striatum; Humans; Levodopa; Parkinsonian Disorders | 2004 |
Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster.
Topics: Animals; Antioxidants; Apoptosis; Brain; Cell Count; Dopamine; Dopamine Agonists; Drosophila melanogaster; Electron Transport Complex I; Insecticides; Levodopa; Locomotion; Melatonin; Nerve Degeneration; Neurons; Oxidative Stress; Parkinsonian Disorders; Phenotype; Rotenone | 2004 |
Parkin disease in a Brazilian kindred: Manifesting heterozygotes and clinical follow-up over 10 years.
Topics: Adult; Antiparkinson Agents; Brazil; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Exons; Female; Follow-Up Studies; Foot; Genotype; Heterozygote; Humans; Levodopa; Male; Parkinsonian Disorders; Pedigree; Point Mutation; Ubiquitin-Protein Ligases | 2005 |
Cerebral glutamate metabolism in Parkinson's disease: an in vivo dynamic (13)C NMS study in the rat.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Carbon Isotopes; Disease Models, Animal; Dopamine; Glutamic Acid; Glutaminase; Glutamine; Infusions, Intravenous; Levodopa; Lipid Metabolism; Magnetic Resonance Spectroscopy; Male; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Sodium Acetate | 2005 |
Carbidopa/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats.
Topics: Animals; Biotransformation; Carbidopa; Drug Evaluation, Preclinical; Levodopa; Male; Microspheres; Parkinsonian Disorders; Rats | 2005 |
L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain.
Topics: Animals; Antiparkinson Agents; Arrestins; Basal Ganglia; beta-Adrenergic Receptor Kinases; Brain; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; G-Protein-Coupled Receptor Kinases; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Phosphoproteins; Phosphorylation; Protein Serine-Threonine Kinases; Receptors, G-Protein-Coupled; Up-Regulation | 2005 |
Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
Topics: Animals; Benserazide; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Models, Animal; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Levodopa; Male; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2005 |
Functional interaction between mGlu 5 and NMDA receptors in a rat model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Dizocilpine Maleate; Drug Synergism; Levodopa; Male; Parkinsonian Disorders; Pyridines; Rats; Rats, Wistar; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate | 2005 |
Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: Animals; Basal Ganglia; Deoxyglucose; Dyskinesia, Drug-Induced; Female; Globus Pallidus; Levodopa; Limbic System; Macaca fascicularis; Motor Cortex; Parkinsonian Disorders; Septal Nuclei; Somatosensory Cortex; Substantia Nigra; Subthalamic Nucleus | 2005 |
3,4-dihydroxyphenylalanine reverses the motor deficits in Pitx3-deficient aphakia mice: behavioral characterization of a novel genetic model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Ataxia; Benserazide; Blindness; Corpus Striatum; Dopamine; Homeodomain Proteins; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Parkinsonian Disorders; Psychomotor Performance; Substantia Nigra; Transcription Factors | 2005 |
Levodopa-responsive infantile parkinsonism due to a novel mutation in the tyrosine hydroxylase gene and exacerbation by viral infections.
Topics: Animals; Antiparkinson Agents; Central Nervous System Viral Diseases; Child, Preschool; DNA Mutational Analysis; Female; Histidine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Mice; Mutation; Parkinsonian Disorders; Rats; Treatment Outcome; Tyrosine; Tyrosine 3-Monooxygenase | 2005 |
Hemiparkinsonism and levodopa-induced dyskinesias after focal nigral lesion.
Topics: Adult; Antiparkinson Agents; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Substantia Nigra | 2005 |
Clinical and genetic evaluation of 8 Polish families with levodopa-responsive parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Chromosome Mapping; Corpus Striatum; DNA Mutational Analysis; Dopamine Plasma Membrane Transport Proteins; Female; Genetic Predisposition to Disease; Genetic Testing; Humans; Inheritance Patterns; Levodopa; Male; Middle Aged; Neural Pathways; Parkinsonian Disorders; Pedigree; Poland; Substantia Nigra; Tomography, Emission-Computed, Single-Photon | 2005 |
Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
Topics: Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesias; Female; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Naloxone; Narcotic Antagonists; Narcotics; Nerve Tissue Proteins; Parkinsonian Disorders; Protein Binding; Receptors, Opioid; Saimiri; Sulfur Isotopes | 2005 |
Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without L-DOPA administration.
Topics: Animals; Basal Ganglia; Cell Count; Cerebral Cortex; Disease Models, Animal; Dopamine Agents; gamma-Aminobutyric Acid; Globus Pallidus; Glutamate Decarboxylase; Immunohistochemistry; Isoenzymes; Levodopa; Male; Neural Inhibition; Neurons; Parkinsonian Disorders; Saimiri; Transcriptional Activation; Up-Regulation | 2005 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Buspirone; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Indoles; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Purines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Reproducibility of Results; Riluzole; Treatment Outcome | 2005 |
Recovery from parkinson syndrome and prolonged visually evoked potentials in hepatic encephalopathy.
Topics: Anti-Bacterial Agents; Antiparkinson Agents; Benzothiazoles; Brain; Chronic Disease; Dipeptides; Evoked Potentials, Visual; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Paromomycin; Pramipexole; Recovery of Function; Thiazoles; Treatment Outcome; Vision Disorders | 2005 |
Activation of mitochondrial ATP-sensitive potassium channels improves rotenone-related motor and neurochemical alterations in rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Catalepsy; Decanoic Acids; Diazoxide; Disease Models, Animal; Dopamine; Hydroxy Acids; Levodopa; Male; Motor Activity; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Parkinsonian Disorders; Potassium Channel Blockers; Potassium Channels; Propylamines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotenone; Substantia Nigra | 2006 |
Different clinical and evolutional patterns in late idiopathic and vascular parkinsonism.
Topics: Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease, Secondary; Parkinsonian Disorders; Prognosis; Treatment Outcome | 2005 |
Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in Parkinsonian monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Kynurenic Acid; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Mixed Function Oxygenases; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors | 2005 |
The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease.
Topics: Age of Onset; Brain; Diagnosis, Differential; Dopamine Agents; Energy Metabolism; Genetic Predisposition to Disease; Humans; Italy; Levodopa; Male; Middle Aged; Mitochondria; Mitochondrial Diseases; Mutation; Parkinson Disease; Parkinsonian Disorders; Phenotype; Protein Kinases; Shy-Drager Syndrome; Sympathetic Nervous System; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2005 |
Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia.
Topics: Adolescent; Adult; Age of Onset; Antiparkinson Agents; Child; Chromosomes, Human, Pair 1; Dementia; Female; Functional Laterality; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Pedigree; Pyramidal Tracts; Severity of Illness Index; Supranuclear Palsy, Progressive | 2005 |
Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesias; Female; Levodopa; Macaca fascicularis; Motor Activity; Naltrexone; Narcotic Antagonists; Ovariectomy; Parkinsonian Disorders; Statistics, Nonparametric; Time Factors | 2005 |
Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila.
Topics: Animals; Blotting, Northern; Blotting, Western; Brain; Chlorocebus aethiops; COS Cells; Dopamine; Drosophila; Drosophila Proteins; Histocytochemistry; Immunoenzyme Techniques; Immunoprecipitation; JNK Mitogen-Activated Protein Kinases; Levodopa; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Mutation; Neurons; Parkinsonian Disorders; Signal Transduction; Tyrosine 3-Monooxygenase; Ubiquitin-Protein Ligases | 2005 |
Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism.
Topics: Aging; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Levodopa; Male; Nerve Tissue Proteins; Neural Pathways; Neuronal Plasticity; Parkinsonian Disorders; Phosphoprotein Phosphatases; Phosphoproteins; Phosphorylation; Presynaptic Terminals; Protein Phosphatase 1; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Substantia Nigra; Synaptic Membranes; Up-Regulation | 2005 |
Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.
Topics: Animals; Antiparkinson Agents; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Female; Immunohistochemistry; Levodopa; Macaca fascicularis; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Degeneration; Nerve Tissue Proteins; Neural Pathways; Neurons; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2005 |
Changes induced by levodopa and subthalamic nucleus stimulation on parkinsonian speech.
Topics: Adult; Dysarthria; Dyskinesias; Electric Stimulation Therapy; Functional Laterality; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Severity of Illness Index; Subthalamic Nucleus | 2005 |
In vivo models of multiple system atrophy.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Corpus Striatum; Levodopa; Macaca fascicularis; Mice; MPTP Poisoning; Multiple System Atrophy; Oxidopamine; Parkinsonian Disorders; Point Mutation; Rats; Substantia Nigra | 2005 |
Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
Topics: Animals; Apomorphine; Behavior, Animal; Benzazepines; Brain; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dopamine Antagonists; Drug Interactions; Female; Gene Expression; Gene Expression Regulation; In Situ Hybridization; Levodopa; Oxidopamine; Parkinsonian Disorders; Protein Isoforms; Rats; Rats, Wistar; RNA, Messenger; Rotation; Substantia Nigra; Synaptotagmins; Time Factors; Tyrosine 3-Monooxygenase | 2005 |
Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
Topics: Animals; Antiparkinson Agents; Benserazide; Benzoxazoles; Corpus Striatum; Dopamine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Piperidines; Protein Precursors; Receptors, N-Methyl-D-Aspartate; RNA, Messenger | 2006 |
ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Blotting, Western; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Dyskinesia, Drug-Induced; Dyskinesias; Enkephalins; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Immunohistochemistry; In Situ Hybridization; Levodopa; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Proto-Oncogene Proteins c-fos; RNA, Messenger; Statistics, Nonparametric; Time Factors | 2006 |
Oculogyric dystonic states in early-onset parkinsonism with basal ganglia calcifications.
Topics: Age of Onset; Antiparkinson Agents; Apomorphine; Basal Ganglia; Calcinosis; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; Humans; Levodopa; Middle Aged; Ocular Motility Disorders; Oculomotor Muscles; Parkinsonian Disorders | 2005 |
Hemiparkinsonism with a discrete lacunar infarction in the contralateral substantia nigra.
Topics: Antiparkinson Agents; Brain Stem Infarctions; Carbidopa; Cerebral Infarction; Diagnosis, Differential; Dominance, Cerebral; Drug Therapy, Combination; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurologic Examination; Parkinsonian Disorders; Substantia Nigra; Tomography, Emission-Computed, Single-Photon | 2006 |
DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Dehydroepiandrosterone; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Severity of Illness Index | 2006 |
Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia.
Topics: Animals; Brain Tissue Transplantation; Dyskinesias; Female; Fetal Tissue Transplantation; Levodopa; Mesencephalon; Nerve Regeneration; Neurons; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2006 |
Dopa-responsive hemiparkinsonism due to midbrain Virchow-Robin spaces?
Topics: Antiparkinson Agents; Female; Functional Laterality; Humans; Levodopa; Magnetic Resonance Imaging; Mesencephalon; Middle Aged; Parkinsonian Disorders; Subarachnoid Space; Tomography, Emission-Computed, Single-Photon | 2005 |
Modulation of torsinA expression in the globus pallidus internus is associated with levodopa-induced dyskinesia in hemiparkinsonian rats.
Topics: Animals; Cell Count; Disease Models, Animal; Dopamine Agents; Down-Regulation; Dyskinesia, Drug-Induced; Entopeduncular Nucleus; Globus Pallidus; Levodopa; Male; Molecular Chaperones; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2006 |
The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat.
Topics: Amphetamine; Animals; Brain Tissue Transplantation; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Female; Levodopa; Movement; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Rotation; Selective Serotonin Reuptake Inhibitors; Substantia Nigra; Transplantation Tolerance | 2006 |
Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Catechols; Disease Models, Animal; Drug Therapy, Combination; Dyskinesias; Levodopa; Male; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Time Factors | 2006 |
Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys.
Topics: Aged; Aged, 80 and over; Animals; Arachidonic Acid; Cerebral Cortex; Chromatography, Gas; Dietary Fats; Disease Models, Animal; Docosahexaenoic Acids; Dopamine Agents; Dyskinesia, Drug-Induced; Fatty Acids; Fatty Acids, Unsaturated; Female; Humans; Levodopa; Lipid Metabolism; Macaca fascicularis; Male; Neurons; Parkinson Disease; Parkinsonian Disorders; Postmortem Changes; Species Specificity | 2006 |
Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome.
Topics: Aged; Antiparkinson Agents; Benzamides; Diagnosis, Differential; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Pyrrolidines; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed, Single-Photon; Tropanes | 2006 |
Microelectrode recording can be a good adjunct in magnetic resonance image-directed subthalamic nucleus deep brain stimulation for parkinsonism.
Topics: Aged; Antiparkinson Agents; Combined Modality Therapy; Dominance, Cerebral; Electric Stimulation Therapy; Electroencephalography; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Microelectrodes; Middle Aged; Outcome Assessment, Health Care; Parkinsonian Disorders; Retrospective Studies; Stereotaxic Techniques; Subthalamic Nucleus; Surgery, Computer-Assisted; Treatment Outcome | 2006 |
Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adenosine; Adrenergic Agents; Animals; Caffeine; Corpus Striatum; Dynorphins; Dyskinesias; Enkephalins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; RNA, Messenger | 2006 |
Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Extracellular Fluid; Female; Levodopa; Microdialysis; Microinjections; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Serotonin; Up-Regulation | 2006 |
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antiparkinson Agents; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinases; Corpus Striatum; Disks Large Homolog 4 Protein; Intracellular Signaling Peptides and Proteins; Levodopa; Male; Membrane Proteins; Motor Activity; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Binding; Protein Interaction Mapping; Protein Processing, Post-Translational; Protein Structure, Tertiary; Protein Transport; Protein-Tyrosine Kinases; Psychomotor Performance; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Recombinant Fusion Proteins; Subcellular Fractions; Synapses | 2006 |
Levodopa-induced dyskinesia and rotational behavior in hemiparkinsonian rats: independent features or components of the same phenomenon?
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Rotation; Time Factors | 2006 |
Three in one: case report supporting different origins of essential and parkinsonian tremors.
Topics: Aged; Antiparkinson Agents; Antithyroid Agents; Combined Modality Therapy; Deep Brain Stimulation; Diagnosis, Differential; Essential Tremor; Female; Humans; Hyperthyroidism; Levodopa; Neurologic Examination; Parkinson Disease; Parkinsonian Disorders; Tremor; Ventral Thalamic Nuclei | 2006 |
Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome.
Topics: Adrenergic beta-Antagonists; Aged; Anxiety Disorders; Benzodiazepines; Carbidopa; Central Nervous System Agents; Cerebellar Ataxia; Cholinesterase Inhibitors; Dopamine Agonists; Female; Fragile X Syndrome; Humans; Levodopa; Male; Memory Disorders; Middle Aged; Neurologic Examination; Parkinsonian Disorders; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Tremor | 2006 |
Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Functional Laterality; Globus Pallidus; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley; Time Factors | 2006 |
MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Fenfluramine; Levodopa; Male; N-Methyl-3,4-methylenedioxyamphetamine; Oxidopamine; Parkinsonian Disorders; Rats; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Antagonists; Serotonin Agents | 2006 |
MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA.
Topics: Adult; Aged; Antiparkinson Agents; Autonomic Nervous System; Cerebellar Ataxia; Death, Sudden; Diagnostic Imaging; Drug Resistance; Female; Follow-Up Studies; Humans; Japan; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Multiple System Atrophy; Parkinsonian Disorders; Phenotype; Retrospective Studies; Vocal Cord Paralysis | 2006 |
Dopa-responsive parkinsonism after acute subdural hematoma.
Topics: Adult; Antiparkinson Agents; Female; Hematoma, Subdural, Acute; Humans; Levodopa; Magnetic Resonance Imaging; Parkinsonian Disorders; Tomography, X-Ray Computed | 2006 |
Levodopa can worsen tremor associated with dystonia.
Topics: Aged; Antiparkinson Agents; Carbidopa; Diagnostic Errors; Drug Combinations; Dystonia; Female; Humans; Levodopa; Neurologic Examination; Parkinsonian Disorders; Psychomotor Performance; Tremor | 2006 |
Assessing nigrostriatal dysfunctions by pharmacological MRI in parkinsonian rhesus macaques.
Topics: Animals; Brain Mapping; Caudate Nucleus; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Functional Laterality; Image Processing, Computer-Assisted; Levodopa; Macaca mulatta; Magnetic Resonance Imaging; Parkinsonian Disorders; Putamen; Substantia Nigra | 2006 |
Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Corpus Striatum; Drug Interactions; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression Regulation; In Situ Hybridization; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Protein Precursors; Radioligand Assay; Receptors, Opioid; Regression Analysis; RNA, Messenger; Subthalamic Nucleus | 2007 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Callithrix; Disability Evaluation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Grooming; Hallucinations; Levodopa; Parkinsonian Disorders; Psychomotor Agitation; Psychotic Disorders; Statistics, Nonparametric; Stereotyped Behavior | 2006 |
Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Dopamine Agonists; Drug Administration Routes; Drug Administration Schedule; Levodopa; Mental Disorders; Parkinsonian Disorders; Severity of Illness Index; Time Factors | 2006 |
Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia.
Topics: Animals; Antibodies, Monoclonal; Antigens; Basal Ganglia; Biomarkers; Blood-Brain Barrier; Bromodeoxyuridine; Cell Count; Cell Proliferation; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Endothelial Cells; Female; Intermediate Filament Proteins; Levodopa; Motor Activity; Neovascularization, Pathologic; Nerve Tissue Proteins; Nestin; Oxidopamine; Parkinsonian Disorders; Platelet Endothelial Cell Adhesion Molecule-1; Proteoglycans; Rats; Rats, Sprague-Dawley | 2006 |
[Case of juvenile parkinsonism in pregnancy].
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Contraindications; Dopamine Agents; Dopamine Agonists; Ergolines; Family Planning Services; Female; Humans; Infant, Newborn; Levodopa; Parkinsonian Disorders; Pramipexole; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Thiazoles | 2006 |
Reversible Parkinsonism and T1W pallidal hyperintensities in acute liver failure.
Topics: Adult; Antiparkinson Agents; Female; Globus Pallidus; Humans; Levodopa; Liver Failure, Acute; Magnetic Resonance Imaging; Parkinson Disease, Secondary; Parkinsonian Disorders | 2006 |
Chronic high-frequency stimulation of the subthalamic nucleus and L-DOPA treatment in experimental parkinsonism: effects on motor behaviour and striatal glutamate transmission.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Interactions; Dyskinesias; Electric Stimulation; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Functional Laterality; Levodopa; Male; Membrane Potentials; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Subthalamic Nucleus; Time Factors | 2006 |
Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amino Acid Substitution; Animals; Catechols; Cell Differentiation; Cell Line, Tumor; Cerebral Cortex; Corpus Striatum; Cytosol; Dopamine; Humans; Levodopa; Mice; Mice, Transgenic; Mutation, Missense; Nerve Degeneration; Neuroblastoma; Oxidation-Reduction; Parkinson Disease; Parkinsonian Disorders; Protein Conformation; Recombinant Fusion Proteins; Solubility; Transfection; Tretinoin; Tyrosine 3-Monooxygenase | 2006 |
Subchronic administration of L-DOPA to adult rats with a unilateral 6-hydroxydopamine lesion of dopamine neurons results in a sensitization of enhanced GABA release in the substantia nigra, pars reticulata.
Topics: Animals; Antiparkinson Agents; Dopamine; Dopamine Agents; Drug Administration Schedule; gamma-Aminobutyric Acid; Levodopa; Male; Microdialysis; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2006 |
T313M PINK1 mutation in an extended highly consanguineous Saudi family with early-onset Parkinson disease.
Topics: Adolescent; Adult; Age of Onset; Amino Acid Substitution; Child; Child, Preschool; Consanguinity; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Genetic Testing; Genotype; Homozygote; Humans; Levodopa; Male; Mutation; Parkinsonian Disorders; Pedigree; Protein Kinases; Saudi Arabia; Treatment Outcome | 2006 |
Dopamine: from pharmacology to molecular biology and back.
Topics: Amphetamines; Animals; Antiparkinson Agents; Brain; Dopamine; Dopamine Plasma Membrane Transport Proteins; Gene Expression Regulation; Humans; Levodopa; Locomotion; Mice; Mice, Knockout; Parkinson Disease; Parkinsonian Disorders; Receptors, G-Protein-Coupled; Signal Transduction | 2006 |
Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy.
Topics: Analysis of Variance; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Functional Laterality; Levodopa; Male; Multiple System Atrophy; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra | 2007 |
The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventral mesencephalon transplants and levodopa-induced dyskinesias.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Combined Modality Therapy; Corpus Striatum; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Fetal Tissue Transplantation; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Levodopa; Mesencephalon; Motor Skills; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Recovery of Function; Severity of Illness Index; Sympatholytics | 2007 |
Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice.
Topics: Adenosine A2 Receptor Antagonists; Animals; Dyskinesia, Drug-Induced; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinsonian Disorders; Prosencephalon; Purines; Receptor, Adenosine A2A | 2006 |
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Exploratory Behavior; Levodopa; Male; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Sympatholytics; Triazoles | 2007 |
Unilateral 6-hydroxydopamine lesion of dopamine neurons and subchronic L-DOPA administration in the adult rat alters the expression of the vesicular GABA transporter in different subsets of striatal neurons and in the substantia nigra, pars reticulata.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Down-Regulation; Drug Administration Schedule; Enkephalins; Functional Laterality; gamma-Aminobutyric Acid; Gene Expression Regulation; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Synaptic Transmission; Up-Regulation; Vesicular Inhibitory Amino Acid Transport Proteins | 2007 |
Exercise improves efficacy of levodopa in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Exercise; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Severity of Illness Index; Time Factors | 2007 |
Effects of 2,3-benzodiazepine AMPA receptor antagonists on dopamine turnover in the striatum of rats with experimental parkinsonism.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Benzodiazepines; Corpus Striatum; Dopamine; Dopamine Agents; Drug Interactions; Functional Laterality; Homovanillic Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 2007 |
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Bicuculline; Drug Synergism; Drug Therapy, Combination; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Injections; Levodopa; Male; Microdialysis; Motor Activity; Neural Pathways; Nociceptin Receptor; Oxidopamine; Parkinsonian Disorders; Perfusion; Piperidines; Postural Balance; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Sodium Channel Blockers; Stereotaxic Techniques; Substantia Nigra; Tetrodotoxin; Thalamus | 2007 |
[Juvenile Parkinson's disease and recurring prematurity. Case report].
Topics: Adult; Antiparkinson Agents; Bromocriptine; Female; Humans; Infant, Newborn; Infant, Premature; Levodopa; Obstetric Labor, Premature; Parkinsonian Disorders; Pregnancy; Pregnancy Complications; Pregnancy Outcome | 2007 |
Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.
Topics: Adrenergic Agents; Animals; Cross-Over Studies; Disease Models, Animal; Double-Blind Method; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Neurotransmitter Agents; Parkinsonian Disorders; Random Allocation; Rats; Rotarod Performance Test; Serotonin Agents; Statistics, Nonparametric | 2007 |
The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Hypnotics and Sedatives; Levodopa; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Saimiri; Vomiting | 2007 |
Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
Topics: Animals; Antiparkinson Agents; Cell Compartmentation; Corpus Striatum; Cytoplasm; Dopamine; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Microscopy, Electron, Transmission; Neurons; Parkinsonian Disorders; Protein Transport; Receptor Aggregation; Receptors, Dopamine D1; Receptors, Dopamine D2; Up-Regulation | 2007 |
Treatment of juvenile Parkinson disease and the recurrent emergence of pathologic gambling.
Topics: Adolescent; Adult; Antiparkinson Agents; Benzothiazoles; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Female; Gambling; Humans; Levodopa; Parkinsonian Disorders; Pergolide; Pramipexole; Recurrence | 2007 |
Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Antiparkinson Agents; Benserazide; Callithrix; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Infusions, Intravenous; Levodopa; Locomotion; Male; Motor Activity; MSH Release-Inhibiting Hormone; Parkinsonian Disorders | 2007 |
Modification of L-DOPA pharmacological activity by MAO inhibitors.
Topics: Animals; Basal Ganglia; Brain; Denervation; Dopamine; Drug Interactions; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin; Substantia Nigra; Synaptic Transmission | 2007 |
Nicotine induces tyrosine hydroxylase plasticity in the neurodegenerating striatum.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Axons; Corpus Striatum; Denervation; Dopamine; Down-Regulation; Levodopa; Male; Nerve Degeneration; Neuronal Plasticity; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2007 |
Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.
Topics: Afferent Pathways; Animals; Antiparkinson Agents; Aphakia; Corpus Striatum; Disease Models, Animal; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Levodopa; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Substantia Nigra | 2007 |
Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Basal Ganglia; Biomarkers; Disease Progression; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Male; Parkinsonian Disorders; Placebos; Presynaptic Terminals; Saimiri; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2007 |
The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Functional Laterality; Levodopa; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Inbred F344; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2007 |
Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson's disease over time.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Cohort Studies; Cross-Sectional Studies; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Levodopa; Longitudinal Studies; Male; Neurologic Examination; Neuropsychological Tests; Norway; Parkinson Disease; Parkinsonian Disorders; Prospective Studies; REM Sleep Behavior Disorder; Sex Factors | 2008 |
In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias.
Topics: Animals; Brain; Cerebrovascular Circulation; Dopamine Agents; Dyskinesia, Drug-Induced; Levodopa; Macaca fascicularis; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D3; Tetrahydronaphthalenes | 2007 |
Amyotrophic lateral sclerosis with dementia showing clinical parkinsonism and severe degeneration of the substantia nigra: report of an autopsy case.
Topics: Aged; Amyotrophic Lateral Sclerosis; Autopsy; Dementia; Diagnosis, Differential; Dopamine Agents; Fatal Outcome; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease; Parkinsonian Disorders; Substantia Nigra | 2007 |
Fracture risk associated with parkinsonism and anti-Parkinson drugs.
Topics: Adult; Age Factors; Antiparkinson Agents; Carbidopa; Case-Control Studies; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Enzyme Inhibitors; Female; Fractures, Bone; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Parkinsonian Disorders; Risk Factors; Sex Factors; Time Factors | 2007 |
L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
Topics: Adaptation, Physiological; Animals; Antiparkinson Agents; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine; Female; Immunohistochemistry; Interneurons; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Phenotype; Tyrosine 3-Monooxygenase; Up-Regulation | 2008 |
Different cerebral cortical areas influence the effect of subthalamic nucleus stimulation on parkinsonian motor deficits and freezing of gait.
Topics: Adult; Aged; Antiparkinson Agents; Brain Mapping; Cerebral Cortex; Combined Modality Therapy; Deep Brain Stimulation; Female; Fluorodeoxyglucose F18; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Neural Pathways; Parkinsonian Disorders; Positron-Emission Tomography; Radiopharmaceuticals; Subthalamic Nucleus | 2007 |
Genetic analysis of SCA 2 and 3 repeat expansions in essential tremor and atypical Parkinsonism.
Topics: Adult; Antiparkinson Agents; Ataxin-3; Ataxins; Cross-Sectional Studies; Diagnosis, Differential; DNA Mutational Analysis; Drug Resistance; Essential Tremor; Female; Genetic Testing; Genotype; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Multiple System Atrophy; Nerve Tissue Proteins; Neurologic Examination; Nuclear Proteins; Parkinsonian Disorders; Phenotype; Polymerase Chain Reaction; Repressor Proteins; Spinocerebellar Ataxias; Supranuclear Palsy, Progressive; Trinucleotide Repeat Expansion; Trinucleotide Repeats | 2007 |
Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Kynurenic Acid; Kynurenine; Kynurenine 3-Monooxygenase; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Quinolinic Acid; Sulfonamides; Thiazoles; Time Factors | 2008 |
Changes in the prodynorphin gene and DARPP-32 state in 6-OHDA-lesioned rats following long-term treatment with l-dopa.
Topics: Amino Acid Sequence; Animals; Basal Ganglia; Brain Chemistry; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Administration Schedule; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Female; Gene Expression Regulation; Levodopa; Male; Neural Pathways; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Phosphorylation; Protein Precursors; Rats; Rats, Sprague-Dawley; RNA, Messenger; Threonine; Time | 2007 |
Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Circadian Rhythm; Dyskinesia, Drug-Induced; Levodopa; Nicotine; Nicotinic Agonists; Parkinsonian Disorders; Saimiri; Substantia Nigra; Time Factors | 2007 |
Novel pattern of levodopa-related motor fluctuations: 'paradoxical'on.
Topics: Aged; Antiparkinson Agents; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinsonian Disorders | 2008 |
Transcranial sonography findings in welding-related Parkinsonism in comparison to Parkinson's disease.
Topics: Adult; Diagnosis, Differential; Dopamine Agonists; Drug Resistance; Echoencephalography; Humans; Levodopa; Male; Occupational Diseases; Parkinson Disease; Parkinsonian Disorders; Substantia Nigra; Ultrasonography, Doppler, Transcranial; Welding | 2008 |
Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of L-dopa-induced dyskinesias in MPTP parkinsonian monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Benzoxazoles; Binding, Competitive; Bridged Bicyclo Compounds, Heterocyclic; Convulsants; Disease Models, Animal; Dyskinesia, Drug-Induced; Female; Flunitrazepam; GABA Modulators; Isotopes; Levodopa; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Binding; Radiography; Receptors, GABA; Substantia Nigra | 2008 |
Parkinsonism in a patient with antiphospholipid syndrome--case report and literature review.
Topics: Adult; Anticoagulants; Antiparkinson Agents; Antiphospholipid Syndrome; Brain; Cerebral Arteries; Corpus Striatum; Dementia, Vascular; Female; Humans; Intracranial Thrombosis; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Parkinsonian Disorders; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Warfarin | 2008 |
A novel phenotype of sporadic Creutzfeldt-Jakob disease.
Topics: Aged; Antibodies; Antibodies, Monoclonal; Antiparkinson Agents; Blotting, Western; Brain; Codon; Creutzfeldt-Jakob Syndrome; Female; Humans; Immunohistochemistry; Levodopa; Magnetic Resonance Imaging; Methionine; Parkinsonian Disorders; Phenotype; Polymorphism, Genetic; PrPSc Proteins; Valine | 2007 |
Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesia, Drug-Induced; Functional Laterality; Intralaminar Thalamic Nuclei; Kainic Acid; Levodopa; Macaca fascicularis; Male; Parkinsonian Disorders; Stereotaxic Techniques | 2008 |
Are parkin patients particularly suited for deep-brain stimulation?
Topics: Adult; Aged; Antiparkinson Agents; Deep Brain Stimulation; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Genetic Testing; Heterozygote; Homozygote; Humans; Levodopa; Male; Middle Aged; Mutation; Parkinsonian Disorders; Treatment Outcome; Ubiquitin-Protein Ligases | 2008 |
Marked diurnal fluctuation and rest benefit in a patient with parkin mutation.
Topics: Adult; Circadian Rhythm; Diagnosis, Differential; Dopamine; Dopamine Agonists; Gait Disorders, Neurologic; Humans; Levodopa; Male; Parkinsonian Disorders; Point Mutation; Positron-Emission Tomography; Putamen; Radiopharmaceuticals; Tropanes; Ubiquitin-Protein Ligases; Videotape Recording | 2008 |
Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease.
Topics: Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Gene Expression; In Situ Hybridization; Intracellular Signaling Peptides and Proteins; Levodopa; Membrane Proteins; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor Activity-Modifying Protein 1; Receptor Activity-Modifying Proteins; RNA, Messenger | 2008 |
Specific induction of PAG608 in cranial and spinal motor neurons of L-DOPA-treated parkinsonian rats.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Brain; Disease Models, Animal; DNA-Binding Proteins; Drug Interactions; Functional Laterality; Gene Expression Regulation; Levodopa; Motor Neurons; Nuclear Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA-Binding Proteins; Spinal Cord | 2008 |
Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Chlorobenzenes; Corpus Striatum; Cyclobutanes; Dynorphins; Enkephalins; Gene Expression; In Situ Hybridization; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger; Substance P; Time | 2008 |
Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation.
Topics: Animals; Astrocytes; Biomarkers; Calcium-Binding Proteins; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agents; Glial Fibrillary Acidic Protein; Immunohistochemistry; Levodopa; Male; Microfilament Proteins; Microglia; Neural Pathways; Neuroglia; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Rats; Substantia Nigra | 2008 |
Homozygous SCA 2 mutations changes phenotype and hastens progression.
Topics: Antiparkinson Agents; Ataxins; Dementia; Disease Progression; Dyskinesias; Female; Follow-Up Studies; Homozygote; Humans; Levodopa; Male; Mutation; Nerve Tissue Proteins; Ocular Motility Disorders; Parkinsonian Disorders; Phenotype; Psychotic Disorders; Spinocerebellar Degenerations | 2008 |
Effect of dopaminergic substances on sleep/wakefulness in saline- and MPTP-treated mice.
Topics: Animals; Dopamine Agonists; Electroencephalography; Levodopa; Lisuride; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Pergolide; Polysomnography; Sleep; Wakefulness | 2008 |
The auditory startle response in parkinsonism may reveal the extent but not type of pathology.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Auditory Pathways; Blinking; Brain Stem; Dementia; Diagnosis, Differential; Facial Muscles; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Neck Muscles; Ocular Motility Disorders; Parkinsonian Disorders; Predictive Value of Tests; Reflex, Startle; Sensitivity and Specificity; Supranuclear Palsy, Progressive; Tauopathies | 2008 |
[L-dopa sensitive Parkinsonism in neurocysticercosis].
Topics: Adult; Anthelmintics; Cerebrospinal Fluid Pressure; Female; Fourth Ventricle; Humans; Hydrocephalus; Levodopa; Neurocysticercosis; Parkinsonian Disorders; Ventriculoperitoneal Shunt | 2008 |
In vivo neurochemical effects of the NR2B selective NMDA receptor antagonist CR 3394 in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adamantane; Amidines; Animals; Antiparkinson Agents; Basal Ganglia; Denervation; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Injections, Intraperitoneal; Levodopa; Male; Medial Forebrain Bundle; Microdialysis; Oxidopamine; Parkinsonian Disorders; Perfusion; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Time Factors | 2008 |
Primitive reflexes distinguish vascular parkinsonism from Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cerebrovascular Disorders; Diagnosis, Differential; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Motor Neurons; Neuropsychological Tests; Parkinson Disease; Parkinsonian Disorders; Reflex | 2008 |
Striatal histone modifications in models of levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetylation; Animals; Chromatin; Chromosome Aberrations; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Extracellular Signal-Regulated MAP Kinases; Female; Histones; Levodopa; Macaca mulatta; Male; Methylation; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Phosphorylation; Protein Processing, Post-Translational; Species Specificity | 2008 |
Preclinical models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Injections, Intra-Arterial; Injections, Intravenous; Levodopa; Macaca fascicularis; Macaca mulatta; Mice; Mice, Inbred C57BL; Motor Activity; MPTP Poisoning; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Primates; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Species Specificity | 2001 |
Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Mice; Oxidopamine; Parkinsonian Disorders; Rats; Sympatholytics | 2007 |
Reversible parkinsonism following ventriculoperitoneal shunt in a patient with obstructive hydrocephalus secondary to intraventricular neurocysticercosis.
Topics: Adult; Antiparkinson Agents; Cerebral Ventricles; Humans; Hydrocephalus; Levodopa; Male; Neurocysticercosis; Parkinsonian Disorders; Ventriculoperitoneal Shunt | 2008 |
Stroke of the substance nigra and parkinsonism as first manifestation of systemic lupus erythematosus.
Topics: Antiparkinson Agents; Female; Humans; Levodopa; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; Middle Aged; Parkinsonian Disorders; Stroke; Substantia Nigra | 2008 |
Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism.
Topics: Aged; Antiparkinson Agents; Brain; Diagnosis, Differential; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Pilot Projects; Predictive Value of Tests; Severity of Illness Index; Surveys and Questionnaires; Tomography, X-Ray Computed | 2008 |
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Dopamine; Drug Evaluation, Preclinical; Endotoxins; Exenatide; Glucagon-Like Peptide-1 Receptor; Levodopa; Locomotion; Male; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Peptides; Rats; Rats, Wistar; Receptors, Glucagon; Substantia Nigra; Tyrosine 3-Monooxygenase; Venoms | 2008 |
Intraocular microinjections repair experimental Parkinson's disease.
Topics: 5-Methoxytryptamine; Animals; Antiparkinson Agents; Circadian Rhythm; Levodopa; Male; Microinjections; Motor Activity; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Retina | 2008 |
Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists.
Topics: Animals; Disease Models, Animal; Imidazoles; Levodopa; Ligands; Molecular Structure; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyrazoles; Pyrroles; Rats; Receptors, N-Methyl-D-Aspartate | 1999 |
Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Drug Combinations; Dyskinesia, Drug-Induced; Dyskinesias; Electrophysiology; Eye Movements; Globus Pallidus; Levodopa; Macaca mulatta; Motor Activity; Neurons; Parkinsonian Disorders | 1999 |
Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment.
Topics: Animals; Corpus Striatum; Denervation; Dopamine; Drug Administration Schedule; Exploratory Behavior; Female; Functional Laterality; Levodopa; Motor Activity; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley | 1999 |
Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.
Topics: Animals; Antisense Elements (Genetics); Bacterial Proteins; Biomarkers; Cell Count; Disease Models, Animal; Dyskinesias; Enkephalins; Female; Levodopa; Neostriatum; Nerve Degeneration; Neurons; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Transcription Factors; Ventral Tegmental Area | 1999 |
Weight gain following unilateral pallidotomy in Parkinson's disease.
Topics: Dyskinesia, Drug-Induced; Eating; Globus Pallidus; Humans; Levodopa; Linear Models; Longitudinal Studies; Motor Activity; Neuropsychological Tests; Nutrition Assessment; Parkinsonian Disorders; Severity of Illness Index; Smell; Stereotaxic Techniques; Surveys and Questionnaires; Weight Gain | 2000 |
Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Dextromethorphan; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Riluzole; Rotation | 2000 |
Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Binding Sites; Carrier Proteins; Caudate Nucleus; Dopamine Plasma Membrane Transport Proteins; Female; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Parkinsonian Disorders; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Saimiri; Substantia Nigra | 2000 |
Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Benserazide; Clozapine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders | 2000 |
A possible association between exposure to n-hexane and parkinsonism.
Topics: Antiparkinson Agents; Carbidopa; Drug Therapy, Combination; Electromyography; Evoked Potentials, Auditory, Brain Stem; Evoked Potentials, Somatosensory; Hexanes; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Occupational Diseases; Parkinsonian Disorders; Selegiline; Solvents | 2000 |
The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.
Topics: Adult; Antiparkinson Agents; Dopamine Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Humans; Levodopa; Male; Memantine; N-Methylaspartate; Parkinsonian Disorders; Treatment Outcome | 2000 |
Dopamine-receptor stimulation: biobehavioral and biochemical consequences.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Haplorhini; Levodopa; Neural Inhibition; Neuropeptides; Parkinsonian Disorders; Proto-Oncogene Proteins c-fos; Receptors, Dopamine; Receptors, GABA; Receptors, Glutamate; Signal Transduction | 2000 |
Expression of metallothionein-III mRNA and its regulation by levodopa in the basal ganglia of hemi-parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Corpus Striatum; Levodopa; Male; Metallothionein 3; Nerve Tissue Proteins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2000 |
MK801 influences L-DOPA-induced dopamine release in intact and hemi-parkinson rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Corpus Striatum; Dizocilpine Maleate; Dopamine; Excitatory Amino Acid Antagonists; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra | 2000 |
Abnormalities of motor cortical excitability are not correlated with clinical features in atypical parkinsonism.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia Cerebrovascular Disease; Case-Control Studies; Electromyography; Evoked Potentials, Motor; Female; Humans; Levodopa; Magnetics; Magnetoencephalography; Male; Middle Aged; Motor Cortex; Multiple System Atrophy; Parkinsonian Disorders; Statistics, Nonparametric | 2000 |
Dopa-resistant parkinsonism, oculomotor disturbances, chorea, mirror movements, dyspraxia, and dementia: the expanding clinical spectrum of hypoparathyroidism. A case report.
Topics: Aged; Antiparkinson Agents; Apraxias; Brain Diseases; Calcinosis; Chorea; Chronic Disease; Dementia; Diagnosis, Differential; Drug Tolerance; Female; Humans; Hypoparathyroidism; Levodopa; Magnetic Resonance Imaging; Oculomotor Nerve Diseases; Parkinsonian Disorders; Stereotypic Movement Disorder; Videotape Recording | 2000 |
Occupational Mn parkinsonism: magnetic resonance imaging and clinical patterns following CaNa2-EDTA chelation.
Topics: Antiparkinson Agents; Benserazide; Brain; Chelating Agents; Edetic Acid; Globus Pallidus; Humans; Levodopa; Magnetic Resonance Imaging; Male; Manganese Poisoning; Metals, Heavy; Middle Aged; Occupational Diseases; Occupational Exposure; Parkinsonian Disorders | 2000 |
L-dopa-responsive infantile hypokinetic rigid parkinsonism due to tyrosine hydroxylase deficiency.
Topics: Humans; Infant; Levodopa; Male; Parkinsonian Disorders; Tyrosine 3-Monooxygenase | 2000 |
Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benserazide; Dopamine Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Motor Activity; Parkinsonian Disorders; Piperidines; Receptors, Dopamine D2 | 2001 |
Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome.
Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; Disease Models, Animal; Dopamine Agents; Epilepsy, Tonic-Clonic; Humans; Inclusion Bodies; Levodopa; Mice; Nerve Tissue Proteins; Neurodegenerative Diseases; Parkinsonian Disorders; Prazosin; Receptors, Adrenergic, alpha-1; Shy-Drager Syndrome; Syndrome; Synucleins; Tyrosine 3-Monooxygenase | 2001 |
The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats.
Topics: Adrenergic Agents; Animals; Clorgyline; Corpus Striatum; Dopamine Agents; Dopamine Uptake Inhibitors; Levodopa; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidopamine; Parkinsonian Disorders; Piperazines; Rats; Rats, Sprague-Dawley; Selegiline; Substantia Nigra | 2000 |
Four novel mutations in the tyrosine hydroxylase gene in patients with infantile parkinsonism.
Topics: Adult; Amino Acid Sequence; Child; Child, Preschool; DNA Mutational Analysis; DNA Primers; Exons; Female; Humans; Introns; Levodopa; Male; Molecular Sequence Data; Mutation, Missense; Parkinsonian Disorders; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Sequence Homology, Amino Acid; Tyrosine 3-Monooxygenase | 2000 |
[Parkinson's disease].
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Catechols; Depressive Disorder; Diagnosis, Differential; Dopamine Agents; Dopamine Agonists; Follow-Up Studies; Humans; Indoles; Levodopa; Lewy Body Disease; Neuroprotective Agents; Nitriles; Parkinson Disease; Parkinsonian Disorders; Pergolide; Psychiatric Status Rating Scales; Psychotic Disorders; Time Factors | 2001 |
New nonsense mutation in the GTP-cyclohydrolase I gene in L-DOPA responsive dystonia-parkinsonism.
Topics: Adult; Aged; Antiparkinson Agents; Codon, Nonsense; DNA Mutational Analysis; Dystonia; Female; Gene Expression; GTP Cyclohydrolase; Humans; Levodopa; Male; Parkinsonian Disorders; Pedigree; Point Mutation | 2001 |
Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dizocilpine Maleate; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Levodopa; Male; Memantine; Mice; Mice, Inbred C57BL; Motor Activity; Parkinsonian Disorders; Recovery of Function | 2001 |
The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Benzophenones; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Hydroxyl Radical; Levodopa; Male; Microdialysis; Nitriles; Nitrophenols; Oxidative Stress; Parkinsonian Disorders; Rats; Rats, Wistar; Tolcapone | 2001 |
SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.
Topics: Adrenergic Uptake Inhibitors; Animals; Ankle Joint; Dopamine Agents; Dopamine Antagonists; Drug Combinations; Electromyography; Haloperidol; Levodopa; Male; Muscle Contraction; Muscle Rigidity; Muscle, Skeletal; Neostriatum; Neuroprotective Agents; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Purinergic P1; Reserpine; Triazoles | 2001 |
Response to levodopa treatment in dopa-responsive dystonia.
Topics: Adult; Antiparkinson Agents; Dopamine; Dystonia; Dystonic Disorders; Female; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Pilot Projects | 2001 |
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Callithrix; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Indoles; Levodopa; Neurologic Examination; Parkinsonian Disorders | 2001 |
Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Dopamine Agonists; Down-Regulation; Drug Interactions; Drug Tolerance; Dynorphins; Enkephalins; Gene Expression; Glutamate Decarboxylase; Isoenzymes; Levodopa; Neostriatum; Neurons; Oxidopamine; Parkinsonian Disorders; Quinpirole; Rats; RNA, Messenger; Sympatholytics; Up-Regulation | 2001 |
Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Denervation; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Levodopa; Male; Motor Activity; Neostriatum; Neural Pathways; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; Substantia Nigra; Sympatholytics; Triazoles | 2001 |
Chronic levodopa therapy does not improve skilled reach accuracy or reach range on a pasta matrix reaching task in 6-OHDA dopamine-depleted (hemi-Parkinson analogue) rats.
Topics: Animals; Antiparkinson Agents; Arm; Cell Count; Drug Administration Schedule; Female; Immunohistochemistry; Levodopa; Motor Skills; Movement; Neurons; Neuropsychological Tests; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Long-Evans; Recovery of Function; Rotation; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase | 2001 |
Levodopa prolongs life expectancy and is non-toxic to substantia nigra.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cadaver; Child; Disease Progression; Dystonia; Female; Humans; Levodopa; Longevity; Male; Middle Aged; Parkinsonian Disorders; Retrospective Studies; Substantia Nigra; Survival Analysis; Tremor | 2001 |
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Drug Therapy, Combination; Dyskinesias; Female; Hypokinesia; Levodopa; Male; Morphinans; Motor Activity; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Posture; Receptors, Opioid, delta; Receptors, Opioid, mu | 2001 |
Levodopa responsive Parkinsonism in adults with Angelman Syndrome.
Topics: Adult; Angelman Syndrome; Antiparkinson Agents; Female; Humans; Levodopa; Male; Parkinsonian Disorders | 2001 |
Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy.
Topics: Acute Disease; Adult; Antiparkinson Agents; Antipsychotic Agents; Corpus Striatum; Female; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Prospective Studies; Psychotic Disorders; Retrospective Studies; Substantia Nigra; Tomography, Emission-Computed; Ultrasonography | 2001 |
Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Chronic Disease; Disability Evaluation; Disease Models, Animal; Dopamine Agents; Drug Administration Schedule; Dyskinesias; Female; Image Processing, Computer-Assisted; Levodopa; Macaca mulatta; Motor Activity; Parkinsonian Disorders; Video Recording | 2001 |
Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Cell Count; Disease Models, Animal; Dopamine; Dopamine Antagonists; Drug Interactions; Homovanillic Acid; Hydroxyindoleacetic Acid; Hypokinesia; Immunohistochemistry; Isoquinolines; Levodopa; Male; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Neurotoxins; Parkinsonian Disorders; Serotonin; Stereoisomerism; Substantia Nigra; Tetrahydroisoquinolines; Tyrosine 3-Monooxygenase | 2001 |
LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Isoquinolines; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Tetrazoles | 2001 |
Up-regulation of secretoneurin immunoreactivity and secretogranin II mRNA in rat striatum following 6-hydroxydopamine lesioning and chronic L-DOPA treatment.
Topics: Animals; Apomorphine; Chromogranins; DNA, Complementary; Dopamine Agonists; Drug Administration Schedule; Gene Expression Regulation; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Neostriatum; Neurons; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Proteins; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Secretogranin II; Sympatholytics; Up-Regulation | 2001 |
Persistent changes in striatal gene expression induced by long-term L-DOPA treatment in a rat model of Parkinson's disease.
Topics: Animals; Bromocriptine; Denervation; Disease Models, Animal; Dopamine Agents; Dopamine Agonists; Drug Administration Schedule; Enkephalins; Female; Gene Expression Regulation; Immunohistochemistry; Levodopa; Neostriatum; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sympatholytics | 2001 |
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dose-Response Relationship, Drug; Female; Levodopa; Macaca fascicularis; Male; Motor Skills; Organic Chemicals; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Species Specificity; Stereotyped Behavior; Substantia Nigra | 2001 |
MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Disease Models, Animal; Dizocilpine Maleate; Dopamine Agents; Dopamine Agonists; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Excitatory Amino Acid Antagonists; Immunohistochemistry; Levodopa; Male; Motor Activity; Neostriatum; Neurons; Neuropeptides; Oxidopamine; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate; RNA, Messenger; Tachykinins; Tyrosine 3-Monooxygenase | 2002 |
Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families.
Topics: Adult; Age of Onset; Aged; Chromosomes, Human, Pair 1; Diagnosis, Differential; Disease Progression; Dyskinesia, Drug-Induced; Female; Functional Laterality; Gait Disorders, Neurologic; Genes, Recessive; Haplotypes; Humans; Italy; Levodopa; Lod Score; Male; Middle Aged; Parkinsonian Disorders; Pedigree; Phenotype; Syndrome; Tremor; Videotape Recording | 2001 |
Spinocerebellar ataxia type 2 presenting as familial levodopa-responsive parkinsonism.
Topics: Adult; Aged; Ataxins; Brain; China; Female; Fluorine Radioisotopes; Gait; Humans; Levodopa; Male; Middle Aged; Nerve Tissue Proteins; Parkinsonian Disorders; Pedigree; Proteins; Spinocerebellar Ataxias; Tomography, Emission-Computed; Trinucleotide Repeats | 2001 |
Anticholinergic drugs: response of parkinsonism not responsive to levodopa.
Topics: Adult; Brain Mapping; Cholinergic Antagonists; Corpus Striatum; Humans; Levodopa; Magnetic Resonance Imaging; Male; Neurons; Parkinsonian Disorders; Pyramidal Tracts; Substantia Nigra; Tomography, Emission-Computed; Trihexyphenidyl | 2002 |
MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Sympatholytics; Synaptic Transmission | 2002 |
Toxicity of Annonaceae for dopaminergic neurons: potential role in atypical parkinsonism in Guadeloupe.
Topics: Annonaceae; Antiparkinson Agents; Apoptosis; Cell Culture Techniques; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Resistance; Guadeloupe; Humans; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Mesencephalon; Nerve Tissue Proteins; Neurons; Parkinsonian Disorders | 2002 |
Life-threatening parkinsonism induced by kava-kava.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Female; Humans; Kava; Levodopa; Middle Aged; Parkinsonian Disorders; Tremor | 2002 |
X-linked dystonia ("Lubag") presenting predominantly with parkinsonism: a more benign phenotype?
Topics: Adult; Antiparkinson Agents; Chromosome Aberrations; Dystonic Disorders; Humans; Levodopa; Male; Parkinsonian Disorders; Phenotype; X Chromosome | 2002 |
Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.
Topics: Aged; Aged, 80 and over; Animals; Basal Ganglia; Binding, Competitive; Callithrix; Dopamine Agents; Female; GTP-Binding Proteins; Humans; Levodopa; Male; Middle Aged; Neurons; Parkinsonian Disorders; Receptors, Cannabinoid; Receptors, Drug; Up-Regulation | 2001 |
Beta-CIT-SPECT combined with UPDRS appears to distinguish different parkinsonian conditions.
Topics: Aged; Antiparkinson Agents; Basal Ganglia; Cocaine; Diagnosis, Differential; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Motor Skills; Parkinsonian Disorders; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2002 |
Tyrosine hydroxylase deficiency: clinical manifestations of catecholamine insufficiency in infancy.
Topics: Consanguinity; Developmental Disabilities; Dopamine; Female; Follow-Up Studies; Humans; Infant; Levodopa; Neurologic Examination; Norepinephrine; Parkinsonian Disorders; Tremor; Tyrosine 3-Monooxygenase | 2002 |
Parkinson syndrome as a manifestation of mitochondriopathy.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Biopsy; DNA, Mitochondrial; Dopamine; Electromyography; Female; Humans; Levodopa; Male; Middle Aged; Mitochondrial Diseases; Muscle, Skeletal; Oxidative Phosphorylation; Parkinsonian Disorders; Point Mutation; Severity of Illness Index | 2002 |
A patient with proximal myotonic myopathy and parkinsonism.
Topics: Aged; Antiparkinson Agents; Brain; Humans; Levodopa; Male; Muscles; Myotonic Disorders; Parkinsonian Disorders | 2002 |